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Abstract 
 
The re-design and controlled self-assembly of natural systems into non-natural functional 
products is a quickly developing area of Synthetic Biology.  Specifically, the manipulation of 
existing, and the introduction of new protein-protein interactions will allow great advances 
in bionanotechnology.  In nature, protein-protein assemblies mediate many cellular 
processes and exhibit complex and efficient functions.   It is thus rational to assume 
human-guided biomolecular assemblies could embody equally complex functionality 
designed to address current human needs. 
Here we present the design and preparation of a Virus-Like Particle (VLP) engineered from 
the cholera toxin B-subunit (CTB).  This was achieved via the de novo design of a protein-
protein interface between CTB subunits consisting of coiled-coil C-terminal extensions and 
modification to the CTB surface.  A combination of computational methods was used to 
suggest mutations which should reduce the ΔΔG of interaction across the interface.  CTB is 
a natural homopentamer with inbuilt cell targeting and endocytic triggering mechanism. 
Future applications for the VLP could include use as a drug delivery vehicle to transport 
protected therapeutic agents to targeted cell types. 
Through our investigations it became apparent that the CTB-VLP structures behaved in a 
similar manner to naturally occurring virus coat proteins, which suggests the successful 
biomimicry of these complex systems.  This study provides a basis for the development of 
further VLPs from other homomultimeric proteins, especially further classes of 
homopentameric bacterial toxins. 
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Abbreviations 
AFM  Atomic force microscopy 
CIP  Calf-intestinal phosphatase 
CT  Cholera toxin 
CTA1  Cholera toxin A-subunit 1 
CTA2  Cholera toxin A-subunit 2 
CTB  Cholera toxin B-pentamer 
DeCrE  A negatively charged coiled-coil motif 
DeCrK  A positively charge coiled-coil motif 
DLS  Dynamic light scattering 
DNA  Deoxyribonucleic acid 
dNTP  Deoxyribonucleotide triphosphate 
DSC  Differential scanning calorimetry 
DSF  Differential scanning fluorimetry 
E. coli  Escherichia coli 
ESI-MS  Electrospray ionisation-mass spectrometry 
HPLC  High Performance Liquid Chromatography 
JR-coil2  A putative trimeric designed coiled-coil 
JR-coil7  A putative dimeric designed coiled-coil 
LB  Lysogeny broth 
LTB  Heat-labile toxin B-pentamer 
MBP  Maltose-binding protein 
MBP-AB5 MBP-CTA2 fusion, with CTB assemble around CTA2 
MS  Mass spectrometry 
PCR  Polymerase chain reaction 
PFU  DNA polymerase (from Pyrococcus furiosus) 
PPI  Protein-protein interaction 
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PWO  DNA polymerase (from Pyrococcus woesei) 
RNA  Ribonucleic acid 
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SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SEC  Size exclusion chromatography 
STNV  Satellite Tobacco Necrosis Virus 
SV40  Simian Virus 40 
SynTri  A homotrimeric coiled-coil 
TEM  Transmission electron microscopy 
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TEV  Tobacco etch virus  
Tris  Tris(hydroxymethyl)aminomethane 
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Introduction 
1 Chapter 1 – Introduction 
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1.1 Overview 
In this project we aim to create a novel virus-like particle (VLP).  Synthetic biology is a field 
which aims to design from scratch, or redesign existing natural, molecules and systems to 
create desirable functions for human needs.  The VLP we aim to construct is designed from 
a modified natural non-capsid protein to which we have introduced the ability to form 
enclosed capsid-like structures.  The VLP will be constructed through the addition of 
scaffolding extensions followed by the redesign of the putative protein-protein interaction 
interface.   This redesign process will use a number of computational protein-protein 
interface design techniques to elucidate mutations which increase the propensity for 
association.  Some natural viruses are also known to assemble through the use of 
scaffolding molecules and extensions and we hope to emulate the process of viral capsid 
assembly with our designed protein capsid.  The subunit for our construction is cholera 
toxin B-subunit (CTB) which naturally triggers its own endocytosis.  Thus a VLP constructed 
from CTB should mediate endocytosis of the constructed capsid.  This would make the CTB-
VLP useful as a delivery vehicle for the intra-cellular targeting of therapeutic agents. 
 
1.2 Synthetic Biology  
1.2.1  Overview 
Synthetic Biology is an emerging bioscience which applies biological molecular theory to 
non-natural systems in order to create useful technologies.  This objective is achieved 
through constructing synthetic gene circuits, by redesigning proteins, building novel DNA-
based structures[1] or creating new forms of life[2].  Synthetic Biology represents the most 
recent genre smudging paradigm and draws interest from a broad range of scientific 
disciplines including mathematics, physics, chemistry, biology, engineering, computing, 
electronics and materials science, due to its capacity to have impact on future work in 
these fields.  The current concept of synthetic biology is seen by many as a form of 
biological engineering[3], mixed with investigative science. In 1988 Richard Feynman left his 
final black board scribblings for us including the famous quote “What I cannot create, I do 
not understand”.  Hopefully as we experiment in synthetic biology and learn how to mimic 
biological mechanisms we will enhance our understanding of the physical processes which 
nature exploits in order to create them in the first place[4].  Applying this new knowledge to 
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the de novo engineering of biology will further teach us the limits of natural biological 
components.  Then, through the redesign or de novo construction of biological systems we 
will overcome these evolutionary constraints. 
 
1.2.2  Historical perspective 
In the 1980s synthetic biology was generally described as the production of synthetic forms 
of life via artificial gene circuits, then in 2004 as the unnatural assembly of natural 
polymers[5],  seen by many as a form of biological engineering [3].  More recently The Royal 
Society of Engineering described Synthetic Biology’s aim as “design and engineer 
biologically based parts, novel devices and systems as well as redesigning existing, natural 
biological systems.”    
 
1.2.3  Standardisation 
Synthetic Biology has made dramatic propositions about fundamentally changing biology 
by providing a platform for standardisation and hence manipulation and design of 
biological parts.  This standardisation is the true power of synthetic biology, and though we 
are not at that stage yet, when it comes, it should allow click and drag biological design and 
snap-together biological functionality.  A deciding factor in this movement will occur when 
the cost of mail order DNA synthesis out competes the cost of the current, more labourious 
molecular biology technologies for designing DNA to the required specification.  A 
standardised approach to strains, plasmids, expression systems etc. would allow greater 
productivity, easier sharing and higher compatibility between laboratories[3].  In 1996 Eric S. 
Lander of MIT stated in ‘The New Genomics: Global Views of Biology’, “One can envision a 
growing handbook of reusable modular components, much as architects of electronic 
circuits use today that would propel studies ranging from basic research to applied gene 
therapy”[6].  The Registry of Standard Biological Parts[7] was founded at MIT in 2003 to apply 
that very idea, through collaboration  with the BioBricks Foundation[8] and the International 
Genetically Engineered Machines (iGEM) competition[9].  They aim to create standardised 
biological parts that can be used for a given purpose in almost all circumstances, i.e., 
snapping any promoter to any gene in any plasmid to transform any chassis (organism).  In 
creating this kind of standardisation they hope to attract non-biologists in order to bring 
interdisciplinary groups into the field.  As biology is highly complex, synthetic biology will 
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have to undergo more standardisation than mechanical and electrical engineering to 
achieve an appropriate degree of standardisation[3].  However, several biological data 
standards already exist, such as the International Nucleotide Sequence Database 
Collaboration[10], microarray data[11], the Protein Data Bank[12], enzyme nomenclature[13], 
systems biology models[14] and restriction endonuclease activities[15], which is at least a 
move in the correct direction. 
 
1.2.4  Synthetic Genomics 
Synthetic biology is a broad subject with many facets, however, the field is currently 
dominated by the sub-field of synthetic genomics.  Much of this work involves the 
standardisation of the genetic code, tuning promoters and ribosome binding sites for 
tailored and timely protein expression[16].  Genes from one, or in fact many different 
organisms, are re-assembled into a specific host cell to create new genetic circuitry that can 
then carry out a unique function not previously available[17]. This area of synthetic biology, 
while extremely powerful, is limited to the molecular machinery currently available 
through biological evolution.  The design of novel nucleotides[18] or redesign of ribosomes 
to accept four-digit codons[19]  are examples of attempts to remove this limitation by re-
engineering native functions or by introducing de novo functionality[20].  A further step 
forward is the prediction and production of nascent biomolecules from scratch[21].  This 
step is yet to be practically applicable as standard, nevertheless, the re-engineering of 
protein domains and motifs is tractable[22].  The redesign or enhancement of enzymatic 
function to increase catalysis or alter substrate specificity is a field well developed long 
before the arrival synthetic biology[23,24].  However, the scaffolding of biomolecules to 
create larger, more complex structures and the control of addressable surfaces is still in its 
infancy.  Controlling the proximity and orientation of biomolecular assemblies will enhance 
the repertoire of components available for future synthetic biology applications both in 
vivo and in vitro.  This area of synthetic biology I will refer to as Synthetic Proteomics. 
 
1.2.5  Synthetic Proteomics 
The rational design of proteins as synthetic components is currently approached in a 
number of ways, from focusing on rationally searching homologue database matches to 
required functions[25], to molecular dynamic simulations allowing ab initio protein design.  
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Other groups are building up from small peptides to larger proteins, in the speculation that 
protein motif scaffolds (tectons) will be instrumental in de novo protein design and 
understanding[26].  Currently there is a heavy reliance upon top-down methods such as 
homology modelling, site directed mutagenesis and directed evolution.  These approaches 
have produced good results, such as advances in DNA sequencing[27], PCR amplification[28], 
addition of unnatural amino acids into protein sequences[29], manufacturing of 
pharmaceutical compounds[3], and the classic, laundry detergents, but have produce very 
few examples of truly novel, functional proteins or protein-protein interactions.   
Nature evolves structure and function from those molecules already in existence, which 
may not produce proteins with maximum turn-over or optimal functionality.  Thus there 
must be structural solutions that will lead to optimised kinetics and diverse functions that 
can be developed outside of nature’s evolutionary context[25].  This is particularly pertinent 
as the computational power required to search homology databases of the future will need 
to be immense, due to the sheer quantities of data.  Truly novel design (atomistic) requires 
high computation levels beyond the processing power of today’s machines.  However, with 
ever increasing computational power, fully parameterised atomistic simulation will one day 
become a reality.  Whatever the method, computational biology will play a major role.  
Today it is widely believed that rational design of future synthetic biological systems will be 
achieved via further advances in computational biology[3]. 
The design of tectons and novel proteins, built to purpose, will allow the construction of 
simple synthetic macromolecules which, in turn, will lead to multifunctional protein 
assemblies and finally to advanced complex synthetic cells and tissues.  Bromley, Woolfson 
and co-workers et al. present this concept in an overview of what they term ‘synthetic-
biology space’[30] (Figure 1-1). 
 
1.2.6  Synthetic Assemblies 
Self-assembly is an important phenomenon for constructing nano-scale biological 
structures and maintaining this property in designed system components will be essential 
to synthetic biology’s success[31].  By controlling association between biological molecules it 
will be possible to build fibers and filaments, precisely designed surfaces and 
macromolecular assemblies with diverse functionality. 
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Figure 1-1:  Synthetic-biology space.  A description of the steps required to increase complexity and divergence 
from nature in the construction of synthetic components which will lead to fully synthetic cell-like systems.  
Starting from natural building blocks such as DNA or peptides, non-natural proteins and DNA structures can be 
constructed.  Additionally non-natural building blocks can also be used such as PNA, peptide nucleic acids, and 
foldamers, synthetic polymers which reliably fold into higher order structures, in order to create more 
complicated components for further synthetic biology uses.  Reprinted with permission from
[30]
.  Copyright 
2014 American Chemical Society. 
The ability to precisely position biofunctional macromolecules on an addressable surface 
with nanoscale accuracy is an important step toward the goal of creating nanotechnological 
devices.  Fu et al. from the Shanghai Institute of Applied Physics have demonstrated the 
non-covalent assembly of DNA origami sheets into tubes which could be addressed with 
two proteins that form part of an enzymatic cascade.  The group showed that proximal 
anchoring of the proteins increased the overall reaction rates and when the enzymes were 
enclosed within tubes that the reaction rates were further increased [32], Figure 1-2.  This 
work demonstrated that simple bioreactors can greatly increase serial enzymatic reactions 
through diffusional restriction of the reaction intermediates. 
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Figure 1-2:  Addressable Nanoscale Bioreactors.  a) GOx forms peroxide upon glucose reduction, HRP utilises 
this peroxide to convert ABTS
2-
 to the chromophore ABTS
-
.   A schematic of the enzymes positioned on the DNA 
origami substrate.  b) AFM of the DNA origami sheets with the enzymes associated.  c) DNA origami tubes with 
the enzymes presented on the interior.  d)  The change in enzyme kinetics from enzymes free in solution, 
addressed to origami sheets or confined to the interior of the origami tubes. Reprinted with permission from 
[32]
.  Copyright 2014 American Chemical Society. 
 
 
1.2.7  Current Government, Academic and Public 
Awareness 
In recent years the UK government has expressed increasing levels of interest in synthetic 
biology.  In 2008 a postnote was released from the Office of Science and Technology[33] to 
inform the public and government on the pros and cons of synthetic biology.  More 
recently Research Councils UK have released a Synthetic Biology Roadmap[34] which details 
how to advance the UK’s position as a world leader in synthetic biology.  Furthermore, the 
government has announced a £600M investment in science, including synthetic biology as 
one of the principal beneficiaries through the creation of six centres for excellence in 
synthetic biology research.   
The academic community has also become increasingly interested in synthetic biology with 
the creation of networks in synthetic biology between UK universities (almost £900K to 
establish communication and networking[35], the iGEM competition[9], as well as a host of 
recent UK-based international conferences such as a recent Harden Conference[36], a joint 
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Biochemical Society and Protein Society conference on protein engineering[37] and this 
year’s BioBricks Foundation Synthetic Biology 6.0 conference[38]. 
1.3 Protein-Protein Interactions 
With the wealth of structural information available on protein-protein interactions (PPI) 
and current theories on PPI requirements converging, the design of protein interfaces is 
now becoming a realistic vision which is bound to have an impact on future synthetic 
biology systems.   
 
1.3.1  Overview 
Protein-protein interactions (PPI) mediate many cellular processes from organisation of 
cellular scaffolds and intracellular signalling cascades to initiation of transcription and the 
immune response.  The mapping of these protein interactions will provide a wealth of 
information on biochemical and metabolic networks[39].  The specific structure of a 
protein’s interaction site, e.g., the position of the van der Waals interactions[40] as well as 
polar contacts and salt bridges[41] along with more general features such as size, shape and 
intrinsic flexibility determines the complementarity with which proteins can bind to form 
stable complexes[42-44].  Methods for designing these interactions into de novo protein-
protein interfaces will allow the construction of larger assemblies to be realised. 
 
1.3.2  Homomeric vs. Heteromeric Interactions 
PPIs can be divided into two classes: homomeric and heteromeric.  Though this 
classification seems obvious and potentially arbitrary, the reality is that these two types of 
interaction differ greatly.  Homomeric protein complexes often associate to form 
“permanent” interactions through extensive van der Waals forces mediated by sterically 
complimentary hydrophobic interaction sites[45].  These specialised and long-lasting 
interactions typically have a solvent-excluded surface area (SESA) of between 1200-4660 
Å2[46].  Conversely, heteromeric complexes more often associate dynamically[47] and, as the 
surfaces are at times solvent exposed, they cannot contain too many hydrophobic residues. 
As these surfaces typically interact through complementary hydrogen bonding, dynamic 
protein interfaces often resemble non-interface surfaces[41].  Heteromeric interfaces often 
have a SESA of between 600-2000 Å2 [46]. A SESA of 600 Å2 is thought to be a reasonable 
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minimum to prevent rapid invasion of the bulk solvent into an interaction site formed from 
a single ‘hot spot’[48].   
1.3.2.1 Hot Spots 
Most PPIs are dominated by only a small percentage of the interaction site residues, 
termed ‘hot-spots’.  Hot-Spots are motifs of the interface that contribute a large portion of 
the binding energy involved in the interaction. Typically they are defined as individual 
residues which are capable of contributing a ΔΔGbinding (change in free energy of binding) of 
-2 kcal/mol or more to the PPI[49].  It has been found that the main hot spot residues 
identified are tryptophan (21%), arginine (13.3%) and tyrosine (12.3%)[50], which can 
contribute up to -4 kcal/mol to the ΔΔGbinding
[49].  These three residues are, of course, large 
residues and their significant improvements in ΔΔGbinding compared to small residues like 
alanine could arise from their larger interaction surface area.  Alternatively, these residues 
are more structurally diverse than the likes of leucine, serine and valine and they could 
thus perform a more diverse range of roles at the interface; for example tyrosine can form 
π-π stacking interactions, hydrophobic interactions and hydrogen bonds.  So, is the larger 
ΔΔGbinding for these residues solely a consequence of their size, or is it the result of their 
specific structural features?  The latter argument is supported by tyrosine being three 
times more likely to be a hot spot residue than phenylalanine, despite reasonably similar 
structures[48].   
 
1.3.2.2 Solvent Effects 
Protein-protein interfaces generally contain a mixture of hydrophobic and polar 
residues[51]. Therefore, PPIs are often characterised by a favourable energy gain in burying 
the hydrophobic parts of the interface from the bulk solvent[52], as well as a compromise 
between polar residues interacting with solvent or forming hydrogen bonds with the 
binding partner[53].  Over larger (wider) interfaces, residues that promote solvation must be 
present to maintain solubility.  The displacement of water within and around the binding 
site in to the bulk solvent often provides, in general terms, an increase in disorder of the 
system even when the increase in order of the new complex is taken into account.  This is 
achieved, in part, by the destruction of hydration shells, i.e., ordered layers of water, which 
extend further into the bulk solvent from unbound PPI than for standard solvated protein 
surfaces. 
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1.3.3  Experimental Characterisation of PPIs 
Experimental validation of PPIs can be assessed by a number of techniques. Examples of 
well used methods to assess PPIs are the yeast two-hybrid system[54], immuno-precipitation 
and affinity pull-down, as well as mass-spectroscopy[55,56].  However these methods are not 
capable of delivering information based on the binding mode of the complex.  It is widely 
accepted that accurate characterisation of PPIs requires the use of several experimental 
techniques in a combinatorial manner[57,58].  Techniques which can provide medium to high 
resolution structures for PPIs are X-ray crystallography, NMR spectroscopy, electron 
microscopy and cryo-electron tomography.  Lower resolution techniques such as FRET, 
analytical ultracentrifugation, ITC and SAXS[59] can also deliver important information on PPI 
formation.  However, which experimental techniques can be successfully used is 
dependent on the type of PPI.  For example, assessing homodimeric PPIs eliminates two-
hybrid, Immuno-precipitation and pull-down as viable choices. However, given a highly 
stable quaternary structure, simple methods such as SDS-PAGE or SEC, or quick and cheap 
techniques such as Differential Scanning Fluorimetry may be all that is necessary to deliver 
the required information.   
 
1.3.4  Coiled-Coils 
Coiled-coils are potentially the simplest of all protein-protein interaction domains. They are 
ubiquitous amongst prokaryotic and eukaryotic cells and are also found in some viruses.   
Consequently, they have received much attention and are well characterised in the 
literature[60].  Coiled-coils are formed by the association of two or more α-helices which 
may associate in parallel, antiparallel or mixed orientations.  The total length can vary from 
14 amino acids to many hundreds of amino acids.  Shorter coiled-coils often form 
oligomerisation motifs of larger proteins, while longer coiled-coils have structural roles in 
the cytoskeleton and in motor proteins.  Crick first proposed their existence in 1953[61] and 
the first crystal structure was obtained by Phillips in 1986[62]. 
The repeating unit of a coiled-coil is a ‘heptad’, i.e., a sequence of seven amino acids.  The 
helices of the coiled-coil twist around the central axis of the oligomer in a left handed 
manner, this superhelical distortion lowers their pitch to 3.5 residues per helical turn.  Thus 
the heptad can repeat every two turns of the helix.  This heptad repeat has the 
nomenclature abcdefg.  Depending on the oligomeric state of the coiled-coil, the 
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residues in the heptad repeat take on different functions (Figure 1-3)[60].  In dimeric, 
trimeric and most tetrameric interactions, the a and d' residues form the hydrophobic 
core, supported by electrostatic interactions between e and g' residues.   
 
Figure 1-3: The structure of a dimeric coiled-coil.  a) The helical wheel representing the coiled-coil heptad 
repeat.  a and d positions associate to form the hydrophobic core, while e and g position support the structure 
with electrostatic interactions.  b) A view down the central axis showing the hydrophobic core. Reprinted with 
permission from
[60]
.  Copyright 2014 American Chemical Society. 
 
In dimeric and trimeric coiled-coils, hydrophobic residues dominate at positions a and d 
which creates a hydrophobic interaction surface between the two coils.  Smaller 
hydrophobic residues such as valine often determine the dimeric oligomerisation site and 
bulkier residues such as isoleucine often prescribe trimeric coiled-coils.  These hydrophobic 
residues interact in a so-called ‘knobs-into-holes’ packing, where side-chains (knobs) of one 
helix pack into gaps between side-chains (holes) on the binding partner.  This interaction 
provides the majority of the coiled-coil binding affinity.  Positions e and g run alongside the 
hydrophobic core and often form salt-bridges between subunits which help to determine 
the specificity by which binding occurs. The remaining positions b, c, and f are usually 
residues with a high helical propensity and also help to maintain the solubility of the coils 
by interacting with the solvent.   
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Many natural coiled-coil sequences contain irregularities that deviate from the basic 
function of the residues in the heptad repeat listed above.  These can include  the 
incorporation of electrostatically repulsive residues or residues with poor helical 
propensities.  Although these deviations likely perform a biological function, such as 
recognition etc., they are of limited use for synthetic biology applications.  However as the 
structural rules for coiled-coils are relatively simple compared to other protein-protein 
interfaces, , these motifs can be designed for specific uses.  The heptad repeat denotes the 
function of the amino acid, therefore each residue can be purposefully chosen to 
contribute to the design.  The first redesign of a coiled-coils, by Hodges[63] produced an 86 
residue disulphide-linked parallel dimer.   
 
 
Figure 1-4:  The de Crescenzo coilE (left) and coilK (right) which heterodimerise.  The hydrophobic core residues 
consist of valine and leucine.  The electrostatic interaction help prevent homodimerisation through electrostatic 
repulsion. Reprinted with permission from
[64]
.  Copyright 2014 American Chemical Society. 
 
In 2003 de Crescenzo et al., in the O’Connor-McCourt group at the Canadian National 
Research Council, designed a number of heterodimeric parallel coiled-coils  with varying 
lengths of the canonical heptad repeats VSALEKE and VSALKEK[64] (Figure 1-4). One coil 
(coilE) had glutamate residues at the e and g positions, while the other coil (coilK) 
contained lysines at the same positions.  The coiled-coil constructed with five heptads had 
a Kd of 63 pM.    They measured the effect of heptad length on the association of the dimer 
and found that smaller coils associated via more complex mechanisms involving 
conformational rearrangements. 
13 
 
More recently Burton et al., in the Woolfson group at the University of Bristol, have 
recently demonstrated the incorporation of reactive thiol groups into a de novo designed 
coiled-coil scaffold and shown these groups to be solvent accessible through their reaction 
with iodoacetamide[65] (Figure 1-5).  This incorporation of reactive groups to truly novel 
scaffolds is a good example of our current ability to engineer proteins at this level.  As this 
de novo protein assembly was created from scratch, the function of each residue is known 
with precision, which leads these kinds of structures to be amenable to further design.  
 
Figure 1-5:  Incorporation of reactive thiol groups into a channel of a de novo protein scaffold.  a) An overlay of 
two hexameric coiled-coils with a ring of cysteines incorporated at different heptad repeats.  b)  a cross-
sectional view of a ring of cysteine residues.  Reprinted with permission from
[65]
.  Copyright 2014 American 
Chemical Society. 
1.3.5  Symmetrical Protein Assemblies 
The production of larger symmetrical protein cages can be exemplified with four examples.  
Firstly Padilla et al., in the Yeates group at the University of California, Los Angeles, 
constructed large symmetrical assemblies via protein fusions including a tetrahedron 
formed from the homodimeric M1 matrix protein of the influenza virus and the 
homotrimeric bromoperoxidase, via the incorporation of 9 residue helical linker[66] (Figure 
1-6a/b).  The Noble group, at the University of Oxford, constructed 2D arrays with the 
streptavidin homodimer and the a homotetrameric ALAD-streptag fusion[67], (Figure 
1-6c/d).  The resulting structures are an impressive feat of construction which rely on the 
correct choice of linker between the fusion proteins to hold the two protein domains at 
specific angles. In each case, they rely on the use of native binding interfaces provided by 
nature. 
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In a third example, the Woolfson group at the University of Bristol,  described the 
construction of protein cages from coiled-coils[68] (Figure 1-7).  These self-assembled cage-
like particles (SAGEs) were built in an analogous fashion to the protein cage from the 
Yeates group, in this case, employing the use of homotrimer and  heterodimer building 
blocks that were linked by disulfide bonds.  However, these coiled-coils were designed ab 
initio to interact with each other which presents another level of complexity in the design 
process.  Molecular dynamic simulations were used to show the propensity for the 2D 
coiled-coil array to form curvature which would lead to enclosed particles. 
 
 
 
Figure 1-6:  Oligomeric fusion strategies which bring about 2D and 3D assemblies.  a)  A semi-ridging linker 
region (yellow) is used to prescribe an enclosed structure of a dimer-trimer fusion.  b)  The crystal structure of 
the tetrahedral particle.  c) Fusion proteins of dimer-tetramers which bind along the same axis of symmetry 
form 2D arrays.  d)  The crystal structure of the 2D array.  Entire figure reprinted from
[69]
, with permission from 
Elsevier.  a and b) from
[66]
.  Reprinted with permission from AAAS.  c and d) Reprinted by permission from 
Macmillan Publishers Ltd: Nature nanotechnology
[67,70]
, copyright 2010 and 2011. 
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Figure 1-7:  SAGE coiled-coils forming nano-scale protein cages visualised by scanning probe microscopy.  a) 
AFM 3D projection showing the height and relative diameter of the collapsed protein cage.  b) Liquid AFM of 
protein cages.  c) schematic of the non-contact LMFM scanning regime.  d) magnified image of the protein cage, 
revealing hexagonal structure.  From
[68]
. Reprinted with permission from AAAS. 
 
Finally, the Baker group, at the University of Washington, have investigated the 
construction of larger synthetic assemblies in the form of symmetrical protein cages[71].  
They used symmetrical docking screens of large protein libraries, followed by redesign of 
the new protein-protein interface with the program Rosetta, to produce both tetrahedrons 
and octahedrons.  It is worth mentioning that the proteins used to construct the 
octahedron naturally form protein cages of a larger dimension, thus this protein cage was 
made by re-engineering of a PPI. However, the protein which form the tetrahedron, 
galactoside O-acetyltransferase, is not thought to naturally form any higher order 
complexes.  TEM and crystal structures of the tetrahedral T3-10 protein cage are shown in 
Figure 1-8.  This work presents the meticulous engineering of a de novo PPI, demonstrating 
our fundamental ability to construct macromolecular assemblies without any need for 
covalent modification or scaffolding of an interaction.  However a screening process was 
used to search for proteins which matched a ‘designability’ criterion to allow the ease of 
redesigning the interface.  Thus, the proteins which form the assemblies were not chosen 
for their native functions; rather, they were selected because they were expected to be 
amenable to redesign into protein assemblies. 
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Figure 1-8:  de novo assembly of a tetrahedral particle T3-10.  a) A representative TEM micrograph with 
averaged structures below.  b) and c) backbone crystal structures of the T3-08-T3-10 and the T3-10 assemblies, 
respectively.  d) A comparison of the crystal structure (green and magenta) to the computational prediction 
(white) from which the designs were constructed. From
[71]
.  Reprinted with permission from AAAS. 
 
The ability to control the assembly of functional biomolecules with atomic precision will 
allow  future technologies to be realised, from simple targeted drug delivery vehicles to 
more complicated assemblies that could be used for biomolecule-based computational 
devices.  
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1.4 Biomolecular Simulations 
 
1.4.1  Overview 
Richard Feynman proclaimed in his 1963 ‘The Feynman lectures on physics, vol-1’ that 
‘everything that living things do can be understood in terms of the jiggling’s and wiggling’s 
of atoms’, and through biomolecular simulation we have a means of visualising these 
movements and extracting useful information from them.  Biomolecular simulation is a 
technique based on the numerical solution of the equations of motion over time, for a 
model that represents a system of molecules. Models differ in the degrees of freedom 
assumed (electrons, nuclei, group of atoms (amino acids), entire proteins, etc.) and the 
interaction between these degrees of freedom. Force-fields which accurately represent 
interactions between atoms in proteins, nucleic acids, lipids, water and small molecules of 
biological and pharmaceutical importance have been developed in the past 30 years.  
These force-fields have been incorporated into a number of software packages, such as 
AMBER and CHARMM, which have been built for the evolving needs of the modern 
biologist.  This type of software allows the study of protein folding, dynamics and changes 
in conformation[72-74], protein association with small molecules and proteins[74-76] and 
assessment of the free energies of ligand  binding[77].   
 
1.4.1.1 Simplified models 
As the size of the system of study increases, the use of such detailed models and force-
fields dramatically limits the timescales that can be investigated, up to a point where the 
necessary computational processing power is reached[78,79].  When studying the association 
of a large number of proteins, fully flexible atomistic models are thus not viable. In order to 
extend modelling beyond the limits of atomistic simulations, a number of coarse-grained 
approaches have been proposed wherein biomolecules are represented by simple spheres, 
cylinders or ellipsoids, or sometimes as rigid atomistic models.  The all-atom approach and 
the course grain approach can be combined to allow the simple modelling of parts of the 
system which are less informative, while rigorously simulating the part of the system which 
is more informative[80]. 
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In all cases (atomistic and course grained) the environment around the target, often the 
solvent, must also be represented numerically.  In a further attempt to reduce complexity, 
the effect of the environment is often represented by an average calculation of its 
influence on the protein, rather than calculated atom by atom (explicit).  For these reasons, 
biomolecular simulations cannot routinely give precisely correct numerical predictions of a 
system[81].  Therefore, it is still essential to combine simulation with experiment to allow 
simulation to steer the experimentation and experiment to optimise the computation[82].   
 
1.4.1.2 Binding orientations and assessment. 
With regard to PPIs, protein-protein docking techniques have become fashionable as of 
late.  Such docking programs include Z-dock[83], Hex[84] and Rosetta-Dock[85].  These 
programs find the most energy-minimised configuration between two proteins, thus 
predicting their binding conformation.  The use of simple linear interaction energy methods 
should also not be over looked.  For example the FoldX package contains a simple energy 
function and a side-chain rotamer library.  It is used to measure the free energy change of 
unfolding, compared to a hypothetical model of the same sequence.  Recently Christensen 
and Kepp[86] have used FoldX in conjunction with MD simulation to successfully estimate 
the stability changes upon mutation of a fungal laccase. 
 
1.4.2  Computational Protein-Protein Interface Design 
The generation of specific protein-protein interactions with designed affinity, specificity 
and kinetics is a long term goal of computational design.  Protein interaction affinities can 
be influenced by a number of factors such as temperature, pH and the ionic strength of the 
solvent.  Interaction sites can occur on any surface of the protein including unstructured 
loop regions.  This binding affinity can be described as a function of the free energy 
difference between the bound complex and the components of the complex, which 
includes both inter-subunit and intra-subunit energy changes as well as entropic 
contributions and ‘external factors’ such as solvent effects.  This variable menagerie is 
partly responsible for the lagging of PPI design compared to computational design 
advances in enzymatic functions[87] and protein folds[21].   
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Many residues in proteins are critical for their structural viability and biological function.  
Identification of mutable positions which maintain tertiary and quaternary structure and 
function but allow a degree of surface association manipulation is an essential first step in 
designing protein interfaces.  A number of initial strategies can be employed to identify 
designable positions in a protein sequence, such as protein sequence analysis to identify 
evolutionarily conserved residues, mutational differences between strains of a given 
species, as well as between structural homologues.  Structurally important residues can 
often be determined in such searches. Furthermore, these conserved residues have been 
shown to overlap with hot spot residues[88].  A more rigorous test for key residues is alanine 
scanning mutagenesis[89]  which can be conducted in silico by simulation using a range of 
commercial modelling packages [48,90]. The use of alanine scans has confirmed that the 
majority of the protein interface energy gain is contributed by just a few important hot 
spot residues[91].   
Schreiber and Fleishman[92] have suggested a number of strategies which can lead to 
successful protein interface design which are highlighted in Figure 1-9. Here we will focus 
on the de novo design strategies. Docking protein scaffolds to find binding partners with 
the most complementary shapes and then optimising the amino acid residues at the 
interface was described above through Baker’s design and assembly of octahedral and 
tetrahedral protein cages [71]. 
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Figure 1-9: A schematic description of possible protein-protein design approaches.  Redesign can be 
accomplished through the grafting of interacting residues from a known PPI on to a new putative interface.  de 
novo design can be achieved through  the docking of scaffolds, hot-spot design, which may include a level of 
grafting, or through metal, or ligand, binding site design, where each strategy is followed by optimisation of the 
binding site. Reprinted from
[92]
. Copyright 2013, with permission from Elsevier. 
A second strategy for de novo interface design is to dock amino acid side chains to the 
target protein surface in a similar way to in silico fragment screening, and then link them 
together using a suitable protein scaffold. This strategy is illustrated by the work of 
Fleishman et al. from the Baker lab at the University of Washington.  They designed a 
binding protein to the conserved stem region of the 1912 H1N1 influenza hemagglutinin 
protein[22].  After docking amino acid residues to the surface of the hemagglutinin protein, 
the possible positions of the Cα rotamers were calculated.  Finally these Cα ensembles 
were screened against a library of proteins to find scaffolds with the correct Cα positions.  
Once these hotspot residues and scaffolds had been deduced, Rosetta was used to suggest 
packing residues which would hold the hotspot residues in the correct orientations and 
contribute additionally to the interface.  Figure 1-10 shows the crystal structure of a 
designed protein HB36 in association with the haemagglutinin protein.  An additional 
mutant HB80 was shown to inhibit the fusogenic conformational change required for 
influenza infectivity at low pH. 
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Figure 1-10  The HB36 designed protein binding to the stem region of hemagglutinin.  a) A superposition of the 
crystal structure of HB36 (red) binding to the two subunits of hemagglutinin (pink and cyan) with the 
computational model (blue).  b) A close up of the designed interaction site.  c)  An unbiased electron density 
map from the X-ray data.  From
[22]
. Reprinted with permission from AAAS. 
 
A third strategy for de novo interface design is to incorporate metal-mediated interactions, 
which may then be augmented by other interactions between amino acids.  The Kuhlman 
group at the University of North Carolina recently attempted to control protein-protein 
interactions through zinc mediated association[93]; they succeeded while inadvertently 
creating a protein capable of catalysing carboxyester and phosphodiester hydrolysis[94].  
They designed a homodimer, wherein each monomer was a helix-turn-helix.  Each 
monomer was designed to coordinate two zinc atoms using two histidine residues.  As zinc 
has a preference for tetrahedral coordination, a dimeric protein complex should form with 
the additional histidines on the binding partner coordinating the free sites on the zinc 
(Figure 1-11).  The authors used the Rosetta program to search the pdb for other zinc 
binding scaffolds and to attempt to graft these onto selected regions of the dimer. 
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Figure 1-11:  The MIDI-zinc homodimer, interacts primarily through zinc mediated association.  a)  the crystal 
structure (blue) and the computational mode (brown) with an Cα rmsd of 1.4 Å.  b)  One of the zinc 
coordination site is not occupied by a histidine which allows the zinc to mediate carboxyester and 
phosphodiester hydrolysis. Reprinted with permission from
[94]
. Copyright 2012 American Chemical Society. 
 
The discovery and implementation of new design protocols is occurring regularly.  
Established force-fields such as CHARMM and AMBER are regularly updated, however they 
do not incorporate some of the more interesting features present in packages like Rosetta.  
Rosetta however does not perform the more conventional MD simulation of the former 
packages.  Additional programs perform a number of specific and important measurements 
however, each of these programs is written in different code and are not regularly 
compatible. 
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1.5 Virus Capsid Assembly 
1.5.1  Overview 
The regulation of capsid assembly is paramount in the construction of infectious virus 
particles.  Often the virus genome provides the common structural denominator for viral 
capsid protein assembly.  However under particular conditions the virus coat proteins 
themselves can spontaneously assemble into virus-like particles.  How do natural viruses 
prevent the formation of these non-infectious particles?  This is achieved through the 
‘process of assembly’ mediated through the ‘regulation of assembly’.  The process of 
assembly is similar to that of many other protein-protein interactions and is based around 
the physicochemistry of the interaction site and the environment in which assembly occurs.  
The regulation of assembly however is more biological in nature, in that the assembly of 
the particle must be spatially and temporally regulated to ensure packaging of the genome 
and the correct assembly of the coat.  Allostery is thought to play a key regulatory role 
through effector molecules and viral or host factors.  Often these allosteric regulators make 
a conformational alteration in the coat protein which leads to ordered assembly. 
 
1.5.2  Assembly 
From a simplistic perspective a capsid protein should associate through Brownian motion, 
in a geometrically precise orientation and bind with high affinity to form stable particles.  
However,  if the binding affinity is very high, then full virus particles would rarely occur as 
most of the subunits would become associated in partially constructed intermediates 
leading to kinetic traps[95].  The use of master equations [96,97] and simulation[98,99] has 
revealed that a general requirement for efficient and precise capsid assembly is the 
interactions between the coat proteins must be weak.  The low affinity ensures that 
intermediate states may disassemble almost as readily as they assemble which minimises 
aberrant capsid growth[100] and formation of kinetic traps (Figure 1-12).  For example the 
average association energy between two hepatitis B virus capsid subunits is approximately 
-4 kcal/mol[101].  However, the multivalency of the full assembly is strong enough to prevent 
the dissociation seen with the part assemblies.  This weak association has an additional 
positive effect on the assembly process: nucleation events are less frequent than the 
association of additional subunits to a growing particle.  The association between two 
subunits is mediated by one interface, however, given a trimer, each subunit make two 
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interactions which mutually support each other. Any further subunits joining the growing 
particle from this point make at least two further interactions and support the global 
stability of the particle.  Furthermore, as addition is more likely than nucleation, this 
ensures that a reservoir of subunits is available for each nucleation event to rapidly 
progress to a full capsid.  
 
 
Figure 1-12:  Efficient virus assembly and kinetic traps.  Given few nucleation events full size capsid formation is 
achieved with pool of capsid protein.  However, if nucleation occurs too frequently aberrant part capsids 
become the dominating species.  Reprinted from
[95]
. Copyright 2011 with permission from Elsevier. 
 
1.5.3  Viral Capsid Scaffolding 
Scaffolding proteins are found in many viruses, for example the bacteriophage P22 contains 
a thermodynamically and kinetically contributive scaffold protein[102,103].  Scaffolding 
proteins can help mediate morphological changes required for the maturation steps that 
lead to the fully assembled virion[104].  These scaffolding effects can also be mediated 
through chain extensions of the virus protein coat, for example by donor strand exchange 
as seen with simian virus 40[105], or with coiled-coils, as seen with satellite tobacco necrosis 
virus (STNV)[106] (Figure 1-13).  In the case of simian virus 40, these donor strands take up 
relatively different positions dependent on the quasi-symmetry of the particle’s geometry.  
The STNV coiled-coils are just one and half heptads in length but act to help assemble the 
coat proteins by providing a stage for RNA binding. 
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Figure 1-13:  N-terminal scaffolding coiled-coil at the 3-fold axis of the satellite tobacco necrosis virus.  From 
1A34.pdb
[106]
 
 
1.5.4  Pentagonal Tiling 
Many virus particles associate to form structures with icosahedral symmetry such as the 
T=1, T=3, T=4 and T=7 structures. Each of these structures, barring the T=1 dodecahedron, 
requires a mixture of both pentagons and hexagons to complete the particle.  However, the 
protein chosen for this project is just a pentagon.  Does this restrict the size of the capsid to 
that of the dodecahedron?  The short answer is no.  Nature provides examples of viruses 
having the T=7d geometry in which five pentagons associate around a central pentagon to 
creates a ‘super pentagon’ which can then go on to form a ‘super dodecahedron’. This 
structure is exemplified by the families of papillomaviridae and polyomaviridae.  In theory, 
an intermediate structure comprising an octahedron of trimers of pentamers[107] (Figure 
1-14a) is also accessible.  The caveat of these T=7d assemblies, however, is the subunit 
interactions do not occur in a uniform manner.  Figure 1-14b shows the tiling arrangement 
in the T=7d capsid, as seen for the simian virus 40.  The grey pentamer sits are the centre of 
the 5-fold axis of symmetry and interacts with five pentamers. However, each of those five 
pentamers interacts with a total of six pentamers with different orientations of 
interactions.  This unusual assembly arrangement is mediated by the scaffolding extensions 
which contribute the majority of the binding surface area.  Therefore if we are to design a 
larger capsid from pentagons, we must follow suit. 
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Figure 1-14:  Particle options for pentagonal tiling capsids.  a)  A dodecahedron pentamers, an octahedron of 
trimers of pentamers and super dodecahedron. Reprinted from
[107]
.  Copyright 2008, with permission from 
Elsevier.  b) Pentagon tiling arrangement for the super dodecahedron. Reprinted from
[105]
.  Copyright 1996, 
with permission from Elsevier. 
 
1.5.5  Structural polymorphism 
The capsids of almost all spherical viruses have icosahedral symmetry.  Assembly of capsids 
without the viral genome often leads to misassembly steps which result in aberrant capsid 
structures[98].  As discussed, dependent on the type of virus, capsid proteins can often bind 
in different orientations to the same subunit. This feature, combined with Brownian 
fluctuations, can give rise to non-target structures.  This point can be exemplified again 
with the SV40 virus: under non-physiological conditions, SV40 has been shown to assemble 
rapidly[108].  This phenomenon leads to a number of kinetic assembly traps producing 
particles of 22 nm icosahedra, spherical particles of 32-35 nm and even tubular 
structures[109]. 
 
The Handa group at the Tokyo Institute of Technology showed that SV40 assembled into a 
range of aberrant capsid structures under non-physiological conditions, 1 M NaCl and 2 
mM CaCl2 (pH 7.2) at room temperature
[108] (Figure 1-15).  This assembly is thought to be 
due to the high NaCl concentration which inhibits disassembly of the VP1 proteins.  
Furthermore, they found no evidence of any assembly occurring in the same conditions but 
using 150 mM NaCl. 
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Figure 1-15: SV40 assembly in 1 M NaCl, 2 mM CaCl2 (pH. 7.2) at room temperature. Tu are tubular structures, 
Ti are tiny particles, V are VLP, I are intermediate particles. Republished with permission of the Society for 
General Microbiology, from 
[108]
; permission conveyed through Copyright Clearance Center, Inc. 
The Zlotnick group at the Hebrew University-Hadassah Medical School, have recently 
shown that incubation of SV40 VP1 with differing sizes of DNA can bring about different 
capsid sizes[110]. This experiment highlights the role that scaffolding molecules play in virus 
capsid assembly.  The group assembled VP1 on both ssDNA at 3200 nucleotide and dsDNA 
2.4 kbp and 5.2 kbp (Figure 1-16).  Perhaps unsurprisingly they found larger particles 
assembled around scaffolds of larger DNA. 
 
Figure 1-16: SV40 VP1 assembled around different sizes of DNA scaffolds, as denoted. Reprinted with 
permission from
[110]
.  Copyright 2013 American Chemical Society. 
Finally, Nguyen and Brooks, from the University of Michigan, used simulations to 
demonstrate a number of T=7 capsid polymorphisms that can theoretically occur[111].  They 
show that from T=1-7 that the aberrant structures produced are larger than the target 
structure, however from T=7-19, the aberrant structures created are often smaller than the 
target structure.  Interestingly, T=7 capsids lie within both groups and thus should be able 
to form aberrant capsids that are either larger or smaller than the expected size. 
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Figure 1-17: Snapshots of the growth of T=7 capsids over time at a concentration of 43.5 µM and 308 K.  a) the 
target T=7 capsid.  b) At high concentrations a larger capsid can form containing 14 extra coat proteins.   c-e)  At 
lower concentrations, smaller aberrant capsids can form.  Structure c) is sometimes referred to as the 
‘intermediate’ structure containing octahedral symmetry. Reprinted with permission from
[111]
.  Copyright 2008 
American Chemical Society. 
1.6 Cholera Toxin 
1.6.1  Overview 
The starting point for the project design is the cholera toxin (CT) (Figure 1-18a), which is an 
AB5 protein toxin of around 85 kDa naturally expressed by Vibrio cholerae.  CT and the 
heat-labile enterotoxin (LT), from enterotoxigenic E. coli, cause cholera and ‘travellers’ 
diarrhoea’, respectively, which induce severe diarrhoea and vomiting, leading to a loss of 
up to 30 litres of fluid a day[112]. Both are rife within the developing world and cause over a 
billion cases of diarrhoea annually[112,113], and together with, the shiga toxin and pertussis 
toxin, form the AB5 protein toxin family which are responsible for over a million deaths 
annually[114]. 
1.6.2  Structure 
CT and LT share 83% sequence identity and consist of an extremely stable[115], 
homopentameric doughnut-shaped B-subunit (Figure 1-18c,d) with a toxic A-subunit 
tethered through its central hole (Figure 1-18b)[116,117]. The toxic component of the A-
subunit (CTA1) is a globular domain which is linked to the B-subunit pentamer via an α-
helical rod (CTA2) that is a non-toxic proteolytic fragment of the A-subunit[118]. The B-
subunit protomer (the monomeric unit) consists of a large α-helix (central, within the 
pentamer), and two adjoining anti-parallel β-sheets. These sheets twist in such a way as to 
make parallel β-sheet interactions in the centre of the molecule; however, they are almost 
perpendicular to each other at the edges of the protomer. 
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Figure 1-18:  Structures of cholera toxin (composite of PDB 1S5E and 3CHB), however all AB5 toxins have this 
same generic structure. a) The AB5 holotoxin, A-subunit in teal and green, B-subunits in red and GM1 
ganglioside in dark blue. b) The A-subunit, A1 in teal and A2 in green. c) The B-subunit pentamer, in red with 
GM1 in dark blue. d) A top down view of the B-subunit pentamer revealing its five-fold symmetry, pentagonal 
shape and GM1 binding sites, in dark blue. 
 
Two β-sheets from adjoining protomers bind in an anti-parallel fashion to form a virtually 
unbroken β-sheet core in a ring around the pentamer. Each protomer contributes residues 
to a carbohydrate binding site located distally to the A-subunit binding site and situated on 
the seam of the dimeric interaction of the protomers. This binding site recognises the GM1 
ganglioside, (Galβ3-GalNAcβ4(Neu5Acα3)Galβ4GlcβCeramide (Figure 1-19), which is found 
on the surface of intestinal epithelium cells[119]. The five binding sites on the toxin[120] have 
one of the highest affinities known for protein-carbohydrate interactions (Kd = 43 nM)
[121]. 
The porcine variant of LTB (pLTB) is also know to bind neolacto-(Galβ4GlcNAcβ-)terminated 
glycoconjugates and the human variant (hLTB) is known to bind blood group A type 2-
(GalNAcα3(Fucα2)Galβ4GlcNAcβ-)terminated glycoconjugates[122,123]. 
 
 
Figure 1-19:  Structure of the GM1 Ganglioside: GM1 is a pentasaccharide containing two galactose (blue), one 
N-acetylgalatosamine (green), one glucose (pink) and one sialic acid (red) residue. The ceramide lipid forms the 
linker attaching the oligosaccharide to the cell surface
[124]
.  Image obtained from Dr Bruce Turnbull, University 
of Leeds. 
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1.6.3  Expression and Secretion 
The CT gene cassette, ctxAB, is found on a virulence plasmid naturally occurring in Vibrio 
cholera as well as the CTXф phage of V. cholera, which is responsible for horizontal gene 
transfer of the cassette[125]. The genes for the A-subunit and B-subunit are found to overlap 
in a polycistronic gene where the Shine Dalgarno sequence for the B-subunit is located 
within the 3’ district of the CTA gene[126]. CTB has a propeptide leader sequence which 
targets CTB expression to the periplasm. In the periplasm the leader sequence is cleaved 
and a disulfide bond is formed between C9 and C86. Once correctly folded, the CTB 
protomers associate around the CTA2 C-terminal domain to form the holotoxin which is 
secreted. The secretion of CTB involves the type 2 secretion system (T2SS), a sophisticated 
piston driven mechanism seen in Figure 1-20[127]. The T2SS is a macromolecular complex 
which spans both the inner and outer membrane of the periplasm and is capable of 
secreting fully folded proteins. The T2SS contains a dodecameric hollow shaft which loads 
the CT holotoxin; a pseudopilus is then used to purge the complex. 
 
 
 
Figure 1-20:  Structure of the Type 2 Secretion System: Proposed mode of action of the T2SS, CT (yellow) binds 
to the pseudopilus tip (grey) while the secretin (blue) is closed or directly to secretin. Pseudopilus tip extension 
pushes the CT free from the complex, whereby CT dissociates from the pseudopilus tip. Reprinted by 
permission from Macmillan Publishers Ltd: Nat. Struct. Mol. Biol
[127]
 , copyright 2010. 
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1.6.4  Function 
Once secreted from the pathogen the peptide backbone between A1 and A2 chains is 
cleaved by host proteases in the case of LT, or secreted proteases in the case of CT, leaving 
only a disulfide bond between the A1- and A2-subunits[125]. Binding to GM1 at the cell 
surface stimulates receptor-mediated endocytosis of the AB5 toxin[128]. The toxins which 
have a KDEL or QDEL sequence at the C-terminus of CTA2, follow the retrograde 
translocation pathway through the Golgi to the Endoplasmic Reticulum (Figure 1-21). 
There, protein disulfide isomerise is thought to break the remaining disulfide bond 
between CTA1 and CTA2[118,129] and help shuttle CTA1 into the cytosol via the sec61p 
channel. 
Once CTA1 enters the cytosol it ADP-ribosylates adenylate cyclase, thus mediating 
constitutive activation of the enzyme. The resulting build-up in cAMP leads to an expulsion 
of salts and movement of water out of the cells into the intestinal lumen[130]. CT and LT 
thereby cause life-threatening diarrhoea. In the absence of the A-subunit, the B-subunit 
pentamer is not toxic; however, it continues to trigger receptor-mediated endocytosis and 
gains access to cell’s interior. 
 
Figure 1-21 The CTB subunit binds to cell surface GM1 gangliosides which trigger the endocytosis of the 
holotoxin. The C-terminal residues of the CTA subunit target the vesicle into the retrograde translocation 
pathway, through the Golgi to the endoplasmic reticulum. Here the disulfide bond between CTA1 and CTA2 is 
cleaved and CTA1 is shuttled into the cytoplasm where it binds to adenylate cyclase, thus mediating its 
constitutive activation. This leads to a build-up in cAMP and transport of salts out the cell, these ions are 
followed osmotically by water
[124]
.  Image obtained from Dr Bruce Turnbull, University of Leeds. 
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1.6.5  CTB as a Target for Bionanotechnology 
CT, CTB, LT and LTB are regularly expressed using Vibrio sp. 60, which is a non-pathogenic 
relative of V. cholera[131]. Co-expression of CTA and CTB has been found to give up to five-
fold increase in overall CTB production[132]. It is thought that the presence of the A-subunit 
facilitates the B-subunit association, reducing degradation (by reducing free protomer) and 
thereby increasing the relative expression of the B-subunit. As the protein is naturally 
secreted, the B-subunit pentamer or holotoxin is isolated from the media supernatant by 
filtration, affinity purification or precipitation. The benefit of this procedure is a relative 
lack of contaminating proteins; however, this advantage is countered by the substantial 
dilution of the protein in the media. Some groups report purification from the 
periplasm[133], but no groups have reported expression from the cytoplasm. 
Due to the abilities of these proteins to induce endocytosis and their high stability, they are 
uniquely positioned to make good oral carriers for transport of products around the 
body[134]. Furthermore, this high structural stability suggests that these proteins could 
harbour more mutations compared to the average protein without compromising its 
stability, making these proteins attractive design targets. The three most similar B-subunits 
of the AB5 family are CTB, LTB (83% sequence identity to CTB El Tor biotype 3)
[135], and 
CFXB, a cholera-like toxin found in Citrobacter freundii (73% sequence identity to the CTB El 
Tor biotype 3)[136].  Each of these proteins exist as several different strains, harbouring 
many different amino acid variations at the positions of the protomer structure. The full 
sequence of the CTB classical Biotype and some homologues are shown in Figure 1-22. 
 
Figure 1-22:  Cholera toxin B-subunit (CTB), heat labile enterotoxin (LTBh) and cholera-like toxin found in 
Citrobacter freundii (CFXB) of various strains. Full sequence for CTB classical biotype is shown in colours 
corresponding to each residues biophysical characteristic. Identical residues displayed as dots. Note subtle 
differences within species and larger changes between species. Figure produced with Bioedit. 
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Mutational studies have been carried out on CTB and LTB since the 1990s mapping the 
expression, transport, assembly, secretion and virulence conferred by the change[137-140]. 
Particular interest has been paid to the GM1 binding site as work has concentrated on 
developing therapeutic inhibitors to prevent holotoxin endocytosis, thus the positions 33, 
34, 35 and 88 have been thoroughly mapped. By combining the information from naturally 
occurring variants and human mutated constructs, a map of the proteins’ mutational space 
can be fashioned which shows the levels of malleability currently known to maintain 
features such as pentamerisation and holotoxin formation, etc. shown in Figure 1-23. 
 
Figure 1-23:  Mutational Space Map: The map shows the residue position down the left-hand side, and lists all 
possible amino acids adjacent to the position number (X = stop codon). The CTB El Tor biotype 3 residues are 
highlighted in dark grey. Light grey positions indicate deviations from this CTB sequence made by close 
sequence homologues (see figure 1.6). Coloured residues represent mutants described in the literature as able 
to secrete as holotoxin (green); able to form pentamers but not the holotoxin (orange); and as not leading to 
expression (red). The NPR, VGP and PAE are C-terminal extensions.
[137-140]
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1.7 Project Summary 
In this project, we aimed to construct a novel virus-like protein capsid to test the ability of 
current computational techniques to estimate changes in free energy of a PPI upon 
mutation as well as to create a useful therapeutic delivery device. The principles used in its 
design and validation will help lay the foundations for further rational protein design 
routines that are generically applicable.  As a secondary aim, the VLP constructed could be 
useful as a drug delivery vehicle or nano-particle scaffold for further augmentation.   
Cholera Toxin B-subunit (CTB) is a pentameric, pentagonal protein and, by its fivefold 
symmetry, can be used as a building block for a dodecahedron containing 12 pentamers or 
larger structures which comply with 3D pentagon tiling theory.  We aim to exploit the CTB 
property which mediates endocytosis at epithelial cell surfaces in our capsid structure.  CTB 
tapers naturally at an angle which would provide a large interaction surface for a capsid-
like assembly. Utilising this natural tapering to create a curved surface would also present 
the CTB GM1 ganglioside binding site on the outside of the particle, which should allow 
triggering of endocytosis, as found in the wild-type protein.   
In order to achieve this assembly process our CTB subunits were modified with C-terminal 
coiled-coil ‘scaffolding’ extensions (Figure 1-24) to bring about self-association. An in silico 
symmetrical docking protocol was developed to assess the most likely interaction face for 
our assembled subunits, based on which a list of interacting residues was constructed.  
These residues were used for an in silico saturation mutagenesis experiment to identify 
which mutations would contribute to binding of the subunits.  Hits from the computational 
process where expressed in vitro with the coiled-coil extensions and characterised for their 
ability to form higher order structures by size exclusion chromatography, dynamic light 
scattering and transmission electron microscopy. 
 
Figure 1-24:  Modified CTB with C-terminal coiled-coils (3-heptad).  a) Top-down view of CTB.  b) Side-on view of 
CTB revealing coiled-coils.  c) Bottom-up view of CTB.  Figure produced from modified pdb 3CHB.  
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2.1 Experimental 
2.1.1  Materials 
2.1.1.1 Instrumentation 
PCR reactions were conducted using a Techne Thermocycler TC-512.  Glassware, 
plasticware and media were sterilised in either a Prestige Medical bench-top autoclave or a 
LTE Touchclave-R autoclave.  Sterile environments were mediated with a Thermo Electron 
Corporation SAFE 2010 Class II laminar flow cabinet or a bench-top bunsen.  Incubation of 
mini-cultures, starter cultures and transformations were performed with a Stuart Orbital 
Incubator, petri dishes and digestions were incubated in a Binder BD23 incubator and scale-
up cultures were incubated in a Kuhner Climo-Shaker ISF1-X.  A Bio-Rad Geldoc XR was 
used for the UV visualisation of ethidium bromide-stained agarose gels and stained protein 
gels under white light.  Centrifugation of volumes up to 1.5 mL was conducted with a 
Heraeus Biofuge pico, volumes up to 50 mL with a Heraeus Multifuge 3 S-R and volumes up 
to 500 mL in a Beckman Coulter Avanti J-30I.  SDS-PAGE was performed in a Bio-Rad Mini 
Protean Apparatus.  Mass spectrometry was conducted with a Bruker HCT Ultra MS System 
with an Agilent 1200 Series Auto Sampler.  DSF experiments were performed with a Bio-
Rad CFX96 Real-Time PCR Detection System.  SEC was conducted on a GE healthcare ÄKTA 
FPLC system.  DLS was performed with a Malvern Zetasizer Nano ZS.  TEM was conducted 
on a Tecnai G2 Spirit electron microscope. 
2.1.1.2 General Materials 
General reagents were purchased from Sigma Aldrich, Fisher Scientific, VWR International, 
Roche Diagnostics, Generon, Merck Chemicals Ltd and MP Biomedicals Europe.  DNA 
Ladders were obtained from New England Biolabs and protein molecular weight markers 
were purchased from Fisher Scientific.  Protein gels were stained with Instant Blue (Triple 
Red Limited).  Antibiotic stock concentrations of 1000× were prepared from 100 mg/mL 
ampicillin supplied by Fisher Scientific. Pwo Polymerase, stored at 3 U/µL, was prepared by 
Dr Louise Kime.  All other DNA modifying enzymes were purchased from New England 
Biolabs.  The gel stain Sypro Orange (5000×) was obtained from Sigma Aldrich and used at a 
working concentration 10× in DSF experiments.  Ni Superflow Plus Resin and Ni-NTA resin 
was purchased from Generon and Qiagen respectively.  α-Lactose Agarose resin was 
supplied by Sigma-Aldrich, amylose-agarose from New England Biolabs and a Superose 6 
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10/300 GL SEC column was obtained from GE Healthcare. Sequencing reactions were 
carried out by GATC Biotech via ABI 3730xl Sanger sequencing.  
2.1.1.3 Buffers 
Pfu Buffer (10×):  200mM Tris-HCl (pH 8.8 at 25 °C), 100 mM (NH4)2SO4, 100 mM KCl, 1% 
(v/v) Triton X-100, 1 mg/ml BSA and 20 mM MgSO4. 
TAE Buffer (50×):  2 M Tris base, 5.71% (v/v) acetic acid, 0.5 M EDTA. 
SDS-PAGE Running Buffer (5×):  125 mM Tris-HCl, 960 mM Glycine, 0.5% (w/v) SDS 
SDS-PAGE Sample Buffer (2×):  100 mM Tris-HCl, 0.1% (w/v) Bromophenol Blue, 200 mM 
DTT, 20% (v/v) Glycerol, 4% (w/v) SDS 
Nickel Suspension Buffer:  100 mM Tris-HCl (pH 7.4 at 25  °C), 100 mM NaCl, 20 mM 
Imidazole 
Nickel Elution Buffer:  100 mM Tris-HCl (pH 7.4 at 25  °C), 100 mM NaCl, 500 mM Imidazole 
Lactose Suspension Buffer:  100 mM Tris-HCl (pH 7.4 at 25  °C), 100 mM NaCl 
Lactose Elution Buffer:  100 mM Tris-HCl (pH 7.4 at 25  °C), 100 mM NaCl, 300 mM Lactose 
Maltose Suspension Buffer:  100 mM Tris-HCl (pH 7.4 at 25  °C), 100 mM NaCl 
Maltose Elution Buffer:  100 mM Tris-HCl (pH 7.4 at 25  °C), 100 mM NaCl, 10 mM Maltose 
SEC Buffer:  100 mM Tris-HCl (pH 7.4 at 25  °C), 100 mM NaCl 
EB Buffer: 10 mM Tris-HCl, pH 8.5 
2.1.1.4 Nucleotide Synthesis 
Oligonucleotides from 18 to 95 nt were purchased from Integrated DNA Technologies.  
These included oligonucleotides for priming PCR reactions against DNA templates, for 
sequencing or for the de novo construction of the CTB gene, and its extensions, by 
assembly PCR. 
2.1.1.5 Heat Shock Competent Cell Strains 
Heat shock competent E. coli strains XL10 and TG1 were obtained from Stratagene and 
Lucigen respectively.  Incompetent DE3 expression stains BL21 Star*, BL21 Gold, C41 and 
C43 were provided by Dr Thomas Edwards, University of Leeds,  which all contained the 
pRARE2 plasmid.  The pRARE2 plasmid encodes the enhanced production of tRNA for a 
variety of underrepresented codons in E. coli, levelling the codon bias. 
2.1.2  General DNA Manipulation 
2.1.2.1 Starter Culture or Mini culture 
Mini-cultures were prepared by adding 5 mL of sterilised LB media to a 50 mL falcon tube 
containing 100 µg/mL ampicillin.  Either a single colony was picked from a petri dish, a 
glycerol stock scraping was added or 5µL of liquid culture was added to the falcon tube 
followed by agitation.  The culture was incubated for approximately 16 hours at 37 °C and 
200 rpm. 
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2.1.2.2 Isolation of Plasmid DNA 
Plasmid DNA was obtained from cells isolated from overnight mini-cultures pelleted via 
centrifugation for 10 minutes at 6000g.  DNA extraction was conducted by alkaline lysis 
using the Qiagen plasmid mini-preparation kit eluting with 50 μL of EB buffer. 
2.1.2.3 Polymerase Chain Reaction Amplification 
General PCR amplifications were performed with a final concentration of 1× Pfu Buffer, 0.6 
U Pwo Polymerase, 0.8 mM dNTP mix, approximately 10 ng of template DNA, 1 µM priming 
oligonucleotides and made to a final volume of 50 µL with water.  This mixture was 
constructed adding the polymerase last, and mixed well, just before initiation of the 
thermal cycling.  Table 2-1 describes a general PCR program.  As standard after each PCR, 
the mixture was purified using the Qiagen PCR clean-up kit. 
 
Cycle Process Time (s) Temperature (°C)°C) 
1 Initial denaturation 180 95 
30 denaturation 30 95 
- Annealing 30  Primer Tm -2 
- Elongation 60 per 500 bp 70 
1 Final Elongation 2.5× Elongation 70 
1 Hold - 4 
Table 2-1:  Standard PCR reaction.  This table shows the generalisations made to the method which most PCR 
reactions require. 
 
Assembly PCR – Also known as Polymerase Cycling Assembly, allows the construction of a 
large section of dsDNA from short overlapping ssDNA molecules.  This technique was used 
to construct a subset of mutant CTB genes.   As shown in Figure 2-1a, the gene is routinely 
constructed from up to eight internal segments in the presence of an excess of flanking 
primers.  PCR amplification leads to the production of the full length gene.  In some cases a 
second amplification is conducted using the product of the first PCR and the flanking 
primers to obtain large quantities of the full length gene. The exact same method used for 
the wild-type gene construction was used to construct the CTB mutants, however the wild-
type parts were substituted for mutant parts.  This technique led to a nomenclature based 
on the parts used to construct each gene.  CTB was constructed from six parts, whose wild-
type parts were labelled A, the wild-type can be written AAAAAA, however, the mutant 
exemplified in the Figure 2-1b, which contains mutant parts, can be written as IQVAGD.   
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Figure 2-1: Assembly PCR.  Short overlapping oligonucleotides, routinely altering between sense and anti-sense 
strands are assembled into one large section of DNA during a modified PCR program.  Typically the 
concentrations of the parts are quite low, however, terminal primers are in excess, thick arrows, and these 
terminal primers dominate the amplification once the parts have bridged the gap between them.  a) 
Construction of the wild-type gene by this technique.   b) Construction of mutant genes.  This technique allows 
multiple mutations to be made simultaneously and allows the construction of large potential libraries. 
 
An alternative wild-type part 4B contains silent mutations to allow binding of a 
amplification primer was frequently used to aid subcloning.  Example oligonucleotides for 
construction of the wild-type CTB gene are described in Table 2-2, mutant parts are 
available in the appendix. 
 
Part Sequence 
Part-1A-T CTGTTCAGGCGCATG 
Part-1A CTGTTCAGGCGCATGCAACTCCTCAAAATATTACTGATTTGTGCGCAGAATACCACAACAC 
Part-2A CTCTTTTTCCCGCTAGCGATTCTGTATACGAAAAGATCTTATCATTTAGCGTATATATTTGTGTGTTGTGGTATTCTGCG 
Part-3A GCTAGCGGGAAAAAGAGAGATGGCTATCATTACTTTTAAGAATGGTGCAATTTTTCAAGTAGAGGTACCAGGTAGTC 
Part-4A GCAATCCTCAGGGTATCCTTCATCCTTTCAATCGCTTTTTTTTGTGAATCTATATGTTGACTACCTGGTACCTCTACTTG 
Part-5A GATACCCTGAGGATTGCATATCTTACTGAAGCTAAAGTCGAAAAGTTATGTGTATGGAATAATAAA 
Part-6A CGAATTACCTGCAGGGAAAACTTAGTTTGCCATACTAATTGCGGCGATCGCATGAGGCGTTTTATTATTCCATACACATAA 
Part-6A-T CGAATTACCTGCAGGG 
Table 2-2:  Example of the overlapping oligonucleotides required to assemble the full length CTB gene using the 
Assembly PCR method. 
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Assembly PCR was performed with a final concentration of 1× Pfu Buffer, 0.6 U Pwo 
Polymerase, 0.8 mM dNTP mix, 1 µM terminal priming oligonucleotides, 10 nM 
oligonucleotide parts (one each of parts 1-6 or 1-8) and made to a final volume of 50 µL 
with water.  This mixture was prepared without polymerase, which was added shortly 
before initiation of the thermal cycling.  The CTB Assembly PCR program can be seen in 
Table 2-3.  As standard after each PCR, the mixture was purified using the Qiagen PCR 
clean-up kit. 
Cycle Process Time (s) Temperature (°C)°C) 
1 Initial denaturation 120 95 
30 denaturation 30 95 
- Annealing 30 47 
- Elongation 60 70 
1 Final Elongation 150 70 
1 Hold - 4 
Table 2-3:  Specific program for Assembly PCR of the CTB gene.  This program can be used for both six part and 
eight part assemblies and also for the second round amplification containing flanking primers. 
Assembly PCR was used to construct approximately half of the alanine scan mutants, the 
coiled-coil genes for MBP C-terminal extensions as well as all additional mutant CTB genes 
both with and without coiled-coils. 
Clonal Screening – The presence of the correct insert was confirmed by PCR screening 
using primers Part-1A-T and part-4B-T.  Part-4B-T is complimentary the sequence of Part-4B 
which is uniquely incorporated into assembly constructs. 
QuikChange Mutagenesis – Routine site-directed mutagenesis of constructs was carried 
out using the Stratagene QuikChange protocol with a pair of complimentary primers 
containing the desired mutation.  The PCR reactions generally described above were 
modified with a 14 min elongation time step.  Following thermal cycling 20 U of DpnI was 
used to digest the methylated template DNA as described for the digestion protocols.  
QuikChange mutagenesis was used to construct approximately half of the alanine scan 
mutant genes. 
2.1.2.4 Restriction Digest 
Basic Digest – Restriction digests of PCR products and inserts were routinely carried out as 
follows.  A 10 µL reaction mixture was prepared containing up to 1 µg of plasmid DNA, with 
1× of the appropriate NEB buffer and 5-10 U of each restriction enzyme.  Reactions were 
incubated at 37 °C for 1 h, after which samples were analysed 1% agarose.  Analytical 
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double digests were conducted by repeating the above for each single enzyme and 
constructing a double digest containing 5-10 U of both enzymes.  Digested samples were 
heat inactivated at 80 °C for 25 minutes or purified using the Qiagen PCR clean-up kit. 
Plasmid Digest for Ligation – Restriction digestion, to generate linear vectors, was 
conducted as for PCR inserts, however the reaction mixture was scaled to allow 5-10 U of 
endonuclease per µg plasmid DNA and 5-10 U of Antarctic phosphatase per µg plasmid 
DNA.  The digested samples were run on a 1% agarose gel.  The gel was visualised briefly 
and the linearised plasmid band was excised with a clean scalpel and purified with the 
Qiagen Gel Extraction Kit. 
2.1.2.5 Ligation 
Ligation mixtures of 10 µL were constructed with 50 ng of linear plasmid vector, a 1:3 molar 
ratio of vector to insert, 1× Ligase Buffer, 20 U of T4 DNA Ligase and made up to 10 µL with 
dH2O.  These reactions were incubated at room temperature for 30 minutes before storage 
at 4°C prior to transformation. 
2.1.2.6 Preparation of Heat shock competent cells 
Chemically competent E. coli strains were grown and prepared as follows.  100 mL of LB 
media was inoculated with 100 µL of starter cultures of the required cell type using 
chloramphenicol for strains containing the pRARE2 plasmid.  These cultures were incubated 
at 37 °C to a final OD600 of 0.3 – 0.4.  The cultures were immediately placed on ice.  The cells 
were isolated by centrifugation in a pre-cooled rotor at 6000g and 4 °C for 10 min and the 
supernatant was discarded.  The pellet was resuspended in 10 mL of cold, sterile 0.1 M 
CaCl2 and incubated for 10 min on ice before isolating the cells again at 6000g and 4 °C for 
10 mins.  The pellets were resuspended in 4 mL of cold 0.1 M CaCl2, 20% glycerol (v/v) and 
aliquoted into 100 µL fractions which were flash frozen in liquid N2 and stored at -80 °C. 
2.1.2.7 Transformations 
5 µL of freshly thawed commercial chemically competent E. coli XL10 cells, or 20 µL of cells 
prepared as described above, were added to pre-cooled micro-centrifuge tubes and held 
on ice.  1 µL of plasmid DNA or 2 µL of ligation mix was added to the cells and mixed.  The 
cells were incubated on ice for 10 min before being exposed to 42 °C for 45 s in a water 
bath.  The samples were then returned to ice for a further 10 min.  990 µL of LB media was 
added to the samples and the culture was incubated at 37 °C for 1 h.  100 µL of the culture 
was applied to and spread on an LB-agar petri dishes of appropriate antibiotic resistance.  
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The remaining culture was centrifuged at 13000g for 4 min and decanted to leave 100 µL of 
media, the pellet was then resuspended and the cells were spread on LB-agar plates using 
sterile glass beads. 
2.1.2.8 Glycerol Cell Stocks 
Stock solutions of cells were prepared from mini-cultures, 500 μL of the culture was added 
to 500 μL of 80% glycerol, mixed and flash frozen in liquid N2 before long term storage 
at -80 °C. 
2.1.2.9 Agarose Gel (1%) 
Small gel – 40 mL of TAE buffer was added to a 250 mL conical flask containing 400 mg of 
agarose which was then heated in a microwave until the agarose was fully dissolved.  The 
molten agarose was decanted into a 50 mL falcon tube and made up to 40 mL with TAE 
buffer.  This was held at 50 °C while the gel cast and comb were prepared.  1.5 μL of 
ethidium bromide was added to the agarose, which was then gently agitated and the 
agarose was poured into the cast.  The agarose gel was fully set within 20 min.  All DNA 
samples were prepared to give final loading buffer concentration of 1×.  10 µL of sample 
was loaded as default onto the gel.  Gels where run at 100 V  for 20 min as standard. 
Large gel – 200 mL of TAE buffer was added to a 500 mL conical flask containing 2 g of 
agarose which was then heated in a microwave until the agarose was fully dissolved.  This 
was held at 50 °C while the gel cast and comb were prepared.  7.5 μL of ethidium bromide 
was added directly to the gel cast and the agarose poured on top ensuring complete mixing 
of the ethidium bromide. The agarose gel was fully set within 40 min.  All DNA samples 
were prepared to give final loading buffer concentration of 1×.  10 µL of sample was loaded 
as default onto the gel.  Gels where run at 100 V  for 40 min as standard. 
2.1.2.10 Plasmid Gene Expression 
Starter cultures were prepared from glycerol cell stocks.  3 mL of a starter culture was 
added per 1 L of autoclaved LB media containing 100 µg/mL of an appropriate antibiotic.  
Incubation was conducted at 37 °C and 200 rpm for 2½ hours.  The optical density was then 
measured to reach 0.6-0.8 at λ600 nm.  Induction was initiated with the addition of a final 
concentration of 300 µM IPTG.  Incubation was then conducted at 30 °C and 200 rpm for 16 
hours.   
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2.1.2.11 Fractionation 
Overnight inductions were centrifuged at 10000g for 10 min, the pellet was discarded and 
the media supernatant was poured into a  2 L beaker per 1 L culture.  570 g of ammonium 
sulfate was added per 1 L initial culture.  The ammonium sulfate was added slowly to 
stirred media and then incubated at room temperature for at least 2 hours while stirred.  
The resultant precipitated media was then centrifuged at 17500g for 30 min to collect the 
pelleted protein.  The supernatant was discarded.  This pellet was resuspended in 75 mL 
suspension buffer per 1 L of initial culture.  These re-suspensions were transferred into 50 
mL falcon tubes and centrifuged at 6000g for 5 minutes, the supernatant was passed 
through a 0.5 µm vacuum filter and then stored at 4 °C 
2.1.2.12 Purification 
Gravity drip columns were assembled with an appropriate affinity resin and allowed to 
form a bed.  A syphon was assembled from a reservoir to the column.  5 column volumes of 
water was washed through the column, then 5 column volumes of suspension buffer.  The 
precipitant fraction was then applied to the column and the flow through was collected.  
The column was then washed with 5 column volumes of suspension buffer.  Elution was 
commenced with 5 column volumes of the appropriate elution buffer and fractions of 1-5 
mL were collected, dependent on the experiment.  This protocol was repeated with further 
samples or the column was washed with 5 column volumes of water, then 5 column 
volumes of 20% ethanol and stored in 20% ethanol at 4 °C.  The fractions collected had 
EDTA free protease inhibitor cocktails added and were stored at 4 °C or incubated at room 
temperature as part of an assembly experiment. 
2.1.2.13 SDS-PAGE (12%). 
Gel Preparation - Clean glass slides were set up to cast the gel.  A 15 mL, 12% resolving gel 
mix was constructed with 6.385 mL of dH2O, 3.80 mL of 1.5M Tris-HCl pH8.8, 4.5 mL of 40% 
acrylamide, 150 µL of 20% SDS, 150 µL of 20% APS and 15µL of TEMED.  This mixture was 
agitated and poured into the gel cast, a layer of isopropanol was applied and the gel was 
allowed to set for 10 min.  Excess isopropanol was removed and the gel was thoroughly 
washed by applying a stream of water to the top of the glass slides.  A 5 ml, 4% stacking gel 
mix was constructed with 3.325 mL of dH2O, 0.945 mL of 0.5M Tris-HCl pH6.8, 0.625 mL of 
40% Acrylamide, 50 µL of 20% SDS, 50 µL of 20% APS and 5 µL of TEMED.  This mixture was 
agitated and applied to the gel cast, a comb was added and the gel was allowed to set for 
20 min.  Gels were used immediately. 
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Gel Running – A 12% SDS-PAGE gel was assembled in the running assembly.  This assembly 
was filled with SDS-PAGE running buffer.  The protein samples were mixed 1:1 with sample 
buffer and heated to 95 °C for 10 min.  A protein molecular weight marker and each protein 
sample was applied to the gel.  As standard SDS-PAGE gels were subjected to 
electrophoresis at 180 V for 47 min.  Ran gels were saturated in Instant Blue for over one 
hour and destained overnight in water.  CTB is known to run as a pentamer on SDS-PAGE 
gels if the sample, when mixed with SDS-PAGE sample buffer, is not boiled.  For non-boiled 
CTB samples, mix with SDS-PAGE sample buffer at the last possible opportunity before 
running. 
2.1.3  Plasmid Construction 
A wide range of plasmid constructs for the expression of cholera toxin and its mutants were 
generated during this project.  Plasmid pSAB2.1 was used for the production MBP-AB5 
complexes and plasmid pSAB2.2 was used for all other CTB mutants including those with C-
terminal extensions.  These two plasmids were derived from the plasmid pSAB2.0 which 
contains the pMAL-p5x backbone and contains a synthetic gene construct, bought from 
Genscript, named SAB2.0.  The process is described below. 
2.1.3.1 Plasmids 
pMAL-p5x and pMAL-c5x – These plasmids were obtained from New England Biolabs and 
contain the MalE gene which expresses maltose binding protein, MBP, with a C-terminal 
polyasparagine linker region.  A MCS follows this linker allowing splicing of an additional 
gene which will translate as an MBP fusion protein.  A FactorX protease site sits just before 
the fusion, allowing cleavage of the product (Figure 2-2).  pMal-p5x contains a periplasmic 
leading sequence which targets translation into the periplasmic space via the SEC pathway.   
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Figure 2-2:  The MAL-p5x plasmid.  This plasmid contains the ampicillin resistance gene, AmpR (pale green), the 
maltose binding protein (MBP) gene, MalE (blue) and is under the control of the lac repressor system (purple).  
A multiple cloning site sits downstream from the MalE gene, which allows the splicing of genes for expressing 
fusion proteins of MBP.  This version of the pMAL plasmid translocated MBP expression to the periplasm.  
Figure produced with SnapGene. 
 
 
2.1.3.2 SAB2.0 Gene Construct in pUC57 
The SAB2.0 gene construct encoding CTA2 and CTB was purchased from Genscript in a 
pUC57 plasmid (Figure 2-3).  This construct was specifically designed to be spliced into the 
pMal-p5x vector to create the plasmid pSAB2.0 encoding MBP-tagged CTA2 and CTB.  This 
981nt section of DNA contains, from 5' to 3', a TEV cleavage domain, the CTA2 gene, the 
rrnb termination sequence, an additional tac promoter, ribosome binding site and finally 
the CTB gene primed with the LTIIb periplasmic leader sequence.  The CTB gene was 
designed to house a number of unique restriction sites throughout the gene to aid 
modification by restriction enzymes.  This gene was also designed to allow facile 
derivatisation into two additional plasmids, pSAB2.1 and pSAB2.2 
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Figure 2-3:  The SAB2.0 gene construct (digested from pUC57).  This gene contains a TEV cleavage domain 
(orange), the CTA2 gene (light blue), the rrnb termination sequence (red), an additional tac promoter (dark 
green) and RBS (light green) and finally the CTB gene (deep purple) primed with the LTIIb periplasmic leader 
sequence (light purple).  Figure produced with SnapGene. 
 
 
 
2.1.3.3 pSAB2.0 
pSAB2.0 should yield two products via individual mRNA, an MBP with a C-terminal fusion of 
the CTA2 protein and CTB.  Both gene products are targeted to the periplasm to facilitate 
the assembly of CTB pentamers around the MBP-CTA2 fusion to create a MBP-AB5 complex.  
pSAB2.0 was generated via subcloning of the BamHI-PstI fragment from pUC57-SAB2.0 into 
pMAL-p5x as shown in Figure 2-4. 
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Figure 2-4:  The pSAB2.0 plasmid.  This plasmid is created from splicing the SAB2.0 gene construct into the 
pMAL-p5× vector after digesting both parts with BamHI and PstI.  When induced the plasmid should express the 
MBP-CTA2 fusion protein (dark blue to light blue) containing a TEV cleavage site and CTB pentamers (purple), 
each on separate mRNA.   Figure produced with SnapGene. 
2.1.3.4 pSAB2.1 
pSAB2.1 encodes a polycistronic mRNA for the expression of both MBP-CTA2 and for CTB, 
generated by the digestion of pSAB2.0 with XhoI followed by re-ligation (Figure 2-5).  This 
digestion removes the additional terminator and promoter sequences between the MBP-
CTA2 and the CTB genes. 
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Figure 2-5: The pSAB2.1 plasmid.  This plasmid is derived from the pSAB2.0 plasmid via digestion with XhoI.  
When induced this plasmid should promote transcription of a polycistronic mRNA containing the MBP-CTA2 
(dark blue to light blue) fusion as well as CTB (purple).  Figure produced with SnapGene. 
2.1.3.5  pSAB2.2 
Alternatively, pSAB2.2 encoding CTB alone was generated in a digest of pSAB2.0 with MfeI 
and re-ligation (Figure 2-6).  This digestion removes the MBP gene (MalE), the CTA2 fusion 
protein as well as the additional terminator and promoter regions leaving the CTB gene 
downstream of the native tac promoter region of the pMAL-p5× plasmid.  On expression, 
this plasmid yields a single mRNA containing the CTB gene. 
 
Figure 2-6:  The pSAB2.2 plasmid.  This plasmid is derived from the pSAB2.0 plasmid via digestion with MfeI.  
When induced this plasmid should promote transcription of a mRNA containing the CTB gene (purple).  Figure 
produced with SnapGene. 
2.1.3.6 pSAB2.2, Backbone Plasmid for CTB mutations 
All site directed mutagenesis for the generation of alanine scan mutants was carried out on 
this plasmid.  The mutants created through site directed mutagenesis were D7A, A10G, 
Q16A, I17A, T19A, N21A, K23A, F25A, S26A, T28A, G33E, T41A, K43A, A46G, K81A, 
W88K, N89A and H94A, mutagenesis primer pairs are available in the appendix.  All 
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mutant CTB genes from assembly PCR, including the remaining alanine scan mutants and all 
interface design mutants, both with and without coiled-coil extensions, were spliced into 
this vector via SphI and PstI digests of the plasmid and PCR product, followed by ligation 
(Figure 2-7). 
 
 
Figure 2-7:   Introduction of mutant CTB genes into plasmid pSAB2.1.  The pSAB2.1 plasmid and the assembly 
PCR product are digested with SphI and PstI.  These are ligated together to form the pSAB2.1 plasmid 
containing the mutated gene.  Figure produced with SnapGene. 
 
For the addition of the C-terminal coiled-coils to CTB, eight parts were used instead of six.  
The general assembly PCR protocol used for assembling six parts was also used to assemble 
eight parts.  The parts required for the extensions are listed in Table 2-4. 
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Coiled-coil Part-7 Part-8 
coil-2 A A 
coil-7 E F 
DeCr-E O J 
DeCr-K P K 
SynTri N I 
Table 2-4:  Assembly PCR parts required for the addition of coiled-coils to the CTB C-terminus 
 
 
2.1.4  General Protein Manipulation 
2.1.4.1 Plasmid Gene Expression 
Starter cultures containing 100 µg/mL of the appropriate antibiotic in LB media were 
inoculated from glycerol cell stocks and incubated at 37 °C overnight.  The starter cultures 
were used to inoculate 1 L of LB media, with 100 µg/mL of appropriate antibiotic, 
contained in 2 L conical flasks (3 mL of starter culture/L of media).  The cultures were then 
incubated at 37 °C with shaking at 200 rpm until the optical density at 600 nm reached a 
value of 0.6-0.8 (typically 3 hours).  Protein expression was induced by the addition of IPTG 
(final concentration 300 µM) and the cultures were incubated for 16 hours (overnight) at 
30 °C and 300 rpm. 
2.1.4.2 Fractionation 
Cells were isolated by centrifugation at 10000g for 10 min and the cell pellet was discarded.  
Protein was isolated from the media supernatant by ammonium sulfate precipitation; 
ammonium sulfate (570 g per 1 L culture, 90% saturation at 0 °C) was added slowly to the 
stirred media before incubation with stirring for a further 2 h at room temperature.  The 
precipitated protein was isolated via centrifugation at 17500g for 30 min and the 
supernatant was discarded. The pellet was resuspended in 75 mL suspension buffer per 1 L 
of initial culture, before clarification via centrifugation at 3500g for 5 min.  The supernatant 
was filtered (0.5 µm vacuum filter) and stored, or immediately purified. 
2.1.4.3 Purification 
Protein was purified via affinity chromatography under gravity flow.  The affinity resin 
(lactose-agarose, Ni-NTA agarose or amylose-agarose) was packed under gravity and 
equilibrated with five column volumes of water followed by five column volumes of 
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suspension buffer.  The precipitant fraction was applied to the column.  The column was 
washed with five further column volumes of suspension buffer.  Protein was eluted using 
five column volumes of the appropriate elution buffer and collected in fractions of 1-5 mL.  
Following protein elution, the column was washed with five column volumes of water, 
followed by five column volumes of 20% ethanol before and storage in 20% ethanol at 4 °C.  
The protein containing fractions were pooled and had protease inhibitors added prior to 
storage at 4 °C. 
2.1.4.4 SDS-PAGE 
Gel Preparation – Protein identity and purity was routinely assessed by SDS-polyacrylamide 
electrophoresis using the tris-glycine buffer system.  Stacking and resolving gels were 
prepared as shown in Table 2-5.  This mixture was gently agitated and poured into the gel 
cast followed by a layer of isopropanol.  After polymerisation the isopropanol was removed 
using a stream of water.  Stacking gel mixture was then applied to the cast with a comb of 
choice and allowed to polymerise.  Routinely 12 resolving gels were used. 
Reagent Stacking   Resolving 
  5%   7% 10% 12% 15% 
H2O 3.325   8.260 7.135 6.385 5.260 
0.5M Tris pH6.8 0.945           
1.5M Tris pH8.8     3.800 3.800 3.800 3.800 
40% Acrylamide 0.625   2.625 3.750 4.500 5.625 
10% SDS  0.050   0.150 0.150 0.150 0.150 
10% APS 0.050   0.150 0.150 0.150 0.150 
TEMED 0.005   0.015 0.015 0.015 0.015 
total 5.000   15.000 15.000 15.000 15.000 
Table 2-5: Preparation of SDS-PAGE gels.  All values are in µL.  Routinely 12% gels were made.  TEMED was 
added last. 
Gel Running – Protein samples were prepared by mixing 1:1 with SDS-PAGE sample buffer 
and heating to 95 °C for 10 min.  SDS-PAGE gels were developed at using SDS-PAGE running 
buffer at 180 V for 47 min.  After development, protein was visualised using Instant Blue gel 
stain.   Monomers of CTB were obtained if the protein samples were boiled before loading.  
If the samples were prepared shortly before gel development and not boiled, pentamers of 
CTB were observed on the gel. 
2.1.4.5 Assembly of Virus-Like Particles. 
Assembly of VLP was conducted at a variety of CTB concentrations (often 2 mg/ml) via 
room temperature incubations over a variety of differing periods of time. 
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2.1.5  Biophysical Characterisation 
2.1.5.1 Mass Spectrometry 
2.1.5.1.1 Overview 
MS allows the measurement of the mass to charge ratio (m/z) for an ionised molecule.  The 
samples in this project were ionised by electrospray ionization which creates quasi-
molecular ions by the addition of protons to the sample.  As proteins are large molecules 
there are often many possible positions for protons to bind.  This causes a protein mass 
spectrum to give many charged states which can be deconvoluted to give the total mass. 
2.1.5.1.2 Method 
Protein samples were prepared by diluting in water or by mixing 1:1 with 30% methanol, 
1% formic acid, or alternatively were used neat.  10 µL samples were directly injected via 
the autosampling system and analysed by electrospray ionisation mass spectrometry.  Data 
processing was conducted by ESI Compass 1.3 DataAnalysis V4.0 software (Bruker 
Daltonik). 
 
2.1.5.2 Differential Scanning Fluorimetry 
2.1.5.2.1 Overview 
Differential scanning Fluorimetry (DSF) was used to determine the melting temperature 
(Tm) of protein samples.  In this assay the gel stain, Sypro Orange, is used as a fluorophore 
to detect the melting of the protein.  Binding of the dye to hydrophobic portions of the 
protein causes a change in the dye’s emission wavelength.  Protein samples were heated at 
a rate of 0.125 °C/s in a 96 well real-time PCR machine.  Each run takes approximately 17 
min; making DSF highly suitable to high-throughput investigations.  Differential scanning 
calorimetry, the gold standard for label free Tm measurements, measures the change in 
heat upon unfolding; but cannot observe more entropically driven protein transitions such 
as disassembly of complexes and is not suited to high-throughput investigations.  
Correspondingly DSF cannot be used to observe the unfolding of proteins which lack a 
pronounced hydrophobic core, such as calmodulin. 
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2.1.5.2.2 Method 
CTB Assay – Assays mixtures were prepared to a total volume of 25 µL containing up to 
22.5 µL purified CTB/mutant CTB and 2.5 µL 100× Sypro Orange (Sypro Orange is a gel stain 
supplied as a 5000× concentration, DSF uses a 10× final concentration).  These assay 
mixtures were prepared directly in a 96 well polystyrene PCR plate and sealed with an 
optically transparent adhesive seal.   
Thermocycling Program – Samples in the prepared plates were well mixed and any bubbles 
were removed by centrifugation before placing in the real-time PCR machine (Bio-Rad 
CFX96).  The following program was run.  Starting temperature of 25 °C, 75× cycles of 8 s, 
with 1 °C temperature increments per cycle.  This takes the temperature from 25 °C to 100 
°C over about 9 min.  The dyes excitation wavelength is 488 nm and the emission is read at 
570 nm. 
2.1.5.2.3 Analysis 
The data from the DSF experiments was obtained as the total fluorescence emission over 
each 1 °C increment.  The melting temperature (Tm) was calculated as the inflection point in 
this signal (Figure 2-8).  The numerical differentiation of the data yields a simple 
visualisation of the Tm as the peak maximum (Figure 2-8b).  In Figure 2-8a the fluorescence 
of the most concentrated sample becomes saturated, in this instance the steepest point of 
the curve has already been reached maintaining the Tm information.  Those data which 
became saturated before the inflection point is reached were discarded.  
 
Figure 2-8: Data processing from DSF.  a) The raw absorbance at 570 nm for each cycle.  b) The derivative of the 
raw data, where the peak maxima represents the steepest incline of the curve from the raw data, revealing the 
protein melting temperature. 
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2.1.5.3 Size Exclusion Chromatography 
2.1.5.3.1 Overview 
SEC was primarily used analytically in this project rather than as a method of purification.  
SEC separates proteins by their average hydrodynamic radius and can thus be used to 
determine the size of different species of proteins in complex mixtures.  The components 
of the sample are separated by size and shape by as they flow through a bed of beads.  The 
beads contain pores of differing sizes which either allow or exclude entry to particular parts 
of the beads interior.  Samples with a cross-sectional area which permits entry to a given 
channel have a greater volume of diffusible solvent to access than those which are 
excluded from the channel and thus are retained for longer within the matrix; larger 
particles suffer exclusion from this greater diffusible volume and thus elute more rapidly.  
Particles which are too large to gain access to any of the pores in the beads all have the 
same volume to diffuse through and thus elute together in the void volume of the column. 
2.1.5.3.2 Method 
Samples across a range of volumes and concentrations were applied to a Superose 6 
10/300 column and isocratically eluted at 0.35 mL/min using SEC buffer.  After 2 mL of 
elution, 300 µL fractions were collected in 96 well plates and their absorbance was 
measured at 280 nm.  The plates were sealed and stored at 4 °C. 
2.1.5.3.3 Analysis 
Peak sizes were quantified using Unicorn software (GE healthcare).  Peak baselines were 
often manually adjusted before numerical integration was performed to yield the peak 
area.  In the presentation of the data we often use the relative retention volume (rrv) 
rather than the retention volume in mL.  The rrv was normalised about a peak from a 
protein ubiquitously purified with CTB preparations.  Unlike mutant CTB peaks, this protein 
was present at consistent concentrations. 
2.1.5.4 Dynamic Light Scattering 
2.1.5.4.1 Overview 
DLS (or photon correlation spectroscopy) was used to calculate the hydrodynamic diameter 
of particles in a given solution.  Particles in an aqueous solution diffuse in accordance with 
3D Brownian motion and the scattering of monochromatic light (here 633 nm) through this 
liquid fluctuates in a time-dependent manner based on the particle’s diffusion constant as 
governed by Brownian motion.  This scattering undergoes constructive or deconstructive 
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interference from surrounding particles and this fluctuation in intensity yields information 
on the time-scale of diffusion of the particles.  The non-randomness of the fluctuation can 
be quantified using the autocorrelation function which can then be used to determine the 
diffusion coefficient for the particles in solution.  From this, the Stoke-Einstein equation can 
be applied to give the particle’s hydrodynamic diameter. 
 
 ( )  
  
    
 
Equation 1: The Stokes-Einstein equation.  d(H) is the hydrodynamic diameter, k is the Boltzmann constant, T is 
the temperature, ƞ is the viscosity and D is the translational diffusion coefficient. 
2.1.5.4.2 Method 
DLS experiments were conducted at 20 °C by measurement of the backscatter at 173° at a 
wavelength of 633 nm.  Protein samples of 100 µL, and of at least 0.5 mg/mL were 
prepared after filtration through a 0.45 µm syringe filter.  Each experimental reading was 
an average of ten independent 10 s measurements, three readings were taken per sample.  
Intensity values were transformed into volume and number percentages using the inbuilt 
function in the Malvern data processing software. 
2.1.5.5 Transmission Electron Microscopy 
2.1.5.5.1 Overview 
For transmission electron microscopy the sample of interest was applied to UV irradiated 
carbon coated grids; this UV irradiation applies a negative charge to the carbon making the 
surface hydrophilic.  The samples were then washed with a negative stain, here uranyl 
acetate, to provide contrast.  When visualised under the electron beam, the negative stain 
causes scattering of the electrons which are not detected on the CCD detector, thus areas 
heavy in stain appear dark.  As proteins stand pronounced from the surface of the carbon, 
the stain only collects around the edge of the protein.  Thus the protein scatters less 
electrons and appear light on a dark background. 
2.1.5.5.2 Method 
Carbon TEM grids were UV irradiated for 30 minutes and left to rest for 10 minutes.  8 µL of 
protein sample was applied to the grid which was incubated for 30 s before the droplet was 
blotted off.  The sample was left to air dry for 30 seconds before 8 µL of 1% uranyl acetate 
in H2O was added to the grid and blotted after 7 s.  This sample was left to air dry for 30 
seconds.  Grids were inserted in to the G2 Spirit and visualised under a number of 
magnifications. 
56 
 
 
2.1.5.5.3 Analysis 
TEM micrographs were analysed with the ‘Plot Profile’ function of the program ImageJ 
(Figure 2-9).  This function displays the average pixel intensity along a selected section of 
the image.  The total width of the selection within the profile plot gives the total pixels of 
this new selection.  By using this function with the scale bar a pixel per nanometre ratio is 
calculated with is then applied to measurements of particles within the micrograph. 
 
 
Figure 2-9:  Analysis of micrographs by ImageJ.  First the pixel per nm ration is determined, then this is applied 
to measurements of particles. 
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2.2  Computational 
2.2.1  Materials 
All computational work was carried out on a 64 bit Dell Precision WorkStation T7500 with 2 
× 6 core Intel® Xeon® CPU X5690, 32 GB RAM, Nvidia GeForce GTX 680 and 4 TB MegaRAID 
SAS 1078 running Ubuntu 12.04.3 
2.2.2  Methods 
2.2.2.1 Molecular Dynamic Simulation 
Molecular Dynamics (MD) is a simulation technique in which Newton’s laws of motion are 
solved numerically for a set of atoms, interacting through a given potential under specific 
conditions over time.  While in principle all the thermodynamic and kinetic properties of 
the system can be obtained from a trajectory (i.e., coordinates and velocities as a function 
of time) in practice this is only possible for simple, rapidly converging systems (e.g., small 
molecules in gas or liquid phase). Macromolecules of biological relevance cannot be fully 
characterised (e.g., folding and binding rates and equilibrium constants) by MD simulation. 
To reduce the complexity of all-atom simulations water can be considered “implicitly”, i.e., 
its effect on the protein, such as screening charges, are included by modifying the protein-
protein interaction potential. Coarse-graining of atomistic degrees of freedom is another 
strategy often used to reduce the complexity of the system. These simplifications allow 
long time course simulations to be run, which are required to sample large scale 
movements.  However with simplification come inaccuracies.  The best results still come 
from all-atom models in explicitly represented solvent under accurate electrostatic 
representations, this is however, infeasible for larger molecular systems, without the use of 
state-of-the-art machines[141]. 
2.2.2.1.1 Basic Algorithms 
The Chemistry at HARvard Molecular Mechanics package (CHARMM)[142] was used to 
conduct all molecular dynamic (MD) simulations.  Through the numerical solution of 
Newton’s equation of motion,            (  ), MD simulations calculate the 
trajectory of a set of atoms (i.e., coordinates, ri, and velocities, vi for each atom, i) at each 
time t.  Integration of the equations of motion can only be performed by discretising time. 
Many finite difference integrators are available; the Leap-Frog Verlet algorithm chosen 
here is accurate and stable with an integration timestep    of 2 fs when bonds to hydrogen 
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atoms are constrained.  The Leap-Frog Verlet, unlike some Verlet schemes, require 
velocities to be calculated, for biomolecular simulations velocities are useful for calculating 
kinetic energies as well as for temperature control.  However, as the name suggests, this 
algorithm leap-frogs position and velocity calculations, which are thus asynchronous. 
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2.2.2.1.2 The Empirical Energy Function 
For a force, F, and accelerations, a, to be calculated on the atomic positions, r, using 
Newton’s second law the potential energy function,  ( ), requires definition.  The 
potential energy function is defined by the sum of the bonded and non-bonded terms. 
                    ( )                       
The bonded term is described by the sum of bond stretching, angle bending and bond 
rotation (dihedrals and impropers) terms. 
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The        term describes covalent bond stretching, where b is the bond length, kb is the 
bond force constant and b0 is the equilibrium bond length.  The         term describes the 
bending of angle θ between three bonded atoms, with the angle force constant kθ and 
equilibrium bond angle θ0. The           term describes torsional steric clashes, where kφ is 
the dihedral force constant, n is a coefficient of symmetry, φ is the dihedral angle and δ is 
the phase shift. The final             term describes out of plane bending, or improper 
torsion which helps to maintain chirality, where kω is the force constant and ω and ω0 are 
the improper torsion and equilibrium improper torsion angles, respectively.  
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The non-bonded term of equation 4 includes van der Waals and electrostatic energy terms. 
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The Lennard-Jones 6-12 potential was used to estimate the van der Waals interaction 
energy governing both short range repulsive electron-electron interaction forces and 
longer range attractive forces from dipole fluctuations which give rise to the classic energy 
minima. The constants Aij and Bij are determined by the chemical types of the atoms. The 
Coulomb potential determines the electrostatic interaction energy where ϵ is the effective 
dielectric function for a given medium between two atoms with qi and qj charges. 
2.2.2.1.3 Langevin Thermostat 
Most experiments are carried out at a constant temperature, whereas the Verlet described 
above, based on Newton’s laws of motion, represents a microcanonical ensemble where 
the number of particles (N), the volume (V) and total energy (E) are kept constant, not the 
temperature.  All simulations run use Langevin dynamics to maintain the temperature (T), 
so called constant NVT ensemble rather than constant NVE with the addition of a friction 
coefficient .  Two additional forces are used to supplement the force derived from the 
force-field,          ( ), which mimic the effect of a heat bath.  These are          ( ), 
which is directly proportional to the particle velocity, and the        ( ), which introduces 
solvent effects. 
                 ( )           ( )           ( )         ( ) 
                  ( )     ( ( ))     ( )         ( ) 
The        ( ) term is uncorrelated with the velocity of particles and the forces acting 
upon them, obeying a Guassian distribution about zero. 
2.2.2.1.4 The EEF1 Implicit Solvent Model 
All atom simulations are time consuming due to simulation of the water molecules, MD 
performance is roughly proportional to the number of atoms in the system squared, thus 
removal of water atoms allows an improvement in efficiency of simulations.  The Effective 
Energy Function EEF1 is an implicit solvent model[143] which reduces the solvent to a 
continuum representation incorporating its dielectric constant and surface tension.  EEF1 
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assumes the total free-energy of solvation,       , is given by the sum of the solvation 
energies of external chemical groups such as amino acid side chains or carbonyl carbons 
etc..  
                        ∑   
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The term    
     can be further broken down, equation 12, where    
   
 describes the 
solvation free energy of a fully solvent exposed chemical group,     is the distance between 
the two groups, i and j,     gives the volume of the chemical group j in proximity with i and 
      describes a Gaussian function that estimates the solvation free energy density around 
group i.  
2.2.2.2 CHARMM MD runs 
We used the CHARMM19 force-field with the EEF1 implicit solvent.  Minimisations were 
conducted for 500 steps with the steepest descent to a local energy minima at 0 K.  The 
system was then heated to 300 K over 100 ps and simulations were routinely run for 40 ps 
with 2 fs time steps.  Coordinates and velocities were saved at intervals of 100 time-steps, 
200 fs.  The program VMD was used to extract PDB files from the trajectory.  Scripts are 
available on the accompanying DVD. 
2.2.2.3 FoldX 
FoldX is an algorithm which was originally proposed to estimate the free energy of folding 
of a protein given its native conformation.  FoldX contains a library of amino acid rotamers 
which it uses to sample the ∆Gstability (Equation 12) of different conformations and choose 
the most energy minimised protein structures.  Therefore FoldX can be used to suggest 
conformations and mutations that increase the stability of a protein or a complex.  These 
computed energies have been weighted to and validated from empirical protein 
engineering data.  FoldX has been used to rapidly compute the free energy of proteins[144] 
and used to make quantitative assessments of the energetic impact of mutations on 
protein and complex stability[145].  There is an online FoldX webserver which can be used 
without downloading the software [146].  A benefit of the FoldX program is the ability to use 
a batch file which allows not only simultaneous running of a number of commands but also 
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for these commands to be used on a number of starting models, making the assessment of 
ensembles trivial.   
                                                            
                                          
 
Where       is the sum of all van der Waals interactions with respect to the same 
interactions against the solvent.         and         are changes upon unfolding of the 
solvation energy differences for apolar and polar groups respectively.          is the intra-
molecular hydrogen bond free energy difference compared to intra-molecular hydrogen 
bond formation to the solvent.       is an additional stabilising free energy for  water 
molecules making more than one hydrogen bond to the protein that is not estimated with 
non-explicit solvent approximations.       is the charged group electrostatic contribution.  
     accounts for the entropy penalty for the fixed backbone in the folded state.       
accounts for the entropic penalty for fixing side-chains in a particular conformation.        
accounts for the effect of electrostatic interaction on association constant kon for subunit 
binding energies in complexes. 
The values for      ,         ,          and         which are attributed to each atom 
are derived from experimental data,       and      are theoretical estimates and all 
weighting factors (W) are 1 except for the vdw weighting factor which is 0.33.  The FoldX 
default conditions are 25 °C, pH 7, with a 50 mM ionic strength.  The components of the 
program used mostly here are described below. 
Stability – Measures the total ΔGstability (equation 12) of unfolding of the molecule 
compared with a hypothetical unfolded protein of the same sequences and gives a 
breakdown of various energetic properties. 
AnalyseComplex – Measures the ∆∆Ginteraction between two molecules.  The ∆Gstability of the 
whole complex is first calculated, then the ∆Gstability of the components of the complex.  The 
difference in the free energy of unfolding between the entire complex and the sum of its 
components is given as the ΔΔGinteraction in kcal/mol (Equation 13) 
                                                (                         ) 
 
Where C is the whole complex, A is one component of the complex and B is the rest of the 
complex.  
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Alascan – The FoldX alanine scan replaces each residue of a target structure sequentially 
with alanine and records the ∆Gstability. This figure is then compared to the wild-type residue 
to assess the change in structural integrity given the alanine mutation.  It should be noted 
that alanine is used to simulate the truncation of the residue’s side-chain, thereby 
assessing the impact that particular residue has on the rest of the structure.   The alanine 
scan applied by FoldX is very fast, and is achieved through the simple removal of the side 
chain.  There is no attempt made by FoldX to refine the structure based on the removal of 
the side chain.  This method was used on the initial wild-type structure of CTB and the 
results can be seen in Chapter 3. 
PositionScan – Performs a saturation mutagenesis investigation on selected positions in 
the protein sequence.  First the position is ‘mutated’ to the wild-type residue and then the 
surrounding residues sample rotamers to find the lowest ∆Gstability, this is used as the wild-
type reference.  The selected position is then mutated to each of the 20 amino acids 
sequentially by the same process and the proteins unfolding energy is calculated and 
compared to the wild type reference.  The difference is given as ΔΔGstability in kcal/mol 
(Equation 14) 
                                                             
 
BuildModel – Given a template sequence and structure, FoldX builds new structures 
containing mutations present on additional sequences.  During the construction process 
rotamers are sampled to find the lowest ∆Gstability. 
2.2.2.4 Pymol 
Used to build, view and manipulate pdb files.  It’s “align”, “sculpting” and “mutagenesis” 
functions were used extensively in rebuilding the mutant pentamers from monomers and 
applying new mutations. 
  
63 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
Assessing CTB Stability 
3 Chapter 3 – Assessing CTB Stability 
 
64 
 
3.1 Wild-Type CTB Expression and 
Characterisation 
3.1.1  Overview 
CT is expressed naturally in the Gram-negative bacterium Vibrio cholerae.  Expression of 
CTB in the Turnbull/Webb lab was originally performed with the plasmid pATA13, obtained 
from Prof Tim Hirst at the Australia National University, for expression in Vibrio sp.  60, a 
marine fish pathogen commonly used for expression of CTB and LTB[147].  Vibrio sp.  60 does 
not express a CT homologue; however it does possess the secretory mechanisms required 
for secretion of the toxin.  Whilst Vibrio sp.60 with the pATA13 plasmid expressed large 
quantities of CTB, the transformation of the Vibrio requires tripartite mating and the 
pATA13 plasmid was low copy number and quite large, 9kb, for site directed 
mutagenesis[148,149].  It was decided that transferring the gene into standardised laboratory 
strains of E.  coli in commercially available plasmids would lead to a more efficient cloning 
methodology. 
The structure of CTB (3CHB.pdb) contains an intra-monomer disulfide bond between the 
only two cysteine residues, C9 and C86.  Additionally two of the three prolines, P53 and 
P92 occur in the cis-conformer opposed to the more common trans-conformer[117].  The 
proteins responsible for controlling these modifications, disulphide bond isomerase (DsbC) 
and peptidyl-prolyl cis-trans-isomerase (PPIase), function in the periplasmic space of E.  coli 
[150,151].  Therefore, periplasmic targeting was deemed essential for our expression system.  
As a result of this decision, two fractionation regimes are possible, isolation of secreted 
protein from the culture media or recovery of the periplasmic fraction of cells, dependent 
on the secretion or retention of the protein, respectively. 
CTB is known to bind to nickel NTA columns due to the pentavalency of surface-exposed 
histadine residues H13 and to a degree H94[152].  It has been shown that purification by this 
technique yields intact pentamers as the monomeric species lack the appropriate affinity.  
CTB can also be purified by lactose affinity chromatography columns, by way of the GM1-
ganglioside binding site. 
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3.1.2  Expression Construct for E.  coli 
In order to provide a platform for reliable mutagenesis it was decided to move CTB 
expression from Vibrio sp.60 into E.  coli.  Transformation in E.  coli, in comparison to Vibrio 
sp.60, is robust and efficient, also the plethora of available strains and collected knowledge 
make E.  coli ideal for most routine protein expression.   
pMal-p5x is a plasmid vector which allows the fusion of a protein of choice to maltose 
binding protein (MBP).  MBP is frequently used to improve the solubility of recombinant 
proteins, however it is used here as a pseudo A-subunit as MBP has the same approximate 
size and globular nature as the toxic A-subunit.  Additionally the MBP molecule provides an 
additional high specificity purification tag for isolation of the MBP-AB5 complex.  The 
multiple cloning site (MCS) is located to the C-proximal side of a poly-asparagine linker 
section and a Factor-X cleavage site.  A 981nt section of DNA was designed (SAB2.0, 
obtained from Genscript) containing, from 5’ to 3’, a Tobacco Etch Virus protease (TEV) 
cleavage domain, the CTA2 gene (which links the A1-subunit to the B-subunit pentamer), 
the rrnb termination sequence, an additional tac promoter and ribosome binding site (RBS) 
and finally the CTB gene primed with the LTIIb periplasmic leader sequence[153].  This 
SAB2.0 section of DNA was cloned into pMAL p5x.  It also contained a number of restriction 
sites to allow future manipulation of this parent plasmid, pSAB2.0, to give the truncated 
variations pSAB2.1 and pSAB2.2 (as described in the methods).  The annotated sequences 
of each are available in the appendix (10.1.1 and 10.1.2).  Expression of pSAB2.0 should 
yield two products.  Firstly an MBP with a C-terminal fusion of the CTA2 protein, and 
secondly, CTB pentamers.  Both gene products are targeted to the periplasm.  With CTA2 
being present in the periplasm at the same time as CTB is expressed into the periplasm, it 
was hoped that CTB pentamers would associate with the MBP-CTA2 fusion to create the 
non-toxic complex MBP-AB5
[154]. 
CTB expressed without the MBP complex can be affinity purified via two techniques.  
Firstly, by the pentameric nature of the protein and two surface histidines, CTB pentamers 
bind nickel NTA columns to a similar affinity as his-tagged proteins allowing nickel affinity 
purification.  Furthermore, the native GM1 binding site which lies across the monomeric 
interfaces of the pentamer allow purification by lactose affinity. 
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3.1.2.1 Construction and Expression of pSAB2.0 
pSAB2.0 was prepared by ligation of the synthetic gene construct SAB2.0 into pMal-p5x 
after digests of both parts with BamHI and PstI.  This placed a TEV cleavage site directly 
after the FactorX cleavage site, included as ‘Turbo TEV’ was available in the laboratory.  The 
plasmid was designed to express two mRNAs producing the MBP-CTA2 fusion and CTB, 
respectively.  The rrnb terminator followed by the tac promoter was positioned between 
the MBP-CTA2 fusion and the CTB gene; however expression of this plasmid did not yield 
protein.  It is possible that by duplicating the promoting and termination sequences in the 
plasmid, homologous recombination could have occurred[155]. 
3.1.2.2 Construction and Expression in pSAB2.1 
Digestion of pSAB2.0 with XhoI allowed the removal of the additional terminator and 
promoter sequences between the MBP-CTA2 and the CTB genes, but maintained the 
second RBS.  This construct was designed to produce a polycistronic mRNA containing both 
genes, which would allow the co-expression of an MBP-CTA2 fusion protein with CTB.  Both 
proteins were directed to fold in the periplasm under control of the SEC translocon via the 
innate MalE periplasmic tag and the LTIIb periplasmic tag preceding the CTB gene[126].  
Expression of this plasmid followed by SDS PAGE analysis of the culture medium confirmed 
the presence of both MBP-CTA2 and CTB.  These proteins were extracted, purified and 
characterised. 
Initial screens for optimal expression conditions, cell type and expression time were 
performed revealing qualitatively higher yields for this construct in C43 cells expressed at 
30 °C for 16 hours.  The cells were pelleted by centrifugation and the clarified media was 
passed over an amylose column.  Elution with 10 mM maltose gave MBP and MBP-AB5 
complex (Figure 3-1).  These elutions were further purified by nickel affinity 
chromatography to isolate pure MBP-AB5 complex (Figure 3-1).  The MBP-AB5 complex 
migrates on SDS PAGE as the whole complex if the sample is not boiled prior to loading the 
gel, however if boiled for 10 minutes before running SDS PAGE, the proteins run as their 
constituent parts.  After amylose purification, there were few contaminating species of 
other proteins; however there did appear to be at least two distinct sizes of MBP.  This 
could be due to proteolysis of the CTA2 fusion from the MBP.  CTB monomers can be seen 
in the boiled samples; however CTB pentamers, as seen in the positive control, run at an 
analogous size to MBP and are indistinguishable in non-boiled samples.   Purification by 
amylose affinity chromatography retrieves only CTB pentamers which are associated with 
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the CTA2 fusion, thus in non-boiled samples most CTB pentamers run as the high weight 
MBP-AB5 complex.  In order remove the MBP molecules which are not bound to CTB, a 
nickel affinity column was run.  CTB pentamers readily bind nickel columns without a his-
tag, thus this technique was used to remove MBP molecules which were not associated 
with CTB.  From the flow through it is noticeable that both sizes of MBP bands are collected 
suggesting that the ratio of MBP to CTB is not optimal for complex formation and the MBP-
CTA2 fusion is in great excess.  However after elution from nickel purification which is 
selective for CTB only, the primary band in the non-boiled sample is that of the MBP-AB5 
complex and two minor bands which correspond to MBP-CTA2 and CTB pentamer, 
respectively.  Another important observation is the presence of a weak smudge in the 
nickel elution running from the MBP-AB5 complex down to the MBP and CTB pentamer 
bands.  This smudge is suggestive of disassembly during the course of SDS PAGE.  This 
disassembly may be due the presence of SDS in the gel and buffers, the increase in 
temperature of the gel during the run, or a combination of both.  In the boiled lane from 
the nickel elution there are only two bands seen, the MBP-CTA2 and CTB monomers. 
 
Figure 3-1: SDS-PAGE of the purifiedMBP-AB5 complex stained with coomassie blue.  The positive control (+) 
shows migration of WT-CTB both non-boiled (N) and boiled (B) prior to SDS PAGE.  MBP was targeted for 
purification with an amylose column: the wash (W) shows the majority of contaminants were washed from the 
column; eluent E1 is shown non-boiled and boiled.  The non-boiled lane shows the presence of a band at 
approximately 80-90 kDa which is not present in the boiled sample.  The boiled sample shows a band running at 
the same size as the WT-CTB monomers.  In both non-boiled and boiled samples two MBP variants are seen, 
presumably MBP and MBP-CTA2.  These eluents were combined and CTB was then targeted for purification 
with a nickel column: the flow-through (F) from this purification reveals large amounts of MBP.  The elutions 
from the nickel column (E) in the boiled lane show just two bands corresponding to MBP-CTA2 and CTB 
monomers, however in the non-boiled sample these can be seen complexed in the MBP-AB5 complex, as well as 
products of ‘on gel’ complex disassembly at the sizes corresponding to MBP and CTB pentamers. 
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3.1.2.3 Expression in pSAB2.2 
Digestion of plasmid pSAB2.0 with MfeI removed a section of DNA comprising everything 
from the MalE gene to the additional promoter and terminator regions.  The resulting 
plasmid (pSAB2.2) encoded only the CTB gene with the LTIIb periplasmic targeting 
sequence, sited directly after the original pMal promoter and RBS sequence (plasmid map 
available in the appendix (10.1.1.7).  During purification trials on pSAB2.1 it was found that 
application of the clarified media directly to nickel affinity columns caused stripping of the 
column by agents within the media.  This presented a problem for the purification of CTB 
uncomplexed with MBP-CTA2.  In order to overcome this problem, the protein component 
of the clarified media was precipitated with ammonium sulfate[156] over 2 hours at room 
temperature.  Centrifugation yielded a protein precipitate which, when re-suspended in 
PBS and purified by nickel affinity chromatography, gave CTB pentamers.  Further 
purification on a lactose affinity column, making use of the CTB GM1 binding site, removed 
impurities remaining after nickel purification.  It is worth noting the faint high weight band 
in the non-boiled lanes highlighted by the red arrows.  This is thought to be a dimeric 
interaction of two CTB pentamers as elucidated by tryptic MS in chapter 6. 
 
Figure 3-2: Purification of CTB.  Elution of the ammonium sulfate precipitation fraction after binding to a nickel 
column reveals purified CTB in both the non-boiled (N) and boiled (B) lanes, which migrate in a similar manner 
as the control WT-CTB (+).  When these elutions were applied to and eluted from a lactose affinity column, pure 
CTB was obtained.  Other minor impurities are highlighted with black arrows and the dimer of CTB pentamers 
with red arrows 
Despite the greater purity achieved though lactose purification, it was found that the 
process was rather inefficient, requiring three passes of the nickel eluent over the column 
to retrieve the same yields as from nickel affinity chromatography.  This step was not 
routinely used in the purification of further mutants as the ratio of contaminants to CTB 
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was minimal.  Towards the end of Chapter 6 a tryptic digest of these contaminants is 
performed. 
3.1.3  Assessment of CTB Thermostability 
In order to assess the stability of CTB and its mutants in a high throughput manner we 
turned to differential scanning fluorimetry (DSF).  In this technique, 1 °C increments in 
temperature are made every 8 seconds over a 25 °C to 100 °C temperature range and the 
emission from a fluorophore is measured.  Sypro Orange changes its emission wavelength 
upon binding hydrophobic moieties to 570 nm.  Thus upon protein unfolding, and the 
resultant exposure of the hydrophobic core, an increase in the 570 nm emission is 
detected.  Earlier experimentation by differential scanning calorimetry (DSC) identified CTB 
to have a Tm of 76.5 °C at pH 7.5
[157].  It is worth noting that DSC measures only the heat 
required to equilibrate the sample cell to the reference cell, and thus measures enthalpic 
changes but does not measure entropically based unfolding.  However DSF detects the 
exposure of hydrophobic residues, thus a slight discrepancy between the techniques is 
expected.   
3.1.3.1 Differential Scanning Fluorimetry of MBP, the MBP-AB5 complex 
and CTB 
The construct pSAB2.1 was used to express and purify the MBP-AB5 complex.  The protein 
analysed by DSF at a concentration of (0.3 mg/ml) 2.7 μM (Figure 3-3a).  As the MBP-CTA2 
and CTB5 were likely to melt at different temperatures, two distinct melting events were 
expected.  However, as seen in Figure 3-3a, only a melting peak at 58 °C is observed; this 
was attributed to the melting of MBP at 58 °C (discussed below).  Unusually, a trough was 
observed with a minimum at 80 °C which is not often seen in DSF experiments.  This 
experiment was conducted in parallel with CTB alone at a similar concentration of 5.2 μM 
(0.3 mg/ml) seen in Figure 3-3b.  This trace did not contain the melting curve observed with 
the MBP-AB5 complex but it did contain a small peak followed by a distinct trough as 
observed previously.  Thus, the 58 °C melting peak is attributable to MBP and the trough, 
attributable to CTB.  This trough is suggestive of a reduction in the fluorescence emission of 
Sypro Orange, which could arise from the dissociation of Sypro Orange from hydrophobic 
moieties.  This observation is counter intuitive as the peak at 65 °C seems insufficient to 
signal full denaturation of the protein at the concentration assayed.  In order to find an 
accurate CTB melting temperature a more rigorous DSF experiment was required. 
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Figure 3-3: Differential Scanning Fluorimetry (DSF) of MBP-AB5 and CTB.  a) shows the first differential of the 
570 nm emission of the MBP-AB5 DSF analysis.  The features of this trace are a peak at 58 °C and trough at 80 
°C.  Most proteins present a peak upon melting and thus the presence of the trough is unexpected.  b) The trace 
for CTB alone; displays only a trough at 78 °C, suggesting that the 58 °C peak is attributable to MBP, and 78-80 
°C trough to CTB.  A small peak is also present at approximately 65 °C which appears to extend beyond the 
noise of the system. 
 
A concentration gradient of MBP from 2 μM to 50 μM (0.2 to 5.5 mg/ml) was assayed by 
DSF to determine its melting temperature.  MBP has been analysed by DSC and a melting 
temperature of 63 °C was determined at pH 7.4[158].  As seen in Figure 3-4a, a melting 
temperature of 62 °C is consistantly achieved across all concentrations.  As the total protein 
content increases, an increase in total fluorescent emission is observed in line with DSF 
theory.  This melting temperature is within 4 °C of the melting temperature attributed to 
MBP from the MBP-AB5 complex DSF experiment (Figure 3-3a); the difference may be 
associated with a decrease in stability due to the addition of the CTA2 fusion. 
 
Figure 3-4: Further DSF of MBP and CTB.  a) DSF was conducted on increasing concentrations of MBP from 2 to 
50 µM.  A Tm of 62 °C was consistently achieved independent of concentration.  b) DSF was conducted on 
increasing concentrations of CTB from 10 to 250 µM.  A melting peak at 79 °C emerges, given increasing 
concentrations of CTB, from approximately 81 °C.  This emerging peak also makes a left hand shift (reduction) in 
Tm given increasing concentrations of CTB. 
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In order to address the CTB DSF trough issue seen in Figure 3-3b, a CTB concentration 
gradient was also assessed by DSF (Figure 3-4b).  With an increase in concentration of CTB 
from 10 to 250 μM (0.6 to 14.5 mg/ml) a melting peak is gradually seen to protrude from 
the right hand side of the trough.  As the peak intensity increases in a concentration 
dependent manner, there is a concomitant reduction in the apparent melting temperature.  
This observation is intriguing as it is unlikely that the melting temperature of the protein 
decreases with increasing concentration.  A possible explanation for this phenomenon 
would be that the emergence of the melting peak is in competition with the unexplained 
trough; thus, as the intensity of the melting peak increases the trough minimum is 
eventually out-competed.  An additional point of interest is the small peak at 65 °C which is 
barely noticeable above the noise of the original CTB DSF (Figure 3-3b); however, this peak 
is a consistent feature of the DSF data at all CTB concentrations.  Finally, it is worth noting 
that the trough peak minima at 5.17 μM is 78 °C and peak maxima for CTB at 200 and 250 
μM is 79 °C.  I propose that by some obfuscated biophysical process, presumably based on 
the pentameric, doughnut shaped structure of CTB (its dissociation and subsequent 
association with Sypro Orange), that the trough at 5.17 μM represents the CTB melting 
temperature.  However, all further CTB DSF melts were performed at concentrations which 
achieve standard melting curves. 
3.2 Choosing Mutable Surface Residues 
3.2.1  Overview 
In order to increase the rate of particle assembly, deleterious side chains may need to be 
removed and replaced with side chains with no net repulsion to the new interface, or with 
residues which promote the association of the putative PPI.  Creating this new PPI through 
mutations may allow the future removal the coiled coil scaffolding extensions.  Before 
rationally designing surface mutations to CTB it was necessary to determine the effect of 
arbitrary surface mutations at appropriate positions on the CTB pentameric structure.  A 
simple method for achieving this aim is to perform an ‘alanine scan’.  During an alanine 
scan, each mutably desirable position is substituted for an alanine residue.  The result is to 
truncate each side-chain back to Cβ or in the case of a glycine residue the addition of a Cβ.  
The removal of the specific interactions of the side-chain can help suggest the ‘reductive’ 
disruptive forces likely from mutating such a position.  Of course this method does not 
allow prediction of any ‘additive’ disruptive forces incurred from introducing any other 
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side-chain.  Figure 3-5 shows a selection of views of CTB with 30 chosen potential mutable 
positions highlighted in red.  These positions can be seen to encircle the circumference of 
the protein.  Additionally in Figure 3-5c green positions are highlighted for just one 
monomer.  These positions were chosen as they fall on the proposed tapered interaction 
surface, yet leave the GM1 binding site free from mutation.  Alanine scanning can be 
performed both computationally and experimentally.  Here we utilise both of these 
approaches and use the alanine scan as an opportunity to compare the computational 
methods to experimental results. 
 
Figure 3-5: Highlighted alanine scan positions of CTB.  Mutated residues are highlighted in red, for one 
monomer in green, non-mutated residues are highlighted in blue, GM1 oligosaccharides in pink.  a) A top down 
view of CTB, GM1 binding on the front-side of CTB.  b) A bottom up view of CTB, GM1 binding sites on the back-
side of CTB.  c) A side on view of CTB revealing the bottom face of CTB, mutable residues of a monomer.  The 
tapering of the CTB molecule is easily discernible in this figures as in a) there are few visible mutable residues 
however in b) all residues are visible.  Produced from pdb 3CHB. 
 
 
3.2.2  Computational Alanine Scanning 
Computational methods were used to deduce the change in free energy upon unfolding for 
the series of alanine mutants.  The pdb 3CHB.pdb was used as the starting model for the 
computational analysis.  The structure was subjected to a CHARMM minimisation and a 40 
ps molecular dynamics simulation.  A trajectory of this simulation was used to acquire 200 
conformations of the CTB molecule.  These 200 structures were fed into the FoldX program 
and the ‘alanine scan’ function was used to determine the ∆Gstability in kcal/mol, which 
measures the change in free energy between the folded structure and a hypothetical 
unfolded protein of the same sequence.  This ∆Gstability was then compared to the wt-CTB 
energy value to give a ∆∆Gstability in kcal/mol, which predicts the change in ∆Gstability upon 
mutation.  This process is discussed thoroughly in the methods section.  Figure 3-6 shows 
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the wild-type residue position along with the FoldX-derived ∆∆Gstability upon substitution to 
alanine.  These positions are also highlighted on one monomer of the CTB pentamer.  
Figure 3-6a displays a number of interesting values: I17A, G45A and T47A show relatively 
large destabilisations compared with the wild-type.  I17, despite being on the surface of 
the protein, contributes Cδ to a hydrophobic patch shielded from the solvent by Cγ1 and 2, 
which could explain the large destabilisation upon removal of these atoms and exposure of 
this hydrophobic patch.  G45A requires the addition of a side-chain Cβ atom, this would 
introduce a methyl group directly into the bulk solvent as well as create torsional 
constraints to the residue not experienced as glycine.  T47 contributes its Cγ methyl group 
to an inter-subunit interface hydrophobic patch and uses the oxygen at Oγ2 to form inter-
subunit water bridges.  Some surprising values are the relatively weak destabilising effect 
of the E83A substitution, which removed an inter-subunit salt bridge.  Figure 3-6b & c 
shows a ‘chainbow’ of the relative locations of the mutable positions on a monomer of the 
CTB structure.  These two figures also demonstrate that these residues span the breadth of 
the interaction surface and are also confined to only that surface.   
 
Figure 3-6: Computational alanine scan analysis.  a) displays the residue substituted, the position on the 
sequence and the ∆∆Gstability in kcal/mol upon alanine substitution.  The colours are comparable to those 
displayed in b) and c).  b) shows that the residues selected span the breadth of the interaction site with residues 
matching the colours in a).  c) shows an angle aligned to the proposed interface, which shows that the selected 
residues are clustered to the interface.  Also present in the pink surface is the GM1 oligosaccharide binding 
pocket, which has be deliberately excluded from the list of potential mutations.  Structures produced from pdb 
3CHB. 
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3.2.3  Experimental Alanine Scanning 
The alanine scan mutations were applied to the pSAB2.2 plasmid.  Each mutant was 
created either by site-directed mutagenesis or by assembly PCR.  Each of the 30 mutant 
constructs were expressed and the CTB was purified by nickel affinity and some by lactose 
affinity also as described earlier.  SDS-PAGE was conducted on boiled and non-boiled 
samples to verify the pentameric stability and finally a DSF thermostability assay was 
conducted on concentrated samples to find the change in Tm compared to the wild-type 
protein.   
3.2.3.1 Expression and Purification of Alanine Scan Mutants 
The majority of the alanine scan mutants expressed to produce viable pentamers as 
indicated by SDS PAGE of non-boiled samples (Figure 3-7).  An interesting observation is the 
comparative gel retardation of D22A and E83A due to the removal of a negative charge 
and the counter gel acceleration of the K22A due to the removal of a positively charged 
residue.  I47T is naturally occurring variant of the El Tor biotype of CTB, thus it expressed 
to a yield comparable to the wild-type (classical) CTB, in this figure this can be used to 
assess the resultant decrease in expression due to the alanine substitution.  Two positions, 
I17A and G45A did not produce pentamers which endure SDS-PAGE.  However, at the dye 
front of the I17A there is an indication that the monomer is present.  As discussed 
previously, it is thought that nickel affinity purification is only able to purify pentamers of 
CTB as the monomers lack the multi-valency required for strong binding.  Thus, the lack of 
pentamers on the gel hints to reduced overall pentameric stability for the mutant, rather 
than these actually consisting of monomers in solution.  A band for monomers is absent 
from the G45A mutant, suggesting that this mutant form CTB pentamers.  Reassuringly 
these two mutants, I17A and G45A, were highlighted to have large destabilising 
∆∆Gstability’s by the FoldX alanine scan.  Where the native residue is an alanine, a substitution 
to glycine is performed. 
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Figure 3-7: SDS-PAGE of the alanine scan mutants stained with coomassie blue.  Each alanine scan mutant was 
run non-boiled on SDS-PAGE.  Electrophoretic migration deviations were observed in mutants which remove 
either positively or negatively charged residues.  a) shows a selection of mutants after nickel purification, 
various contaminants are observable.  Of interest is G33D, not technically an alanine scan mutant, but a 
mutation which prevents GM1 binding at the associated site.  This mutant appears to preferentially form the 
dimer of pentamers discussed earlier.  Additionally of interest are I17A and G45A which do not seem to produce 
quantities of CTB pentamers discernible on the gel.  b) Shows a selection of mutants purified by lactose affinity 
after the nickel affinity purification.  The samples appear clean with the major band as pentamers, some 
monomers present in each sample and some mutants maintaining the dimer of pentamers, while some mutants 
lose this complex. 
 
 
3.2.3.2 Thermostability Characterisation by DSF of Alanine Scan Mutants 
Each protein was concentrated from a 15 ml elution to 1 ml.  As the total expression of 
each protein was variable it was sometimes not possible to reach the standard protein 
concentration, thus protein concentrations submitted to DSF ranged from 1.2 mg/ml to 3.8 
mg/ml.  A concentration gradient of each mutant was analysed to assess any changes in the   
total signal (Δf/Δt) from the DSF output..  A selection of DSF traces are shown in Figure 3-8 
as representations of the results obtained, all DSF curves are available in the appendix.  As 
seen above in Figure 3-7a, an unboiled sample of I17A does not maintain its pentameric 
structure on SDS-PAGE, however, a monomer band was seen at the dye front.  DSF of this 
mutant, Figure 3-8a, revealed a Tm of 61 °C confirming the presence of protein and that it 
had been destabilised.  However, DSF of the G45A mutant, Figure 3-8d, revealed no 
melting curve.  This trace is useful to show the levels of underlying signal cause by 
contaminants remaining from the nickel affinity purification; at ~25 kDa and 66 kDa in the 
Figure 3-7a.  These contaminants are not at concentrations required to compete with 
signals attributable to CTB.  The DSF of mutant F25A seen in Figure 3-8c shows a left hand 
shift in Tm as the concentration of CTB increases, which is in line with the DSF data shown 
for the wild-type CTB. 
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Figure 3-8: Example DSF traces of alanine scan mutants.  a) shows DSF of I17A which has a relatively low Tm 
and weak signal intensity resulting from a low level of protein expression.  b) a DSF trace of F25A shows a Tm 
that deceases with increasing concentration, as discussed in the main text this is presumably due to 
competition with the trough typical for low concentrations of CTB.  c) shows a representative trace from the 
majority of the other DSF traces, in this case T28A.  d) shows the DSF trace for G45A: no melting peak is 
observable suggesting a lack of a major protein species in the sample. 
 
The majority of the DSF traces do not show this left hand movement of the Tm with 
increasing concentrations.  Some traces show an initial lowering of the Tm with increasing 
protein concentrations, , however, the Tm then becomes constant at higher protein 
concentrations.  Additionally, this phenomenon seems to be independent of a 
concentration threshold as both fixed Tm and shifting Tm are observed among preparations 
of both, comparatively, high and low protein concentrations.  Of interest, the locations of 
mutations which do cause this left hand shift are clustered to a specific location on the CTB 
pentamer shown in purple in Figure 3-9.  This observation shall not be expanded on here, 
but perhaps points to the occurrence of an interesting kinetic event in that area of the 
protein. 
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Figure 3-9: Location of mutations which cause a reduction in Tm with increasing concentrations, by DSF.  Alanine 
scan mutations are highlighted in red against the blue of the un-mutated protein.  Green residues highlight the 
mutable resides present in a single monomer.  The purple residues show the location of residues which present 
a reduction in Tm by DSF upon increasing protein concentration.  Produced from pdb 3CHB. 
 
 
Figure 3-10 shows the combined DSF data across the alanine scan carried out in replicates 
of eight.  As can be seen, the majority of the alanine scan mutants do not perturb the Tm of 
CTB by more than 5 °C.  However the yield of some mutants allowed no reliable Tm could be 
determined, e.g. T41A (low signal), and G45A.  Others mutants showed concerning levels 
of thermostability such N4A, I17A and K84A, which suggests these positions may not be 
suitable for mutation.  This screen makes suggestions as to the structural significance of 
each residue and will inform future mutational propositions. 
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Figure 3-10: The total DSF derived Tm across alanine scan mutants.  Each alanine Scan mutant’s Tm assessed by 
DSF is presented here.  It should be noted that data for E83A is not available.  Most alanine scan mutants 
reduce the Tm of the pentamer to approximately 75 °C and others seem to cause more drastic reductions in Tm.  
This suggests that making mutations at position 17, 41, 45 and 84 would produce structurally deleterious 
effects to the protein. 
 
3.2.4  Comparison of Computational and Experimental 
Alanine Scanning 
The FoldX ‘alanine scan’ function was used to predict a ∆∆Gstability upon mutation compared 
to the wild-type CTB.  The predictions were compared directly to the Tm determined from 
the DSF experiments.  It should be noted that this comparison is rather superficial as the 
thermostability of protein and the free energy change from folded to unfolded protein 
have a convoluted physical relationship.  However, there does seem to be a degree of 
correlation between the computational and experimental values.  Figure 3-11 shows a 
scatter graph of the ∆∆Gstability compared to the Tm derived from DSF and a bar chart 
presenting the same data (note that the sign on the ∆∆Gstability value has been inverted for 
ease of comparison).  The scatter graph (Figure 3-11a) suggests a degree of trending in the 
data.  Figure 3-11b shows a bar chart of the DSF-derived Tm compared to the FoldX derived 
∆∆Gstability in kcal/mol.  The axis of the ∆∆Gstability values were set so that 0 kcal/mol aligns 
with a Tm of 80 °C to represent the relative wild-type data.  This depiction of the data 
emphasises which mutations have a Tm that is reduced in accordance with the predicted 
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loss in ∆Gstability predicted by FoldX.  Obviously these data do not correlate exactly but it 
should be expected that high speed computational assessment such as the FoldX ‘alanine 
scan’ function will have difficulty matching experimental data confidently.  Nevertheless 
the majority of the data agrees well.  It should be noted that protein was not obtained from 
the  G45A mutant and G45A has the lowest ∆∆Gstability among those assessed.  Additionally 
Tm data for E83A was not available.  The destabilisation of T19A and I47A substitutions 
were overestimated by FoldX and the estimations for T6A, Y18A, F25A, S26A, K81A, 
K84A and H94A were underestimated.   
 
 
Figure 3-11: Comparison of computational and experimental stability assessments.  a) A scatter graph of the 
DSF derived Tm against the FoldX ‘alanine scan’ derived ∆∆Gstability in kcal/mol.  b) The same data compared by 
way of a bar chart.  The ∆∆Gstability of 0 kcal/mol is aligned to a Tm of 80 °C, to represent the wild-type data; the 
∆∆G axis was then manipulated to best agree with the DSF Tm.  White space and overlaps represent areas of 
disagreement between the data sets, however, most of the data between the sets agrees well. 
 
3.3 Concluding Remarks 
A synthetic gene construct was obtained from Genscript and spliced into the plasmid pMAL 
p5x.  This new plasmid pSAB2.0 allowed the production of two derivative plasmids pSAB2.1 
and pSAB2.2, which allowed the expression of the MBP-AB5 complex or CTB respectively.  
Expression and purification procedures for both of these products were developed to yield 
a pure protein product.  The MBP-AB5 complex and CTB were assayed by DSF in order to 
determine melting temperatures for the protein.  Although this process required a large 
degree of refinement for CTB, reliable melting temperatures were achieved when 
concentrations of CTB above 100 µM were assessed. 
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Residues were chosen which lay on the side of the CTB pentamer, where we propose our 
interaction to take place.  These residues were chosen to cover the breadth of the side face 
of the protein and used amino acids whose side-chains interacted with the solvent.  These 
chosen residues were substituted for alanine residues by either site-directed mutagenesis 
or through assembly PCR of a new CTB gene.  The alanine scan mutants were then 
expressed, purified and unboiled samples were visualised by SDS PAGE.  The majority of the 
mutants maintained pentameric stability on the gel, however, some were found not to 
express, e.g. G45A, and others dissociated into monomers on the gel, e.g. I17A.   Each of 
the mutants was then assessed by DSF and their Tm was elucidated. 
A computational alanine scan was performed on a group of CTB conformation retrieved 
from a CHARMM molecular dynamics simulation on the 3CHB.pdb structure.  These 
conformations were assessed by the FoldX function ‘alanine scan’ which, when compared 
to the wild-type, gave a ∆∆Gstability in kcal/mol for the mutant protein compared to the 
stability of the wild-type.  On comparison of the experimentally derived Tm for the alanine 
scan mutants with the ∆∆Gstability produced by FoldX, a reasonable correlation in the data 
was observed.  It should be considered that FoldX has no resource for determining the 
likelihood of the sequence to fold into the correct conformation and can consider only the 
stability of the structure submitted to it.  Based on these constraints to the direct 
comparison of computational data to experimental data, we concluded that the observed 
agreement is satisfactory for future use. 
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Chapter 4 
Intrinsic Scaffolds 
4 Chapter 4 - Intrinsic Scaffolds 
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4.1 CTB with C-terminal Coiled-Coil Peptides 
4.1.1 Overview 
As described in the project summary, the C-termini of the CTB pentamers are extended 
with coiled-coil fusions.  The display of these oligomerisation sites at the correct geometry 
should allow construction of an enclosed particle.  A number of design considerations are 
highlighted here.  Due to the tapering of the CTB pentamers and the location of the C-
terminal coiled-coils (Figure 4-1), it should be more energetically favourable for the coiled-
coils to be housed on the interior of the capsid.  Therefore the GM1 binding sites should be 
displayed on the exterior of the particle.  A particle scaffolded on its interior requires that 
the total cross-sectional area of the scaffold is less than the total surface area of a sphere 
with a diameter corresponding to the distal end of the coiled-coil projection to ensure that 
steric clashes do not occur between the coiled-coils.  Thus, using coiled-coils of three 
heptads or more precludes the formation of a dodecahedron and forces the geometry of 
the particle into a more expanded structure.  In order to create a more geometrically 
complex, expanded particle, the association between pentamers must be somewhat 
promiscuous as the interfaces cannot bind to one another in only one conformation as 
seen with a dodecahedron.  This point requires consideration for both the scaffold and for 
the CTB interface.  Finally, the association of the particle by way of homomeric scaffolding 
requires ‘inter-pentamer’ interactions to be more energetically favourable than ‘intra-
pentamer’ interactions between coiled-coils. 
 
4.1.2 GM1 binding site presentation. 
The location of the C-terminus of the CTB monomer is on the face opposite to the GM1 
binding site (Figure 4-1a).  The edge length of the GM1 binding face measures 37.5 Å, 
measuring between H13-Cβ, whereas the edge length of the C-terminus face measures 31.9 
Å, measuring between N44-Cα.  This makes the proposed interaction face tapered with 
respect to the top and bottom face of the pentamer (Figure 4-1b).  This tapering, given the 
orientation shown in Figure 4-1c/e, brings the C-termini into close proximity such that 
protruding coiled-coils can be designed to interact in an inter-pentamer arrangement 
among the entire length of the coiled-coil.  In contrast, the CTB orientation shown in Figure 
4-1d/f would require either a flexible linker region or a portion of unbound coiled-coil to 
bridge the distance between the C-termini of the interacting pentamers.  As any 
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homomeric scaffolded assembly would be required to compete with intra-pentamer 
associations of the extensions; the former orientation provides a thermodynamic 
advantage to assembly compared to the latter.  Thus, the orientation of the assembly 
formed should be controlled thermodynamically using coiled-coils of a reduced length. 
 
Figure 4-1:  The C-terminus and CTB tapering.  The location of the C-terminus of CTB should make coiled-coil 
fusions favourable for constructing enclosed particles.  a) The side profile of CTB with the GM1 binding site 
located at the top and the C-terminal residue highlighted in red.  b) The CTB pentamer with native tapering of 
the molecule highlighted by a wire frame.  c) and e) The proximity of the C-termini given an orientation of CTB 
pentamers that would lead to an enclosed particle presenting the GM1 binding face on the exterior.  d) and f) 
The proximity of the C-termini given an orientation of CTB pentamers that would lead to an enclosed particle 
presenting the GM1 binding face on the interior.  Produced from pdb 3CHB. 
 
4.1.3 An Expanded Dodecahedron 
The addition of coiled-coils with lengths of three or more heptads should preclude the 
formation of the dodecahedron platonic solid (Figure 4-2a) as the internal space of this 
dodecahedron is insufficient to contain the volume occupied by the 60 extensions (Figure 
4-2b).  However, increasing the diameter of the capsid will in turn increase the internal 
volume relative to the volume occupied by the coiled-coils.  A more precise interpretation 
of this theory is that the dihedral angle between pentagons in a dodecahedron is 116.56°, 
by expanding the capsid this dihedral angle increases.  Steric clashes between neighbouring 
coiled-coils is dependent on both the extensions’ length and the particle’s dihedral angle: 
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increasing this angle towards 180° (where infinite extension length would result) eases the 
likelihood for a clash to occur.  Larger capsids will have a greater number of extensions but 
also a greater dihedral angle in order to accommodate the extensions where smaller 
capsids would not.   
 
Figure 4-2:  Pentagon tiling and virus subunit assembly.  a) A proposed dodecahedron of CTB pentamers.  b) The 
interior of a CTB dodecahedron scaffolded with coiled-coils of three heptads in length: only 2/5 of the coils are 
present in this image, which exemplifies the steric clashes of the particle interior.  a) and b) produced from pdb 
3CHB.  c) A pentagon.  d) Tiling arrangement of six pentagons to give one large pentagon, ‘super pentagon’ with 
triangular gaps.  e) The super pentagon arranged in a distorted dodecahedron with T=7d symmetry, giving a 
super dodecahedron.  f) A biological example, Polyomaviridae, which assembles 360 subunits (72 pentamers) 
into to a capsid with T=7d symmetry.  Image modified from ViralZone
[159]
, by permission of Oxford University 
Press.  g) A dodecahedron, an intermediate, octahedral-based symmetrical particle and the T=7d expanded 
capsid.  Reprinted from
[109]
. Copyright 1989, with permission from Elsevier  h)  A schematic representing the five 
different interactions required between subunits in the T-7d expanded capsid, based on a figure from 
[105]
. 
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What options are available for larger capsids to be made from pentagonal subunits?  Figure 
4-2c-e shows steps in the assembly of a pentagonal building block by arranging five 
pentagons around a central pentagon, a super pentagon.  This super pentagon is similar to 
a flattened hemi-dodecahedron, Figure 4-2d, where the dihedral angle of this association is 
greater than 116.56° and gaps are formed between the peripheral pentagons.   The 
dihedral angle is increased to the point where the external interaction faces of the 
peripheral pentamers become parallel, in a hyperbolic plane, with the external face of the 
neighbouring peripheral pentamers, creating a single large, yet curved, pentagon made 
from six smaller pentagons.  This can then assemble into an expanded dodecahedron 
(Figure 4-2e) which possess T=7d symmetry.  An intermediate sized particle of octahedral 
symmetry is also accessible for construction from pentagonal subunits (Figure 4-2g).  
Interesting biological examples of viruses with T=7d symmetry are the polyomaviridae and 
papillomaviridae families, which are both dsDNA viruses with capsids of 45 and ~54 nm 
diameter, respectively.  As discussed in the introduction, these viral families have been 
observed to have a dynamic nature of protein-protein interactions in capsid assembly, 
more so when manipulated in the laboratory.  
The interfaces of the T=7d capsid do not associate in just one arrangement.  In order to 
create a more complex, expanded particle, the association between pentamers must be 
somewhat promiscuous, specifically pentagamous (a marriage of five!), where five different 
conformations of the interface are possible (Figure 4-2h).  This is exemplified in the 
structure of Simian virus 40[105] (Figure 4-3).  These interfaces are determined by a donor 
strand exchange scaffolding structure, positioning the globular units in differing interface 
orientations.  However, the globular subunits must not interact repulsively across any of 
these interfaces.  The 5-fold axis pentamer interacts with its periphery pentamers via a 3-
way domain swap, and an identical globular interface.  The intra-super-pentagon 
interaction of the peripheral pentamers use the same 3-way donor strand exchange, but 
the globular interface deviates from the 5-fold interface in such a way that a triangular gap 
is formed between them.  Peripheral pentamers interact inter-super-pentamer in a further 
three ways, about the 2-fold axis, the 3-fold axis and an additional interface.  Each of these 
interactions are defined by 2-way donor strand exchanges and each requires a different PPI 
for the globular subunit.  This diversity in binding conformations is highlighted in Figure 
4-3b which shows dimers of pentamers representative of the interactions found in Figure 
4-3a.  Each dimer of pentamers is aligned about the lower pentamer and the upper 
pentamer is allowed to sit according to the position of the lower pentamer.  As is distinctly 
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apparent a range of binding conformations are available between the pentamers, with the 
red dimer of pentamers, representing the 5-fold axis interaction, sitting to the extreme left 
and the orange structure, representing the 3-fold axis interaction, sitting to the extreme 
right. 
 
Figure 4-3:  Simian virus 40 tiling and pentamer superposition
[105]
. a) The crystal structure of Simian virus 40 
pentamers positioned as highlighted in the schematic in Figure 4-2h.  b) An alignment of dimers of pentamers 
from the Simian virus 40 crystal structure.  Showing the polydiverse nature of the binding orientations of the 
upper pentamers compared to the lower pentamer.  Produced from pdb 1SVA 
4.1.3.1 Calculating the Expected Capsid Size 
Estimating the size of the capsids formed from CTB pentamers by the tiling theory above 
requires a number of assumptions.  The only structural information available are the 
dimensions of the CTB pentamer, these can be compared to the dimensions of the other 
T=7d forming pentamers such as the SV40 coat protein.  In order to standardise the 
measurement, as edge lengths of the T=7d capsid vary, the centre of mass was used to 
make measurements.  This measurement provided a rough figure for comparison with 
particle sizes observed with TEM and DLS.  The Simian virus 40 capsid (from PDB 1SVA) 
measures 48.4 nm across its diameter, the average distance between the centre of mass of 
neighbouring pentamers measures 9.7 nm and the distance between the centre of mass of 
monomers within pentamers measures 3.4 nm.  Using these parameters we can scale a 
hypothetical capsid size for the CTB particle with T=7d symmetry using the distance 
between monomers in the pentamer, measuring 2.2 nm, which gives a scaling ratio of 1.53.  
Application of this ratio to the sizes observed in SV40 estimates a particle size of 31.6 nm. 
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4.1.3.2 Coiled-Coil Quaternary Structure 
The C-terminus of CTB lies between the suggested 2-fold and 3-fold axes, of a putative 
dodecahedron.  It is thus in an ideal position to create dimeric and trimeric scaffolding 
interactions which could in turn produce particles from pentagon shaped subunits.  
Trimeric coiled-coil extensions could assemble about the 5-fold axis pentamer (Figure 
4-4a); likewise, dimeric coiled-coil extensions could assemble about the 2-fold and 3-fold 
axis (Figure 4-4b).  This heterovalency creates a degree of proximal binding freedom 
allowing experimentation with both types of coils in the assembly mutants.  Moreover, to 
meet the criteria of expanded particle construction from pentagons, the use of coiled-coils 
which can form both dimeric and trimeric interactions is the most advantageous.  
Additionally, as the assembly will be mediated to some respect by the CTB interface, i.e. 
electrostatics, shape complementarity, hydrophobic regions etc., these coiled-coil 
interactions might be forced into non-ideal binding conformations.  These individual coiled-
coil motifs, once initial nucleation of the assembly has occurred, will be held by the 
assembly in the proximity and polarity for further subunit association.  Given two 
homotrimeric coiled-coil motifs held in proximity, it is rational to assume that it is more 
energetically favourable for a dimeric complex to form from these putative trimeric coils, in 
the absence of a third binding partner.  Indeed it is also rational, though possibly less 
energetically favourable than above, that if three homodimeric coiled-coil motifs are held 
in proximity that they could form trimeric complexes over the more favourable dimeric 
complex based on the satiation of the unbound coiled-coil motif’s binding requirements.  
Many coiled-coils indeed have a preference for a particular oligomerisation state but are 
shown experimentally to exist in a dynamic equilibrium between monomer, dimer, trimer 
etc.  In order to assess the ratio of multimerisation of the coils selected we performed a 
number of studies to deduce the quaternary structure of the coiled-coils used, which is 
discussed below.   
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Figure 4-4:  Trimeric and dimeric coiled-coil extensions of CTB.  a) C-terminal trimeric coiled-coil extensions of 
CTB can complex about the putative 3-fold axis of a dodecahedron.  b) C-terminal dimeric interactions could 
also form around the 3-fold symmetry axis.  Produced from pdb 3CHB. 
 
Coiled-coils are ideally suited to provide a platform for an interaction surface capable of 
forming both dimeric and trimeric interactions, dependent on the predicted oligomeric 
state and proximity of binding partners.  This in turn makes them ideal as scaffolds which 
can bridge the gap between structurally supporting platonic solids (homovalent coiled-
coils) as well as more complicated assemblies which contain polymorphic PPI sites between 
subunits (heterovalent coiled-coils). 
 
4.1.4 Choosing a Starting Point for Design 
De Crescenzo et al. (2003)[64] designed a parallel heterodimeric coiled-coil with the 
canonical heptad sequence VSALKEK for the ‘coil K’ and VASLEKE for the ‘coil E’.  This 
sequence included the hydrophobic residues valine and leucine in the ‘a’ and ‘d’ positions 
and electrostatic interactions formed between the dimers from glutamate and lysine 
residues at the ‘e‘ and ‘g’ positions.  The interaction between differing heptad lengths was 
measured by Surface Plasmon Resonance and the five heptad versions of coil E and coil K 
were found to have a 6.3 pM Kd
[64].  The high stability made these sequences an attractive 
starting point for the design of coiled-coil scaffolds for CTB assembly.  However, a 
homomeric coiled-coil would be advantageous to bring about the assembly of a closed 
spherical object as it requires just one protein to be expressed, rather than expressing a 
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pair required for heterodimerisation, which in turn may lead to assembly difficulties via 
electrostatic clashing between two coils of the same type (i.e. K to K, or E to E).   
The use of homomeric coiled-coils presented from the same face of the CTB protein 
potentially provides the complication of intra-pentamer self-association.  Given large 
coiled-coils, such as a five heptad repeat, the most entropically favourable arrangement is 
for the coiled-coils to associate with additional coiled-coil extensions emanating from the 
same CTB pentamer.  However, the first heptad emanating from the C-terminus of CTB is 
unable to contribute to an intra-pentamer coiled-coil (Figure 4-5a) as the distance between 
adjacent C-termini is too large.  However, the position of the C-terminus would allow 
length-long association between coiled-coil extensions for inter-pentamer interactions 
(Figure 4-5c).  Thus, the inter-pentamer association is always the most enthalpically 
favourable from the point of view of coiled-coil formation.  Therefore shorter coiled-coil 
motifs will form inter-pentamer interactions in preference over intra-pentamer coiled-coils.  
However, intra-pentamer interactions could prove problematic for larger coils.  Three 
heptads repeats were chosen as a likely candidate to provide an effective inter-pentamer 
scaffold while deterring intra-pentamer associations with neighbouring extensions (Figure 
4-5b).  Although de Crescenzo et al. found that three heptad versions of the same coiled-
coil bound too weakly to measure a Kd, here the multivalency of the system should allow 
these weakly binding coiled-coils to complex larger assemblies. 
 
Figure 4-5: Intra-pentamer coiled-coil interactions compared with inter-pentamer coiled-coil interactions.  a) 
Three-heptad coiled-coils associate intra-pentamer through two of the three heptads, while the first heptad 
binds with few residues.  This model was constructed with foldit
[160]
.  b) The inter-pentamer coiled-coil 
association however, allows coiled-coils to interact with one another directly as they protrude from the CTB C-
terminus.  The white residues highlighted by the red arrows are G104 which is the first residue of the 
extension.  The inter-pentamer association should be favoured, enthalpically over the intra-pentamer 
association based on the greater interaction surface.  Produced from pdb 3CHB. 
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4.1.5 Coiled-coil Designs 
Two de novo intrinsic scaffolds were designed and evaluated for assembly of wild-type CTB, 
which are listed below with a brief description.  Each sequence follows directly from 
residue 103 of CTB.  Possible electrostatic interactions are indicated in the respective 
colours and changes to hydrophobic residues are green.  The de Crescenzo (DeCr) coils are 
listed for reference only.  Although only two new coiled-coils are described here, several 
other peptide sequences were investigated and are described in the appendix (10.2.4.1).  
The other sequences were less effective than the two described here for producing higher 
order assemblies. 
DeCr-coilK GGGKVSALKEKVSALKEKVSALKEKVSALKEKVSALKEG 
DeCr-coilE GGGEVSALEKEVSALEKEVSALEKEVSALEKEVSALEKG 
JR-coil2 -----------------GVSALEKEVSALKEKVSALEF 
JR-coil7 ----------------GGISAISEKISAIESKISAIES 
 
DeCr-coilK: The coil K described in de Crescenzo et al. (2003)[64].  DeCr-coilE: The coil E 
described in de Crescenzo et al.  
JR-coil2:  In order to allow homodimerisation of the coil, the electrostatic interactions were 
mixed from coil E and coil K motifs.  The N-terminal end of the coiled-coil was truncated to 
remove its electrostatic interaction in case this would interfere with the surface of CTB, 
which left two heptads-worth of electrostatic interactions and three heptads-worth of 
hydrophobic core.  Originally it was thought that by introducing a C-terminal phenylalanine 
in to the coiled-coil the assembled coil would have a hydrophobic cap and potentially 
induce clustering of the other assembled coils in proximity.  Upon reflection this was 
probably unlikely to help in assembly and more likely to create VLPs with a hydrophobic 
interior surface.   
JR-coil7:  This coil was designed to alleviate the potential for weak but potentially 
problematic antiparallel interactions, by reshuffling the electrostatic interactions.  
Additionally, the literature suggests that introducing isoleucine into the ‘a’ and ‘d’ positions 
of the heptad promotes trimeric interactions over dimeric interactions[161-163] as two coiled-
coils are unable to adequately shield the larger hydrophobic centre from the bulk solvent.  
This coil implemented this theory to create a putative homotrimer. 
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4.2 Expression and Characterisation 
4.2.1 MBP Coiled-Coil Fusions 
The construction of the plasmid, the coiled-coil fusions and the expression and 
characterisation of the MBP-coiled-coil fusions was conducted by Michael Johnson, 
University of Leeds, for his Masters project.  Plasmid maps and assembly part sequences 
can be found in the appendix (10.2.4.2). 
In order to determine the oligomeric states of the designed coiled-coils, JR-coil2 and JR-
coil7, these were made as C-terminal extensions of MBP.  Chapter 3 describes the 
construction of the pSAB2.1 plasmid which is used to express MBP fusion proteins, 
possessing a TEV protease site, to the periplasm.  This construct was used to clone the TEV 
protease domain into the pMal-c5x plasmid (which expresses protein in the cytosol), via 
digestion with SacI and PstI, the pSAB2.1 insert was spliced into the pMAL-c5x plasmid to 
give a new vector named pMaCo.  This plasmid directed expression to the cytoplasm and 
allowed coiled-coil fusions to the C-proximal side of the TEV protease site.  This allowed the 
option of removing the coiled-coil from the MBP fusion should it become necessary. 
The genes for the coiled-coils were constructed by assembly PCR from short overlapping 
sections of ssDNA, which were subsequently spliced into the pMaCo plasmid using the 
BamHI and PstI restriction sites.  Expression was induced and the fractionated cell lysate 
was purified by amylose affinity chromatography.  Elutions from the amylose resin were 
analysed on SDS PAGE and revealed a high yield of MBP coiled-coil fusion which was 
adequately purified from the vast majority of the contaminating proteins (Figure 4-6a).  
Both JR-coil2 and JR-coil7 when expressed, concentrated and incubated at room 
temperature for 2 days, revealed no high weight oligomeric states after SEC.  Therefore, 4-
heptad versions of these coils were constructed and analysed.  These 4-heptad versions 
gave a concentration-dependent decrease in SEC retention volume after incubation.  Figure 
4-6b shows the SEC for the 4-heptad version of MBP-JR-coil2.  The red and black lines show 
MBP and MBP with a known trimeric coiled-coil attached[164].  The traces from orange to 
blue show increasing concentrations of the MBP coil fusion.  With increasing 
concentrations, there was an increase in the size of the particle which suggests the 
presence of trimeric, dimeric and monomeric species.  SEC for the 4-heptad version of 
MBP-JR-coil7 (Figure 4-6c) shows a major dimeric species and a smaller proportion of 
trimeric species.  This result was somewhat unexpected as the major predispositions of the 
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coiled-coils were the opposite way round to expected.  For example JR-coil7 which 
contained isoleucine at the a and d heptad positions was expected to favour trimeric 
interactions, however, the SEC suggests dimeric species are in the majority across the range 
of concentrations tested.  In contrast, JR-coil2 with valine and leucine at the a and d 
positions respectively was presumed to favour dimeric interactions, however, given 
concentrations above 5 mg/ml these coils favoured trimeric interactions.  Despite this 
inversion in the predicted behaviour of the coils, the purpose of this exercise was to find 
coiled-coils which could form both dimeric and trimeric interactions, which both coils do.  
Additionally as one coil prefers dimeric interactions and the other prefers trimeric 
interactions, these coils provide a good starting point for investigating which coil produces 
capsids more efficiently.  These investigations were conducted on 4-heptad versions of the 
coiled-coils, however when investigating these coiled-coils on CTB it was decided that 
reverting to 3-heptad coiled-coils was more appropriate.  This change in heptad length 
would reduce crowding on the capsid interior and would lead to a preference for fully 
formed capsids over partially formed capsid intermediates, which would likely have 
stability problems with just three heptads.  Additionally as future mutations in the CTB-CTB 
interface will likely increase the assembly rate independent of the heptad length, a low 
level of initial assembly with the wild-type CTB is an advantageous position for determining 
the kinetic effect on capsid assembly of any introduced mutations. 
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Figure 4-6:  MBP fusions with designed coiled-coils.  a)  An example gel of the eluted fractions from the amylose 
affinity column: the MBP fusion is expressed to a high yield and is well purified from other contaminants.  b)  
The SEC trace from the 4-heptad version of JR-coil2.  The red line depicts the trace from MBP with no coiled-coil 
fusions.  The black line shows the trace from an MBP fusion with a known trimeric coiled-coil, SynTri
[164]
.  This 
trace shows that with increasing protein concentrations of the fusion that the propensity for trimeric 
oligomerisation increases, however there is always a portion of monomeric fusions as well as a proportion of 
dimers.  c)  The SEC trace from the 4-heptad version of JR-coil7, as described in b).  With this coil there is a 
greater proportion of dimeric interactions than trimeric interactions, even when reaching concentrations such 
as 20 mg/ml, however there is a proportion of trimeric coils seen at all concentrations. 
 
4.2.2 CTB-JR-coil2 
Coiled-coil JR-coil2 was assembled with wild-type CTB and inserted into plasmid pSAB2.2, 
which was expressed and purified.  In order to assess the assembly of the capsids, purified 
samples were concentrated to 10 mg/ml and incubated at room temperature for differing 
periods of time from two days to four weeks.  Samples were then analysed by SEC (Figure 
4-7a).  CTB expressed without C-terminal extensions was also incubated for 4 weeks at 
room temperature and can be seen as the red trace.  The 1 week, 2 week and 4 week 
traces produced by the CTB-JR-coil2 showed a high weight peak that gave higher yields 
with longer incubation time suggesting the accumulation of a high weight species with 
time.  As seen in the inset panel, these high weight peaks occur just after the void volume 
of the column (left-hand shoulder of the peak).   
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In order to confirm the presence of the CTB-JR-coil2 protein in these high weight peaks, 
fractions were analysed, both boiled and unboiled, on SDS-PAGE (Figure 4-7b).  This gel 
shows that CTB makes up the majority of the high weight peak.  The gel also suggests that 
the protein in this high weight peak is not the product of aberrant aggregation of unfolded 
protein, as pentamers are clearly visible on the unboiled fractions.  The SEC high weight 
peaks were combined and concentrated before being analysed by DLS.   
 
Figure 4-7:  Characterisation of CTB with JR-coil2.  a) Size exclusion chromatography of wild-type CTB in red and 
of CTB with JR-coil2 in grey to black.  The darker the lines indicate extended periods of incubation at room 
temperature from 1-4 weeks, long incubations gave higher yields of high weight product.  b) The high weight 
fractions from SEC are seen to contain pure CTB when subjected to electrophoresis, both boiled (B) and 
unboiled (N) and stained with coomassie blue.  c) Dynamic light scattering of the wild-type CTB, red, suggests 
particle sizes of 5.6 nm, however the high weight peak from SEC of the CTB-JR-coil2, in black, gives particles of 
between 24 and 50 nm.  d)  Transmission electron microscopy of the high weight SEC fraction reveals particles ≥ 
50 nm.  Very few particles were observed. 
DLS of CTB without coiled-coils gave 5.6 nm for the estimated spherical size of CTB (Figure 
4-7c) in line with the pentamers width of 6.3 nm and height of 3.6 nm.  However the CTB-
JR-coil2 high weight component from SEC gave a range of particles sizes from 24 nm to 50 
nm.  The low concentration retrieved from the high weight peak (0.3 mg/ml) was close to 
the lower limit of concentrations acceptable for DLS.  This could be a reason for the range 
of particle sizes seen by DLS; of course another reason could be the production of a range 
of particle of differing sizes.   
95 
 
The high weight peak from the size exclusion column was then applied to carbon grids, 
negatively stained with uranyl acetate and analysed by Transmission Electron Microscopy 
(TEM).  Particles measuring from 54-78 nm in diameter with the appearance of spherical 
capsid-like structures were observed (Figure 4-7d).  These particle sizes deviate from the 
data obtained through DLS.  It is notable that these three capsid-like structures were found 
after a prolonged search.  Given the yield purified from SEC, evident from its visibility on 
SDS-PAGE, a greater number of capsids were expected to have been found by TEM.  It is 
thought that the low number of particles visible by TEM may be due to the intrinsic 
instability of the capsid structures.  These capsids are held together solely through the 
interactions of the JR-coil2, which in turn must out-compete the unfavourable interactions 
which native CTB  possess to prevent its own aggregation.  The negative staining technique 
requires the hydrophilic, negative, charging of the carbon grid by exposure to UV light, 
application of the sample followed by air drying and then fixing with uranyl acetate, before 
exposure to the TEM under vacuum.  This process exposes the capsids to a combination of 
potentially destabilising forces and it is possible that the preparation process itself resulted 
in the dissociation of a large number of the capsids. 
4.2.3 CTB-JR-coil7 
This coiled-coil was assembled with wild-type CTB, cloned into pSAB2.2, expressed and 
purified as described in the methods.  Purified samples were concentrated to 10 mg/ml and 
incubated at room temperature for one week.  Samples were then analysed by SEC (Figure 
4-8a).  CTB expressed with JR-coil2 was also incubated for one week at room temperature 
can be seen as the black trace and JR-coil7 as the blue trace.  As is evident from the 
enlarged panel, after one week CTB-JR-coil7 produced a larger proportion of high weight 
product than CTB with JR-coil2.  Notably, the high weight peaks of CTB-JR-coil2 makes up 
1.8% of the total area of the SEC trace, whereas the high weight peak of CTB-JR-coil7 makes 
up 3.4% of the total peak area, suggesting greater oligomerisation with the JR-coil7.   
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Figure 4-8: Characterisation of CTB with JR-coil7.  a) Size exclusion chromatography of CTB JR-coil2 is in black 
and CTB JR-coil7 is in blue, both after one week incubation.  Given the same period of incubation, the JR-coil7 
extension seems to produce a larger yield of high weight product, additionally as discernible on the SEC of the 
pentameric peak, there is less overall pentamer, thus the ratio of assembled to unassembled is much greater.  
b) The high weight fractions from SEC are seen to contain pure CTB when run both boiled (B) and non-boiled (N) 
on SDS PAGE.  The concentrated sample however shows a number of contaminants.  c) Dynamic light scattering 
of the wild-type CTB, red, suggests particle sizes of 5.6 nm, however the high weight peak from SEC of the CTB-
JR-coil7, in blue, gives particles of 28 to 32 nm.  d) Transmission electron microscopy of the high weigh SEC 
fraction reveals particles of an agreeable size to the DLS results.  These TEM structures were resolved more 
clearly than the particles for the CTB JR-cloi2 TEM and reveal the interior surface of the capsid.  This is likely due 
to stain penetration of the capsid. 
Figure 4-8b shows both boiled and unboiled samples analysed by SDS-PAGE for CTB-JR-coil7 
with a positive control, (+) wild-type CTB.  It is evident in the concentrated sample that 
despite CTB-JR-coil7 making up the largest component of the sample, other contaminating 
proteins are pulled through the purification procedure.  However after SEC and isolation of 
the high weight peak only CTB-JR-coil7 is present.  DLS of the high weight SEC fractions 
revealed particles of 28 to 33 nm, in blue (Figure 4-8c) in contrast to the particle size seen 
for wild-type CTB of 5.6nm in red.   
Under observation with TEM, particles were found which possessed capsid like structures 
(Figure 4-8d) measuring from 29 to 36 nm in size.  Dye penetration seems to have occurred 
more readily with the capsids produced from JR-coil7 than with JR-coil2 which revealed the 
appearance of the inside wall of the capsid.  This might suggest that CTB-JR-coil7 may hold 
the CTB pentamers in a slightly different orientation, compared to JR-coil2.  This potential 
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change in rotational orientation may lead to gaps in the capsid which allow leaching of 
uranyl acetate into the capsid interior.  The capsids produced with JR-coil7 were more 
convincing examples of capsid like structures than those found with JR-coil2, which had 
poor contrast.  Described below are a selection of TEM negative. 
 
4.3 Electron Microscopy Controls 
 
4.3.1  Buffer Control 
In order to confirm that the particles seen under TEM relate to the CTB mutant protein 
found in the high weight peak from SEC, a number of control experiments were conducted.  
Firstly buffer taken from the SEC before the appearance of the high weight peak, 4 ml 
retention volume, was prepared for TEM as described in the methods (Figure 4-9). 
 
 
Figure 4-9: Buffer control from SEC.  a) best attempts were made to find particles similar to those observed in 
the high weight peak.  These particles are amorphic and do not appear similar to the CTB capsids.  b) the 
particles seen in a) can be seen in the upper right of this micrograph with similar amorphic particles.  c) The 
majority of the grid appeared as seen in this micrograph. 
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4.3.2  Pentamer Control 
The pentamer peak from IGFBAA-coil7 was prepared for TEM to observe the appearance of 
the non-oligomerised CTB mutant particles (Figure 4-10).  The CTB particles appear as 
donut shapes with a distinct difference in contrast compared to the buffer only grid. 
 
 
Figure 4-10:  TEM of the CTB pentamer peak from IGFBAA.  a)-c) generic micrographs displaying the appearance 
of the surface.  Compared to the buffer control there is pronounced contrast to the surface which appears like 
small donut shapes reminiscent of CTB.  d) an enlarged view of part of a).  e) an enlarged view of the buffer only 
control at the same scale as d).  There is a striking difference between these two images suggestive of CTB 
bound to the grid. 
 
4.3.3  No-Plasmid Control 
C41 cells which were not transformed with pSAB2.2 plasmid and thus will not express CTB, 
were treated with IPTG and processed in an identical fashion to cells containing a pSAB2.2 
variant.  The resultant nickel-purified precipitant fraction was concentrated to 2 mg/ml (of 
unknown protein) and incubated at room temperature for 2 weeks.  No protein was found 
in or just after the void volume, where capsid structures are eluted.  However there was a 
small peak at 12 ml retention volume which was prepared for TEM (Figure 4-11).  These 
micrographs revealed the presence of polymorphic aspherical structures of which did not 
exceed 15 nm in size.  Compared to the CTB capsids the overall shape of these structures 
was not spherical and appeared random. 
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Figure 4-11:  TEM of the high weight peak of the ‘no plasmid’ preparation of C41 cells.  a) Particles were found 
in this preparation, however these sample particles are also observed under CTB mutant high weight peaks and 
are distinct from the particle thought to be constructed from CTB.  The particles in this micrograph are 
amorphic and do not exceed 15 nm in size.  b) The majority of the grid appeared as seen in this micrograph.  c)  
We also found this triangle. 
 
 
4.4 Concluding Statements. 
 
Simple C-terminal extensions possessing coiled-coils were sufficient to create particles of a 
relatively discrete size.  These particles had a more consistent morphology when the JR-
coil7 was used as the scaffolding protein.  This observation may be the result of JR-coil7 
having a bias for dimeric interactions which are the dominant scaffolding interaction in the 
proposed T=7d geometry.   
The MBP-coiled-coil studies suggested that the oligomeric state preference of the coils was 
inverted compared to that expected based on the peptide sequence.  Although these data 
should be reliable enough, it is worth considering that these coils were extensions from 
MBP and, given the experiments described, it is not possible to rule out that an interaction 
of these coiled-coils with MBP may have caused an altered behaviour which is not present 
when these coils are attached to CTB.  Fortuitously, and despite the inversion in predicted 
oligomeric state, both coils displayed a propensity to form both dimeric and trimeric 
interactions which could be desirable for the formation of the T=7d capsid.  Despite the 
ubiquitously reported lack of a measurable binding affinity between 3-heptad coiled-coils in 
the literature, coiled-coils of this length were sufficient to promote assembly of capsids.  
Each additional pentamer that adds to the assembly after the first two reinforces the 
interactions of the initial two pentamers.  Thus, providing a transient association is 
100 
 
maintained for long enough for the third pentamer to interact with the nucleating dimer of 
pentamers, then the total assembly becomes strengthened and addition of further 
pentamers becomes more favourable. Although longer coiled-coils, with their increased 
interaction affinity may have produced particles more quickly and in higher yields, these 
slowly assembling particles with low yields provide the ideal starting position for the 
investigation of CTB to CTB surface interaction mutations.   
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Chapter 5 
Computational Interface Design 
5 Chapter 5 – Computational Interface Design 
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5.1 Computational Selection of Mutants 
5.1.1  Overview 
Modelling and simulation have been instrumental to the success of this project. The main 
utility of modelling has been to provide a rational strategy to select mutations that have 
the largest chance to increase the stability of the capsid assembly. In this chapter it is 
reported how target capsid states have been generated, how these have been optimised, 
how interfaces between pentamers have been characterised and how the free energy 
difference between capsid and pentameric states has been estimated. By determining a 
well-defined and robust protocol and applying it to a number of point mutants we have 
been able to perform high-throughput scoring of many more mutations than we could have 
experimentally handled.  
5.1.1.1 Modelling the 3-Fold Axis in T=1 Particles 
The atomistic simulation of the larger particles, such as the proposed protein cage 
described in the previous chapter are unfeasible given the current computational power of 
standard research computers. Constructing an in silico model which captures the non-
identical interactions in the T=7d model would require a system of seven pentamers 
containing around 65000 atoms. However, given the symmetrical nature of such 
complexes, interactions at a given position can be assumed to be replicated in 
geometrically identical positions making simulations of entire capsids redundant. 
In order to construct a simpler model, a dodecahedron of CTB pentamers is used in silico.  
There is much evidence in the literature, described in the introduction, that particles 
capable of forming more complicated spherical tiling geometries, such as T=7d, are also 
capable of forming more simplistic smaller capsids given different driving forces for 
assembly.  Based on this theory we presume the modelling of an interface which would 
allow dodecahedral assembly would also promote, rather than deter, assembly of more 
complicated structures such as the T=7d particles, given that the driving force for assembly 
would be supplied by the coiled-coil extensions and that the mutations made would 
remove repulsive interactions.  The dodecahedral model reduces the number of 
asymmetric modelled interfaces from five to one.  This allows models containing fewer 
atoms which in turn reduce the computational cost of each assessment.   
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To further decrease processing times, quarter dodecahedrons, trimers of pentamers, were 
used in simulations.  This trimer of pentamers captured interactions about the two-fold and 
three-fold axes of symmetry for dodecahedral assembly and brings the atom count to less 
than 30000.  Furthermore, each model contains three interfaces which allows the 
assessment of three interactions for the price of one simulation. And thus reduces the 
number of ensemble conformations required. 
 
 
5.1.1.2 Determination of Interface Orientations 
Given this reductionist model, the possible binding interfaces are described by the 
alignment of the pentamers to each other under T=1 symmetry constraints and rotated  
through 72° and a variety of z-axis translations, which define the distance from the centre 
of the dodecahedron.  A computational approach was developed to estimate minimum 
energy conformations with perfect dodecahedral symmetry for all possible rotations and 
translations.  This model provides a sort of “energy landscape” that allows identification of 
the optimal dodecahedral conformer.  
 
5.1.1.3 Ensembles in High-Throughput Interaction Determination 
Once an energetically optimised initial dodecahedral conformer had been determined, a 
trimer of pentamer model from this conformer was simulated by molecular dynamics to 
probe their stability at finite temperature, and to determine an ensemble of representative 
structures compatible with the imposed symmetry; this also allowed for the initial structure 
to relax into more stable states and explore alternative conformations of the individual 
monomers in each pentamer that allow lower energy, higher entropy conformers to be 
explored with their appropriate Boltzmann weight. This step is very important for the 
estimation of the thermodynamic stability of designed mutants and an original aspect of 
the research presented here. Simulations were performed with CHARMM [142] and the EEF1 
implicit solvent.  
The stability of the capsid corresponds to the free-energy difference between the capsid 
state and a state where all monomers do not interact. Calculation of free-energy 
differences using molecular dynamic simulations is in principle possible, but requires 
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repeated simulations of the association and dissociation of the capsid, which is by no 
means practical for such large systems. However, a number of qualitative, empirical 
methods have been developed that provide an estimation of the free energy difference 
between two conformers of a protein, or between the bound and unbound state of a 
complex (assuming that in the monomeric state the components do not change 
conformation and are at infinite distance). One such method, that has been shown to 
provide good estimations for complexes with known stability is FoldX[145]. FoldX estimates 
the free energy difference as a sum of terms that represent the change in enthalpy 
between the bound and unbound forms and the entropy involved in the loss of 
conformational freedom. Such calculations could be performed using a single capsid 
conformation (e.g., that obtained by the energy minimisation procedure described above). 
However, the value obtained will depend largely on small changes in the conformation of 
the subunits and changes at their interfaces and would not be a good indicator of the 
stability of the complex. For this reason, the calculation of free energy was performed on 
the whole ensemble of 200 structures obtained from the simulations. While the values of 
the free energy difference vary considerably for different structures, ensemble averages 
converge rapidly to a well-defined value that we used to select the most stable mutants.  
 
 
5.2 Computational protocol 
5.2.1  Overview 
A computational protocol was developed to allow the design of an interaction surface 
between three CTB pentamers based on dodecahedral symmetry (Figure 5-1).  This routine 
performs a basic set of instructions three times, each referred to as a phase, and the whole 
routine can then be iterated again.  The first of the three phases introduces a point 
mutation into a single subunit of a trimer of CTB pentamers and then identifies if the 
mutation improves ∆∆Gstability relative to the starting model. In the second phase, each 
chosen single mutation is applied to all subunits in a trimer of CTB pentamers and the 
∆∆Ginteraction between pentamers is assessed for each single mutation. In the final phase, the 
single point mutations are combined and  ∆∆Ginteraction between pentamers is assessed for 
the combinatorial mutations. 
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As seen in Figure 5-1, each phase contains five main steps.  The methods for each step are 
described in the methods section and the appropriate scripts can be found on the 
accompanying DVD, however a brief description follows: 
 
1. A starting model is constructed, either based on the wild-type sequence, or if the 
process is iterated, based on a successful mutant from the previous investigation. 
 
2. The trimer of pentamers is minimised with CHARMM by finding a quick energy 
minima and removing unfavourable interactions brought about by the introduction 
of the new mutations. 
 
3. Ensembles of the initial structure are generated by conducting a CHARMM 
molecular dynamics simulation and deconvoluting the coordinates from the 
simulation trajectory. 
 
4. The conformations are passed to FoldX which, dependent on the phase, performs a 
stability-based analysis. 
 
5. The results of the analysis are processed and ‘hits’ are identified. 
 
 
These phases, steps and the appropriate considerations for each are described in more 
detail below. 
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Figure 5-1:  Overview of the computational routine, of which there are three mains parts.  Saturation mutagenesis, where a FoldX ‘position scan’ is used to find mutations which increase the 
total stability of an ensemble of structures derived from a CHARMM trajectory of a starting complex.  Single Mutant Analysis, in which ensembles of these ‘single mutant’ structures are 
analysed by FoldX ‘Analyse Complex’ to find changes in the free energy of interaction.  Finally, Combinatorial Mutant Analysis takes place after a round of experimental validation, allowing 
the assembly of combinatorial mutants and their analysis in the same manner 
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5.2.2 Constructing the Starting Structure 
This method was used to determine the template configuration of the wild-type protein, 
additional mutations suggested by the routine were applied to this model. 
5.2.2.1 Symmetrical Docking 
The interfaces at which the CTB-CTB interaction occurs in the CTB-JR-coil2 and CTB-JR-coil7 
assemblies are unknown; furthermore, this interface is likely to be polymorphic.  The 
coiled-coils hold the surfaces of the pentamers in a given orientation.  With the wild-type 
protein this arrangement is naturally repulsive, given that CTB does not readily aggregate.  
The first step in the design process was to elucidate the most likely interaction surfaces 
given the constraints imposed by the coiled-coils and the shape and chemical 
complementarity of the surface.  As discussed above, the most attainable estimation of 
capsid-like interactions was to construct an in silico dodecahedron. 
A novel protocol was developed with CHARMM which allowed the symmetrical docking of 
target proteins using symmetry matrices obtained from other proteins in the PDB.  The 
initial structure of a dodecahedral capsid was obtained by applying the crystal symmetry 
matrix for the biological unit from the PDB structure 1NQU (Lumazine Synthase (LS) from 
Aquifex aeolicus), which forms a dodecahedron from pentamers of a similar size as CTB, to 
the coordinates from the PDB structure 3CHB (Cholera Toxin B-subunit).  The method 
aligns LS to the coordinate origin with its longest dimension along the x-axis, then the next 
longest perpendicular axis to the y-axis and records the total transformation.  CTB is then 
aligned to the origin in the same manner and the recorded transformation from LS is 
inverted to align CTB to the original structure of LS on a geometric basis as opposed to 
more intricate structural alignment.  As LS is a larger pentamer this initial placement leaves 
CTB ‘out of contact’ with its neighbouring CTB pentamers in the dodecahedron.  CTB, and 
its dodecameric neighbours, were then systematically rotated through 360° in 1° 
increments and translated toward the centre of the dodecahedron, i.e. along the z-axis, in 
steps of 1 Å up to a total transformation of 10 Å. Each structure was then minimised by 
CHARMM.  At each step CHARMM was asked to output a total ΔG (kcal/mol) for the system 
and FoldX was used to calculate an interaction energy in ΔΔG (kcal/mol).  These results can 
be seen in Figure 5-2.  A video of this process can be found on the accompanying DVD.  The 
red lines in Figure 5-2 represent the pentamer at 0 Å z-axis translation.   
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Figure 5-2:  Symmetrical docking of CTB pentamers.  a) CTB was placed in a range of orientations and 
transformations (relative to the original lumazine synthase cage structure) which would lead to a symmetrical 
particle, the total energy of the system was derived by CHARMM.  b) These structure were then assessed by 
FoldX to elucidate an interaction energy.  As the total size of the capsid is reduced, i.e. translation of the CTB, 
the CTB proteins start to clash sterically, however these transformations (~5-8 Å translation) show energy 
minima at around 44° and 62° rotation.  This suggests that for interfaces with these rotations, there is reduced 
repulsion compared to other orientations of contact.  c) An example of a repulsive interface at 28° rotation, the 
side chains, not shown, clash in this rotational conformation.  d) An example of an energy minimum, which is 
less repulsive than most other orientations.  e) An example of a less repulsive interface at a relatively expanded 
transformation of 4 Å, compared to d) which is the same rotation but translated by 8 Å.  f) Another energy 
minimum rotational conformation.  Structures produced from pdb 3CHB. 
The CTB pentamers at the origin of rotation are not in contact with each other, creating an 
‘expanded capsid’ with part of each pentagonal edge facing one another.  As these 
pentamers are rotated, the vertices come into proximity with each other and make contact.  
A steric clash, and accompanying decrease in stability, is observed at 30° rotation in both 
ΔGstability and ΔΔGinteraction as the vertices of the pentamers make contact with one another.   
The total ΔG in Figure 5-2a between 40° and 60° at 0 Å translation can be regarded as the 
total energy of the unbound system, as the pentamers remain out of contact and the ΔG 
remains constant despite further contractile translations of up to 2 Å.  Further contractions 
of the capsid in this rotational range start to cause deviations in the ΔGstability which become 
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more evident as the contraction of the capsid increases.  Notably, with translations of 3 Å 
to 6 Å and rotations of 44° and 62° from the origin, energy minima become distinct from 
the rest of each trace.  This observation is replicated the ΔΔGinteraction energy calculated by 
FoldX for rotations of 41° and 62°.  The emergence of these energy minima suggests areas 
of contact between the pentamers which, although they destabilise the total structure, the 
perturbation is less than that of neighbouring rotational orientations.  As discussed earlier, 
native CTB is not expected to have an attractive binding affinity between pentamers and 
thus it is not surprising that the ΔΔGinteraction energies are positive.  It is worth noting that as 
the capsid contracts the ΔΔGinteraction becomes less negative, indicating the increase in 
repulsive interactions.  When the capsid is at 0 Å translation this ΔΔGinteraction is 
approximately zero.  This is an indication of the separation of the pentamers, being too 
distant to interact, rather than a neutral proximal interaction. 
5.2.2.2 A Trimer of Pentamers 
As seen in Chapter 4, the particles made by including the JR-coils are larger in size than 
would be predicted for dodecahedrons comprised of 12 pentamers.  The supramolecular 
structure is unknown, so how can algorithms be applied to design this interface, given its 
unknown configuration?  Based on the symmetrical docking data above, two interface 
configurations are clearly energy minimised with respect to the other rotational 
configurations; therefore they provide reasonable starting points for the design process. 
Molecular dynamic simulations are renowned for being computationally demanding so 
rather than simulating an entire capsid, a trimer of pentamers was used as a base model 
for all simulations.  This trimer comprised three pentamers and three interfaces, as 
opposed to a dimer of pentamers which would contain just one interface.  The trimer of 
pentamers also captured interactions restricted to the three-fold symmetry axis.  A trimer 
of pentamers model was constructed based on the docking data at 44° rotation and 8 Å 
contraction, (Figure 5-3), which was used as a starting position for future mutagenesis 
work. A second model considered to be a good starting position for investigation was at 62° 
rotation and 8 Å contraction.  The two-fold axis of the 44° model contains a loop which 
extends into a cavity in the side face of CTB, seen in the centre of Figure 5-3c. This 
interaction was considered likely to increase the surface area for interaction and thus 
provide a number of design opportunities, as well as displacing water from the interface, 
which should allow the design algorithms to be more accurate.  Additionally the interfaces 
are aligned in a flush manner.  In contrast, the 62° model does not contain such a 
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protrusion and respective cavity or line up flush and the proposed interfaces are staggered, 
thus the total surface area for interaction is reduced.  The three fold axis of the 44° model 
contains β-sheets running down the interface, it should be possible to mutate a number of 
these residues to add three-fold axis interactions without seriously perturbing the 
pentamer structure.  The loop which extends into the cavity described on the two-fold axis 
of the 44° model extends into the 3-fold axis in the 62° model.  This should also provide an 
adequate framework for mutation, however, the cavity described earlier is in an 
unfortunate position on the 62° models and would remain solvated upon assembly.  Based 
on these discussions the 44° model was chosen as a suitable starting model for future 
computational work. 
 
Figure 5-3:  Structural views of the two best energy minima conformations (a) 44°and b) 62°) elucidated from 
the symmetrical docking studies.  Overall views of the trimer of pentamers used in simulations as well as close 
up views of c) and d) the 2-fold and e) and f) 3-fold symmetry axes.  Produced from pdb 3CHB. 
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5.2.3  Constructing Mutant Structures 
In the first phase of the computational routine the wild-type protein is studied and 
saturation mutagenesis is performed by FoldX which introduces the relevant mutations.  
However, for the second and third phase of the computational routine mutations are 
introduced across the template structure.  A script, named ‘threading’ was designed which 
implements the Pymol mutagenesis function.  A library of target sequences or ‘parts’ of 
sequence are input into Pymol which in turn mutates those positions which differ from the 
wild-type template.  The mutagenesis function of Pymol is efficient but not rigorous, thus in 
order to correct van der Waals clashes, the Pymol ‘sculpting’ function was implemented on 
the final structure.  This technique was able to process large numbers of mutations in a 
timely manner; however, the final structures were often in energetically unstable 
conformations.  These structures underwent minimisation by CHARMM before molecular 
dynamic simulations were conducted. 
 
5.2.4  Minimisation and Molecular Dynamics 
In order to produce a large ensemble set of conformations for each target protein, 
molecular dynamic simulations were conducted and the resultant trajectories 
deconvoluted to yield individual conformations per time step.  Energy minimisation was 
conducted on the starting structure after the Pymol mutagenesis.  Both minimisations and 
molecular dynamics were implemented from within the script ‘run-fullcharmm’ which 
performs the calculations on a list of supplied pdb files.  
 
5.2.5  Analysis by FoldX 
FoldX makes reductions in the total free energy of a protein by applying a rotamer library of 
amino acid side-chain conformations to specific sequence positions.  FoldX then performs a 
fast energy calculation on the target protein structure and/or complex.  In this project 
FoldX was used for the high throughput calculation of protein stability, ΔG (kcal/mol), and 
protein-protein interactions, ΔΔG (kcal/mol) as well as for making suggestions of side-
chains which improve the total stability of the target structure. 
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5.2.5.1 Ensemble construction 
As FoldX makes calculations based only on the submitted structure and minor deviations of 
the structure can have a large impact on the result, large ensembles of structures were 
used to calculate an average ΔGstability.  The ensembles were retrieved from the molecular 
dynamic simulations produced by CHARMM.  These ensembles once calculated also 
provide an insight into the total entropy of the given target through the width of the 
distribution of energies observed. 
5.2.5.2 Analysis 
A number of different functions of the FoldX program were used, however three functions 
were used routinely.  The ‘stability’ function was used to derive a ΔGstability in kcal/mol for a 
particular structure.  The ‘positional scan’ function was used to perform saturation 
mutagenesis at selected positions of CTB.  Finally the ‘analyse complex’ function was used 
to estimate the ΔΔGinteraction of a proposed interface. 
5.2.5.2.1 Stability 
FoldX calculates the ΔGstability of a target protein compared to a hypothetical unfolded 
version of the same sequence.  This calculation forms the basis of all other FoldX 
calculations which measure the difference between a series of stability calculations, before 
and after mutations and given differing rotamers of side-chains.  This calculation is 
described under the methods section. 
5.2.5.2.2 Position Scan 
The position scan performs in silico saturation mutagenesis across the target protein at 
selected positions. The function first builds a wild-type reference structure, from which the 
chosen amino acid is removed. It then re-builds the initial wild-type residue and searches 
for the most energetically minimised rotamer.  The program then tries to ‘repair’ 
surrounding side chains by refining their rotameric positions.  FoldX returns a ΔGstability in 
kcal/mol for the wild-type reference and then performs the same actions for each 
saturation mutant.  The wild-type reference ΔGstability is then compared against each of the 
remaining 19 amino acids in this position to give the ΔΔGstability, i.e., the change in ΔGstability 
compared to the wild-type reference.  Each round of position scan is conducted upon one 
CTB monomer which lies on the putative three fold axis in the centre of the trimeric model 
discussed above. In the second phase, the selected point mutations are replicated in all 
subunits of the trimer of pentamers prior to assessing the interaction energy of the 
complex. 
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5.2.5.2.3 Analyse Complex 
The analyse complex function calculates the ΔGstability for the total complex and then 
calculates the ΔGstability for the two components of the complex.  These individual ΔG are 
subtracted from the total ΔG to give the ΔΔGstability between the bound and unbound 
structures which is inferred to be the ΔΔGinteraction of the complex.  Typically one pentamer 
in the trimer of pentamers is assessed for its ∆∆Ginteraction against the two remaining 
pentamers in the trimer, Figure 5-4.  Towards the end of this chapter FoldX was 
benchmarked against previous experimental data for both ∆Gstability and ∆∆Ginteraction 
assessments. 
 
                                  (                                           ) 
Figure 5-4:  The ∆∆Ginteraction calculation.  The sum of the ∆Gstability of the components is subtracted from the 
∆Gstability of the whole complex.  Structures produced from pdb 3CHB 
5.3 Initial Computational Strategies 
5.3.1  Overview 
Three strategies were pursued to select mutants likely to increase the binding affinity of 
the proposed interface.  In strategy #1.0 (S#1.0), which is described in this chapter, 
suggestions from FoldX which had the lowest predicted energy were used with minimal 
manual curation of the mutant list.  This mutant set underwent a second round of in silico 
mutagenesis prior to experimental validation and thus incorporated a relatively large 
number of mutations.  In strategy #2.0 (Chapter 7), however, suggestions made by FoldX 
were used as guidance for introducing a small number mutations through rational design 
based on the structural model.  The subsets, S#1.1, S#2.1, S#2.2 all involved modest, yet 
computationally-driven second round mutations based on successful mutants from the first 
round libraries.  Finally, all successfully expressible mutants from the previous two 
strategies were combined in strategy #3.0 (S#3.0) to derive combinations of these mutants. 
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5.3.2  Strategy 1.0 (S#1.0) 
During the discussion of this set of mutants, a thorough description of the computational 
steps and evaluation of the data for a selection of mutants will be presented.  
 
5.3.2.1 Objective 
Strategy 1.0 (S#1.0) was designed to evaluate the reliability of pushing the computational 
routine through two rounds of mutagenesis prior to experimental validation.  Effectively, 
the routine described in Figure 5-1 was followed twice, however different methods for 
generating the combinatorial mutants were used in each iteration.  Furthermore, the first 
round of combinatorial selection was based solely on ΔΔGinteraction estimations from FoldX; 
no manual inspection of the structure of the proposed interaction surface was made.   
The computational routine predicted a set of point mutations which were then assessed for 
their ΔΔGinteraction by FoldX.  These mutants were manually combined into 39 combinatorial 
mutants, based solely on the FoldX analyse complex ΔΔGinteraction estimations (no in vitro 
expression testing was used in this iteration).  Hits from these multi-mutant models were 
subjected to a second full iteration of the computational routine: the combinatorial 
mutations were re-evaluated for additional favourable point mutations which were added 
to the mutated sequence and assessed again for their ΔΔGinteraction.  During the course of 
this investigation the assembly PCR method was implemented in on-going molecular 
biology work, therefore the sequences of the computationally-derived mutants were 
broken down, in silico, to represent mutant ‘parts’ compatible with the assembly PCR 
method.  These ‘parts’ were recombined in silico to generate a combinatorial library which 
was assessed for the best ΔΔGinteraction. This strategy initially was investigating prolonged in 
silico rounds of the routine, however, the implementation of the assembly PCR ‘part 
recombination’ added an extra level of complexity.   
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5.3.2.2 Pass One 
5.3.2.2.1 Starting Structure 
In S#1.0 the wild-type-44°-8Å model, described above, was used to initiate the routine. 
5.3.2.2.2 Saturation Mutagenesis 
After minimisation of the starting structure, a 40 ps room temperature simulation was 
performed.  An ensemble of 20 configurations was retrieved from the trajectory at 2 ps 
periods.  These structures were passed to the FoldX function ‘Position Scan’ which 
performed saturation mutagenesis across the interaction surface residues.  An example of 
the results from the FoldX position scan is presented in Figure 5-5.  This position scan was 
performed across 36 positions in the protein, over 20 protein conformations, assessing 20 
amino acid substitutions which gave 14’400 ΔGstability estimations.  These data were 
compared to the wild-type reference and averaged over the 20 conformations of the 
protein to give 720 averaged ΔΔGstability values, Figure 5-6a.  Of these data, 148 mutations 
predicted an improvement in ΔΔGstability and, of these, 39 mutations gave a ΔΔGstability 
change below a threshold of -1.0 kcal/mol (Figure 5-6b).  FoldX suggested mainly 
hydrophobic residues (Figure 5-5, highlighted in green) from the position scan, however, 
some residues with hydrogen bonding potential were also identified (highlighted in yellow) 
along with three positively charged lysine residues (blue).   
The position scan, apart from suggesting changes in ΔGstability, also discloses something 
more subtle. The number of mutants having a ΔΔGstability less than 0.0 kcal/mol for a given 
residue position highlights which wild-type residues are particularly unfavourable for the 
hypothetical complex (Figure 5-7). Residues H18, D22, T41, E83, N89 and R94 each have 
between 8 and 14 suggested favourable mutations.  Given that for these residues more 
than half of the suggested mutations result in a more stable conformation, it can be 
assumed that the wild-type residue is particularly unfavourable and that these positions 
should be targeted for mutagenesis.  Additionally, these residues are biased towards 
charged residues which may present unfavourable electrostatic interactions across the 
proposed binding site.  It should be noted that a small anomaly arose during the single 
mutant analysis section: Model #3, as seen in Figure 5-5 actually contains two mutations, a 
proline at position 3 and an isoleucine at position 6.  Therefore, despite there being 39 
mutations predicted, only 38 ‘single’ mutants were analysed.   
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Figure 5-5: A list of the ‘hits’ from the FoldX position scan run on the wild-type trimer of pentamers.  The first 
list is ordered by ∆∆Gstability and the second list is ordered by residue position.  The ∆∆Gstability is measured in 
kcal/mol, where green denoted the best stabilisation and red, the worst.  The residues chosen by FoldX have 
been highlighted in colours to represent their biochemical properties where green is hydrophobic, yellow is 
hydrogen bonding potential and red and blue are charged respectively. 
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Figure 5-6:  The average change in ∆Gstability for the trimer of pentamers upon saturation mutagenesis in a single 
CTB subunit.  a) The energy change in kcal/mol for the 720 substitutions that were analysed which have 
∆∆Gstability values ranging from 35 to -2.5 kcal/mol.  b) The same data but presenting only those with a ∆∆Gstability 
below 0.0 kcal/mol.  Those which fall below -1.0 kcal/mol are highlighted in green. 
 
 
Figure 5-7:  The frequency of mutations at each position which stabilise the complex.  This graph shows the 
number of mutations at each position which are predicted to be more favourable than the wild-type residue.  
Those positions with many suggested mutations can be thought of as destabilising residues for complex 
formation.  The biochemical property of the wild-type residue is highlighted in green for hydrophobic, yellow 
for hydrogen bonding potential and in red or blue for charged side-chains respectively. 
 
5.3.2.2.3 Single Mutant Analysis 
The position scan revealed mutations which could improve the ∆Gstability of the complex.  
However, the process mutates only one subunit out of 15 in the trimer of pentamers 
model, therefore the hits need to be built into the remaining structures and simulated fully, 
which is done here.  Each of the models was constructed using the threading script and 
minimised with CHARMM before conducting molecular dynamics simulations of 40 ps 
(Figure 5-8).  Ensembles of 200 configurations were produced from these trajectories and 
analysed with the FoldX ‘analyse complex’ function.  To account for the period of relaxation 
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seen at the beginning of the simulations (Figure 5-8a), an average of the final 20 ps (100 
conformations) was used as the total ΔΔGinteraction.  Figure 5-8a shows the change in 
interaction energy over the course of the simulation for the wild-type CTB and one of the 
single point mutations, model #33 (E83V).   
 
 
Figure 5-8: Analysis of molecular dynamic simulations of the mutant CTB.  a) A plot of the ∆∆Ginteraction of the 
complex across the structures retrieved from the CHARMM trajectory.  The wild-type is in red, compared to the 
reduced energy of the mutant Model #33.  b) A histogram of the interaction energies showing the distribution 
of ∆∆Ginteraction over the 40 ps time frame. 
 
Analysis of the wild-type model revealed that E83 and D22 lie in very close proximity 
across the proposed interface, therefore eliminating this charge clash removes a strong 
repulsive interaction.  The total distribution of free energy differences for the final 20 ps is 
shown in Figure 5-8b. In each case the energy reaches a well-defined average value and 
fluctuates around it. Fluctuations are sizable and physically relevant (their amplitude 
reflects the variety of conformations making up the capsid state at room temperature). 
Such fluctuations also highlight the fact that free energy estimations performed on single 
structures are less relevant than those performed on ensembles of structures. In the 
present case, while the free energy distributions are large, the difference between the 
average ΔΔGinteraction for Model #33 and the wild-type are large relative to the width of the 
distributions. The length of the simulation, 40 ps was chosen such that the distributions of 
free energy differences converge.  Table 5-1 shows the top ten mutants from the single 
mutant analysis as well as the wild-type.  As discussed above, the best improvements in 
ΔΔGinteraction are obtained for mutants that remove the E83-D22 charge clash, therefore, 
these mutants populate the top end of the list. 
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Table 5-1:  Single mutants ranked by minimisation of ∆∆Ginteraction.  The top ten hits from the single mutant 
analysis are shown along with their average ∆∆Ginteraction.  The residue position is highlighted across the top and 
the wild-type residue is shown below.  Each single mutant is highlighted in green. 
5.3.2.2.4 Combinatorial Mutants 
A combinatorial library based on the hits from this round would consist of 216K mutant 
structures, which would require an infeasible amount of computation.  Therefore, based on 
the hits from the first round point mutations, a small manually curated combinatorial 
library was developed as shown in Figure 5-9.  This library was based around the two main 
combinatorial mutants, model 1 and model 17 which incorporate the best mutant hits 
(green) for unique positions from the single mutation analysis, namely Q3P, T6I, H18W, 
D22A or D22S, K43P and E83V, along with other variants including secondary (yellow), 
tertiary (orange) and quaternary (red) hits at the same positions.  It should be noted that 
no reference to the structure of the protein was made when making choices for the 
combinatorial mutants, simply the ΔΔGinteraction energy, the initial residue and the 
substitution were considered. 
As with the single mutants, 40 ps simulations were conducted and conformations from the 
last 20 ps were analysed and their ΔΔGinteraction was estimated by FoldX.  Interestingly the 
mutants that incorporate the best mutations from the single mutation round, models 1 and 
17, lie at 12th and 10th respectively in the ΔΔGinteraction ranking and mutants which substitute 
these primary mutations with secondary and tertiary mutations give the best interaction 
energies.  This re-ranking following the combinatorial mixing step is interesting as it 
highlights that synergetic interactions between mutations are a factor for consideration in 
mutation design.  Selected models from these combinatorial mutants were then passed 
through the computational routine a second time. 
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Figure 5-9:  Combinatorial library selection and analysis.  Model numbers run down the left hand side of each 
list and position numbers across the top.  The wild-type residue is backed with white.  Primary mutations, i.e. 
with the best ∆∆Ginteraction for each position are highlighted in green, secondary in yellow, tertiary in orange and 
all others in red.  The left hand list shows the mutants chosen.  The right hand list shows the same 
combinatorial mutants ranked by ∆∆Ginteraction in kcal/mol.  Some mutation positions only contain secondary or 
tertiary mutations to suggest that these mutations only made minimal improvements during the single mutant 
analysis stage. 
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5.3.2.3 Pass Two 
Three models from Figure 5-9, model  7, 18 and 31 were passed through the computational 
routine for a second time as these models housed a diverse range of different mutations 
5.3.2.3.1 Starting Structure 
The progress of model 7 from Figure 5-9 is documented below. 
5.3.2.3.2 Saturation Mutagenesis 
Saturation Mutagenesis was conducted as described above for the previous round.  As 
mutations had already been made in the sequence which removed native repulsive 
interactions in the proposed binding surface, the output of the second round of saturation 
mutagenesis produced a more evenly distributed list of positions for mutagenesis.  
Additionally, the total number of substitutions which yielded ΔΔGstability values of less than -
1 kcal/mol was just 17, compared to 39 in the wild-type saturation mutagenesis 
investigation.  The total number of substitutions follows a similar trend to the wild-type 
study; however, the positions which are highly populated are different to those seen for 
the wild-type protein (Figure 5-10). 
 
Figure 5-10:  Comparison of positional mutation frequency between the wild-type and a first round mutant, 
model 7.  As with Figure 5-7, these graphs show the number of mutations at each position which improve the 
total ∆Gstability of the complex.  Here we compare the wild-type mutational frequency with that derived for 
model 7. 
Analysis of the ΔΔGstability results for this saturation mutagenesis experiment suggested the 
primary positions to mutate were K84, T47 and D7.  These three positions populated the 
top ten positions of the saturation mutagenesis table (Figure 5-11).  However it is 
noteworthy that these positions are not the top of the list for the frequency of mutation 
(Figure 5-10), which identifies positions 16, 89 and 92 as the most repulsive positions.  
Thus, mutation of positions 7, 47 and 84 may act toward promoting association rather 
than just reducing repulsion. 
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Figure 5-11: A list of the ‘hits’ from the FoldX position scan ran on model 7 from the first iteration of the 
computational routine.  The first list is ordered by ∆∆Gstability and the second list is ordered by residue position.  
The ∆∆Gstability is measured in kcal/mol, where green denoted the best stabilisation and red, the worst.  The 
residues chosen by FoldX have been highlighted in colours to represent their biochemical properties where 
green is hydrophobic, yellow is hydrogen bonding potential and red and blue are charged respectively.  Notably 
the top ten mutations are comprised of just three positions. 
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5.3.2.3.3 Single Mutant Analysis 
Each of the proposed single mutations was applied to all subunits in the current starting 
model and the single mutant analysis process described above was conducted.  A portion 
of the results from the single mutant analysis is presented in Figure 5-12.  With the 
introduction of additional point mutations to the starting model only modest 
improvements in ΔΔGinteraction were made.  In the wild-type single mutant analysis, of 38 
mutants, the wild type was ranked 31st with a difference of -31 kcal/mol between its 
interaction energy and the mutant ranked 1st.  On this second round position scan, 
however, the starting model was ranked 7th of 40 analysed point mutations and the 
difference between the starting model and the best mutants was just -2.5 kcal/mol.  This 
result is suggestive of an approach to a local energy minimum; however, further iterations 
of the routine were not performed on the model to test this hypothesis.  Additional runs 
were performed, using different first round combinatorial mutants, however, the relative 
ranking of the starting models were 12th of 41 and 22nd of 45, which could also suggest the 
encroachment upon local energy minima.   
 
Of Interest is the reproducibility of the ΔΔGinteraction values obtained. In the initial single 
mutation round, the wild-type model gave a ΔΔGinteraction of 33.1 kcal/mol with a standard 
deviation of 5.6 kcal/mol.  In the combinatorial mutant analysis the average ΔΔGinteraction of 
the wild-type was 31.5 kcal/mol with a standard deviation of 5.6 kcal/mol.  This compliance 
with previous data is replicated in model 7: in the combinatorial mutant analysis it was 
found to have a ΔΔGinteraction of -14.3 kcal/mol and standard deviation of 4.7 kcal/mol.  In 
the second round single mutation analysis, using model 7 as the starting model, its 
ΔΔGinteraction was estimated at -16.7 kcal/mol with a standard deviation of 4.8 kcal/mol 
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Figure 5-12:  Single mutant analysis of saturation mutagenesis on model 7.  Model numbers are on the left hand 
side and positions across the top.  Original mutations from model 7 are in green and new single mutations are 
highlighted in blue.  Models are ranked by ∆∆Ginteraction which are noted on the right hand side.  The majority of 
the mutations do not provide increases in interaction energy, however six structures do provide a modest 
improvement. 
5.3.2.3.4 Assembling Mutant Parts 
Mutated sequences based on model 7 and the other mutants identified during the 
computational procedure thus far, were broken down into six ‘parts’ that were compatible 
with the assembly PCR strategy, described in the methods, and can be seen in Figure 5-13.  
Model 7, for example, can be constructed from parts 1I, 2H, 3F, 5F and 6N with the wild-
type part 4B (most wild-type parts are labelled A and/or B).  Therefore, we can rename 
model 7 by the parts used to create it, IHFAFN.  This nomenclature will be used 
throughout the remainder of the thesis to refer to specific mutants in order to avoid 
confusion between mutants coming from different iterations of the computational 
protocol.   Some mutations were modified at this stage if experimental difficulties were 
anticipated.  For example, the mutation Q3P was replaced with Q3A to avoid potential 
proline isomerisation problems.  
 
Figure 5-13:  A sequence alignment of the mutant ‘parts’ ordered for assembly PCR.  Different combination of 
these parts allows the construction of different full length mutants, i.e. model 7 can be constructed from parts 
1I, 2H, 3F, 5F and 6N with the wild-type part 4A, not listed. 
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5.4  Experimental evaluation of mutant 
designs 
5.4.1  Analysis of Individual Mutant Parts 
DNA oligos for the individual parts were ordered and each of the mutant DNA parts were 
assembled by assembly PCR with the remaining five wild-type parts before cloning into the 
pSAB2.2 expression vector.  These constructs were expressed and purified and the protein 
was run, unboiled, on SDS PAGE  (Figure 5-14). Note, constructs containing parts 2I and 3G 
failed to progress in a timely manner through the cloning procedure and were not 
expressed.  Parts 1I, 1J, 2G, 3E, 3F and 6J expressed to give comparable yields to the 
wild-type and were able to maintain their pentameric structure when run unboiled on SDS 
PAGE.  Part 6N displayed a band at the appropriate size for CTB however its level of 
expression is severely reduced. There was also a suggestion of an appropriately size band 
for pentameric CTB when using part 5E, however, this is of negligible quantity.  Parts 1H, 
5E and 5F did not have pentameric bands on the gel, however a monomer band can be 
seen towards the dye front. As our purification process is known to bind only pentameric 
CTB, we can attribute the presence of only a monomer band to a reduced pentameric 
stability which is inadequate to maintain pentamers under the conditions of standard SDS 
PAGE.  Of note are the smears emanating from the 1I, 1J and 2G part mutants which 
indicate a small proportion of pentamer dissociation during the SDS PAGE run.  It is 
interesting to note that part 1H contains Q3A and T6I substitutions and does not express 
well, whereas 1I and 1J respectively substitute A3L and I6L into the 1H sequence and in 
each case expression is recovered.  These examples provide a nice demonstration of 
recovery mutations in which a leucine substitution at either of the two deleterious 
positions restores near native expression. 
126 
 
 
Figure 5-14:  SDS PAGE of S#1.0 single part mutants.  SDS PAGE was conducted on non-boiled samples of the 
mutant protein.  As is evident a number of the mutants did not express any protein.  Of additional interest 
some of the mutants were seen to run as monomers rather than pentamers, such as 5E and 5F.  Also, some 
mutants display a ‘smudge’ from the pentamer band to the monomer band indicating the pentamer 
disassembling during the course of the SDS PAGE, such as 1I, 1J and 2G. 
 
DSF was also performed in order to gain a better understanding of the impact of these 
mutations on the stability of the pentamers.  Melting curves were not obtained for mutants 
containing parts 1G, 1H, 1K, 1L, 2D, 2E, 2F, 2H, 2J or 6N, which suggests the absence of 
stable folded protein. However 1I, 1J, 2G, 3E, 3F, 5E, 5F and 6J did produce melting 
curves, which are summarised in Figure 5-15.   Figure 5-15 shows a correlation between 
morphology of the protein on SDS PAGE and its melting temperature by DSF.  This data set 
is limited in size but there are other observations which also follow this trend.  Part 5E 
shows a marginal amount of pentameric CTB whereas 5F shows none and their respective 
Tm values of 62°C and 57°C agree with this observation.  Additionally, the smear of 2G 
appears darker than that of 1I and 1J which each have a Tm 2°C higher than 2G.  This 
correlation is interesting as it allows us to make assumptions of relative stability based on 
the morphology of pentamers on SDS PAGE.  For example the addition of multiple 
destabilising mutations is likely, though of course not inevitable, to increase the 
destabilisation beyond that of the single parts.  Thus SDS PAGE can be used to inform us 
about the likelihood of expressing stable multiple mutants based on the stability of the 
single parts, but as described above, this assumption will not identify recovery mutations. 
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Figure 5-15:  DSF comparison to stability during SDS PAGE.  The DSF-derived Tm values for single part mutants in 
this strategy are compared to the behaviour of the mutants during SDS PAGE.  Those mutants with the lowest 
melting temperature are found to be unable to maintain pentamers during SDS PAGE, however those with 
higher melting temperatures maintain pentamers on the gel.  Additionally those with intermediate Tm are seen 
to create smears during SDS PAGE suggesting dissociation of the pentamer during SDS PAGE. 
 
5.4.2 Analysis of Combinatorial Mutants 
The mutant and wild-type parts were rearranged in all possible combinations having one 
member from each mutant part set 1-6, to give a combinatorial library of 2016 mutant CTB 
models.  This saturation combinatorial library production removes human bias and is 
feasilble given a reduced number of initial parts (approximatly 20).  Each model was 
assessed in the same manner as described earlier for the combinatorial mutant analysis.  
This intensive combinatorial approach ranked the interaction energy of the wild-type at 
1932nd of the 2016 models, showing that in most case, any of these parts were predicted 
to give an improvement on the interaction relative to the wild-type.   
By comparing every combination of the parts shown to express protein in the single mutant 
analysis, 72 combinatorial mutants are feasible (Figure 5-16).  A number of mutants were 
selected which incorporated the parts 1I or 1J with 2G and 3F, as these expressed well, 
along with 5E, 5F, 6J or wild-type parts. As described above, the mutant containing parts 
1I, 2G, 3F, 5F with wild-type parts 4A and 6A is written as IGFAFA.  From the 
combinatorial analysis, one mutant IAFAEJ gave a ΔΔGinteraction of -18.6 kcal/mol which 
predicts a much greater interaction energy than the next nearest mutant JGFAAJ at -7.4 
kcal/mol, however, this mutant contained part 5E which shows increased 
thermoinstability.  Thus it was decided not to attempt to express this mutant.  The mutants 
highlighted in Figure 5-16 were expressed with C-terminal coiled-coils, as described in 
chapter 4, these mutants are characterised in the next chapter. 
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Figure 5-16:  Combinatorial analysis of parts found to be experimentally expressible.  The ∆∆Ginteraction was 
assessed for the 72 combinatorial mutants built from parts which expressed protein.  Highlighted mutants were 
expressed experimentally and described in Chapter 4. 
 
The mutant IGFBAA (identical to IGFAAA above, as part-4B is a silent mutation of the 
wild-type) was chosen to produce a rotational and z-axis translational energy landscape 
based on dodecahedral symmetry as conducted previously for wild-type CTB and shown in 
Figure 5-2a & b.  A comparison between this energy landscape for the wild-type and for the 
mutant IGFBAA can be seen in Figure 5-17.  The initial structure, on which the IGFBAA 
mutant was designed, lay at 44° rotation and 8 Å z-axis translation.  This energy landscape 
shows stabilisation of the 44° rotation area with respect to the rest of the landscape, 
including the competing minimum at around 62° rotation, which is evident from the 6 Å to 
8 Å translations.  This observation suggests that the method we have used effectively 
optimises the interface presented to the design routine.  Although there is no evidence of a 
negative interaction energy from these mutations, the removal of repulsive residues has 
resulted in a lowering of the ∆∆Ginteraction of the interface. 
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Figure 5-17:  Wild-type and mutant symmetrical docking landscape.  The ∆∆Ginteraction energy as calculated by 
FoldX on a selection of structures produced by CHARMM encompassing 72° of rotation and 10 Å of capsid 
contraction (z-axis translation).  a) Shown previously in Figure 5-2b, the dodecahedral docking results for the 
wild-type protein.  As is evident, energy minima appear in the 4 Å to 7Å ranges at around 44° and 62°.  b) After 
application of the suggested mutations from FoldX calculations, based on a model positioned at 44° rotation 
and 8 Å translation, the energy minimum at around 44° rotation is amplified with respect to the other rotations 
and also enriched with respect to the 62° energy minimum.  Therefore, after mutation with respect to a specific 
orientation, that orientation is minimised with respect to the other possible orientations. 
 
5.5 FoldX benchmarking 
 
The Im9-E9 complex is a well-documented protein-protein interaction[165-168].  The E9 DNase 
is an endonuclease colicin belonging to a family of cytotoxically active bacterial toxins.  The 
activity of E9 is inactivated by the host immunity protein Im9 upon complexation.  An 
alanine scan was conducted on the Im9 protein in order to gain understanding into PPIs by 
Wallis et al.[169].  In that study, dissociation kinetics were determined by radioactive subunit 
exchange monitored by stopped-flow fluorescence.  The stability of the complex was 
determined by fluorescence spectroscopy under guanidinium hydrochloride gradients.  
Their experiments revealed a number of thermodynamic parameters for the complex 
including the ∆∆Ginteraction and the ∆∆Gstability.  These values were used to retrospectively 
benchmark the performance of FoldX.  A 2 ps MD simulation of the pdb 1BXI was 
conducted in order to generate ensemble structures.  These structures were passed to 
FoldX to perform an alanine scan (Figure 5-18a/c) which simply truncates side-chains from 
Cβ as described in the methods.  The ∆∆Gstability data provides a reasonable agreement with 
the experimental data.  The mutagenesis function of FoldX was used to create models 
containing the appropriate alanine mutation.  These structures were then analysed by the 
‘analyse complex’ function to give ∆∆Ginteraction energies for the complex (Figure 5-18b/d). 
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However the ∆∆Ginteraction energies show little correlation between the experimental values 
and the computational predictions.  This data suggests that alternative computational 
methods may improve the frequency at which mutations which improve the ∆∆Ginteraction 
are discovered. 
 
 
Figure 5-18:  Experimental data vs. computational prediction for both ∆∆Gstability and ∆∆Ginteraction against the 
Im9-E9 complex.  a) The ∆∆Gstability comparison, which shows a reasonable correlation between experimentally 
determined values and those predicted by FoldX.  b) The ∆∆Ginteraction comparison, which shows little correlation 
between the experimental and computational data.  c) a scatter between computational and experiments 
assessments of ∆∆Gstability, revealing R2 of 0.39.  d) a scatter between computational and experiments 
assessments of ∆∆Ginteraction, revealing R2 of 0.09.   
5.6 ∆∆Ginteraction Benchmarking 
Lumazine synthase in Aquifex aeolicus is a dodecahedral protein cage constructed from 
pentameric subunits of a slightly larger size than CTB.  A recent paper by Chen and 
Woycechowsky (2012)[170] lists a number of mutations which prevent assembly of this 
protein cage to leave soluble pentamers.  This provided an excellent test bed to compare 
our computational strategy to protein cage assembly experimental data.  SEC revealed 
changes in oligomeric state upon mutation; some mutations resulted in the loss of 
dodecahedral assembly, while others caused no change in oligomeric state (Table 5-2).   
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Nomenclature Mutations Pentamers Assembled 
w1 Wild-Type 12 
w2  R40E/H41E 12 
w3  R21E/R40E/H41E 12 
w4  H41R/L121R 1 
w5  R40E/H41E/L121E 1 
w6  R40E/H41E/I125E 1 
w7  R40S/H41S/I125S 1 
w8  R40S/H41L/L121E 1 
Table 5-2:  Description of the nomenclature and oligomeric state of Lumazine synthase mutations found by 
Woycechowsky et al
[170]
.  The mutants w2 and w3 maintain dodecahedral assembly.  the remaining mutants 
cannot assemble into higher order structures. 
 
All-atom CHARMM MD simulations of the mutants were conducted on a single pentamer 
with periodic boundary conditions applied to emulate simulation of the entire capsid.  
FoldX analysis of the interactions was conducted, the MD and FoldX analysis was conducted 
by a first year Wellcome Trust PhD rotation student, Sam Hickman. Analysis with Pisa 
(CCP4) was conducted upon these CHARMM simulations by Dr Emanuele Paci and Rosetta 
was applied to evaluate the CHARMM simulations by me. 
Unlike CTB, the LS simulations were conducted on one pentamer and periodic boundary 
conditions were applied to estimate the interactions of the complete capsid.  As with the 
computational routine developed for CTB, the trajectories from these simulations were 
used to generate 600 ensemble structures of each simulation.  Figure 5-19 presents the 
data from this investigation.   Foremost, the ∆∆Ginteraction presented is as the Relative 
∆∆Ginteraction, compared to the wild-type, which is a negative value. 
 
                        
                       
                    
 
 
Therefore an increased in Relative ∆∆Ginteraction shows an improvement in ∆∆Ginteraction. There 
are a number of interesting features.  The expected outcome was that w2 and w3 would 
show an improved ∆∆Ginteraction over the destabilised mutants, yet the wild-type would 
maintain the best ∆∆Ginteraction.  For both Pisa and Rosetta this is mostly true with the 
exception of mutant w7.  However for FoldX this does not follow suit and w3 has one of the 
worst ∆∆Ginteractions of the set.  Additionally, Pisa and Rosetta follow almost an identical 
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ranking of the mutants, which was exciting to see.   FoldX however did not rank the 
mutants in a similar order.  The fact that all three programs ranked w7 better than the 
mutants which maintain capsid assembly was an interesting find as the three programs 
were simultaneously incorrect which may point to underlying problems with which 
computational programs assess ∆∆Ginteraction energies, or problems with the method of 
experimental assessment of the oligomeric state.  In dashed lines on the graph are 
potential threshold values for capsid assembly.   
 
 
Figure 5-19:  Software comparison for calculating the ∆∆Ginteraction of Lumazine synthase.  The ∆∆Ginteraction (in 
kcal/mol) was scaled relative to the wild-type (w1).  The boxes underneath the bar chart signify the number of 
pentamers which oligomerise according to experiment, where dark green (w1) is the wild-type LS, pale green 
(w2 & w3) are the mutants which still formed dodecahedrons and orange (w4 - w8) are the mutants which did 
not assemble.  Dashed lines are potential assembly threshold ∆∆Ginteraction energies for each of the investigated 
techniques. 
This investigation suggests that programs such as Pisa and Rosetta are better equipped to 
calculate accurate ∆∆Ginteraction energies as their results agree with the experimental data 
more so than FoldX does.  Another exciting outcome of this investigation is how close the 
relative predictions of Pisa and Rosetta are to each other. 
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5.7 Closing Statements 
The routine described in this chapter successfully predicts reductions in ∆∆Ginteraction across 
the proposed interface in silico.  This is achieved by selecting mutants which reduce the 
total ∆Gstability for one monomer in a trimer of pentamers model; building this mutation into 
each subunit and assessing the ∆∆Ginteraction; and finally constructing and assessing 
combinatorial mutants.  It was found that the majority of the saturation mutants that were 
suggested translated into mutations which improved the assessed ∆∆Ginteraction.  Of course, 
validating an in silico technique by using the same technique could be seen as a rather 
obvious and somewhat redundant method for determining a correlation.  One argument 
against this view is the transfer of the assessed structures between Pymol, CHARMM and 
FoldX, i.e. before each assessment the models are constructed in Pymol and simulated by 
CHARMM before being analysed by FoldX.  However the calculations are made by FoldX 
and thus any problematic residues or interactions would be miss-calculated in both the 
saturation mutagenesis and the PPI analysis.   
Surprisingly approximately half of the suggested mutations did not produce a workable 
yield of CTB, however the respective alanine substitutions in these positions did allow 
expression.  This observation is suggestive that the bulky residues introduced are having a 
greater negative effect on the pentameric stability than just the removal of the native 
amino acid side-chain.  In the next chapter we discuss the improvement these mutations 
make up on the assembly of the capsids.  
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6.1 Mutated and Scaffolded CTB VLPs 
6.1.1  Overview 
As discussed in the project summary in the introduction,  It was anticipated that the 
addition of coiled-coils to CTB pentamers would provide an assembly scaffold for creating 
CTB virus-like particles.  These particles were not expected to be stable as CTB does not 
readily aggregate in solution. Therefore, the plan was to remodel the proposed interface to 
make the formation and final stability of these particles more favourable.  The steps 
discussed previously are reiterated below, before presenting the VLPs that have been 
constructed. 
6.1.2  Mutating Wild-Type CTB 
Chapter 3 revealed the mutability of CTB, I.e., that many of the positions on the proposed 
interactions surface are mutable to alanine without destabilising the pentamer.  However 
certain positions were identified to be quite destabilising.  Differential Scanning Fluorimetry 
was employed to measure the Tm of alanine mutants and, in chapter 5, other mutations.  
This technique revealed a correlation between morphology of the pentamers on SDS PAGE 
and the overall thermostability of the protein. Therefore, the morphology of the pentamers 
on SDS PAGE can be used as a qualitative measure of the pentameric stability in solution. 
6.1.3  Scaffolding Wild-Type CTB 
In chapter 4 the scaffolding of the wild-type CTB to produce capsids was discussed.  The 
two coiled-coils, JR-coil2 and JR-coil7, were able to make both dimeric and trimeric 
interactions, but each with a preference for a different oligomeric state. These peptides 
were found to scaffold the assembly of CTB into capsids with varying success, but as the 
coiled-coils are short, their interaction affinities are weak.  The pentavalency introduced via 
fusion to CTB, however, should allow enhanced binding interactions based on multivalency 
after the initial nucleation event.  These weak binding interactions should make partial 
assemblies relatively unstable and hopefully lead from pentamers to assembled capsids 
with a relatively low number of kinetic assembly traps. 
6.1.4  Mutating the Interface  
It was argued that the slow assembly rate and yield, and relatively low stability of the 
particles were a product of unfavourable interface interactions between the wild-type CTB 
surfaces.  Removal of these repulsive interactions should allow the assembly rate and yield 
136 
 
of product to be improved.  Starting from a discrete low yielding product is an optimal 
position to investigate the effects of future mutations as it allows the effect of the removed 
repulsive interaction to be more discernible against the ‘native’ assembly rate.  Chapter 5 
described a computational routine developed to remove repulsive interactions from the 
proposed CTB interface.  However this routine has little feedback until some experimental 
evidence suggests if the chosen mutations have any effect on the assemblies. 
6.1.5  Scaffolding the Mutants. 
Here, in chapter 6, the scaffolding of the mutants with coiled-coils is discussed.  The 
computational design strategy developed in chapter 5 is evaluated experimentally.    The 
introduction of JR-coil2 is discussed first, followed by JR-coil7.  The majority of the analysis 
in this chapter is performed by SEC and TEM as these methods allow a quantitative yield of 
product to be calculated (through integration of the SEC 280 nm trace) and direct 
visualisation of the final product. 
6.2 Characterising First Generation Mutants 
(S#1.0) 
6.2.1  Strategy S#1.0 
The computational routine to suggest mutations was performed on wild-type CTB, 
described in chapter 5    A number of combinatorial mutants were chosen for expression, of 
which the mutants in Figure 6-1 were assembled in the pSAB2.2 plasmid, expressed and 
purified as described previously and in the methods. 
 
Figure 6-1:  The amino acid sequence for combinatorial mutants from S#1.0.  The expressible mutants from this 
round of single mutants were combined.  Only seven were chosen for extension with coiled-coils. 
These mutants were first expressed with the JR-coil2 coiled-coil as a C-terminal fusion, and 
then selected mutants which showed the production of high weight species under SEC 
were reassembled with the JR-coil7.  For future reference the wild-type CTB is also referred 
to as AAAAAA and as BAABAA, based on the parts used for assembly PCR, part-1B contains 
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a A1T mutation but as this is a known natural CTB biotype mutation, it will still be referred 
to as the wild-type. 
6.2.1.1 Characterisation of Mutants with JR-coil2 
The chosen mutants from the computational screen were assembled from parts as 
described in the methods, each with the addition of the JR-coil2 coiled-coil sequence.  
Following expression, the proteins were precipitated and purified by nickel affinity 
chromatography. Figure 6-2a shows a gel of a selection of these mutants expressed and 
purified.  Lanes 3 to 10 show the nickel column elution followed by the ammonium 
sulphate precipitate fraction.  As is evident, only IGFBAA maintains pentameric stability on 
the SDS PAGE.  Mutant CTB is not discernible in the other mutant elutions.  JGABAA does 
not appear to express.  IGFBAA elution fractions were combined, when ran on SDS PAGE 
boiled and non-boiled in lanes 13 and 14.  Lanes 15-20 contain the boiled and non-boiled 
elutions from IGFBAA, IGFBEA and IGFBFA which have been concentrated.  As is 
evident in lanes 5 and 7, there is very little protein for IGFBEA and IGFBFA, however, 
after concentration the mutant CTB can be seen, although the purity is compromised.   
These mutated CTB molecules containing three or more mutant parts were not expressed 
well, therefore mutants containing fewer mutant parts were constructed.  These mutants 
expressed to a higher degree than those with more mutant parts (gel not shown).  Figure 
6-2b displays the SEC trace for a selection of these modest mutants, IAABAA, IGABAA and 
IGFBAA after differing lengths of incubation.  IAABAA displayed a standard pentamer 
peak at 0.85 relative retention volume (rrv), but with a negligible high weight peak at 0.4 
rrv despite the addition of the JR-coil2 sequence.  IGABAA showed a high weight peak at 
0.4 rrv which increased over longer incubations, however IGABAA also showed an increase 
in a peak at 1.15 rrv, which is thought to be monomeric CTB, suggesting that this mutant’s 
pentameric stability is compromised.  The part 2G contains a D22S mutation (as well as the 
bio-type variant Y18H) which removes an intra-subunit salt bridge between D22 and K43.  
This may cause monomer instability which in turn may lead to the disassembly of the 
pentamer.  Surrounding D22 are another two lysine residues: K23 and K81. The removal 
of D22 may dramatically alter the local electrostatics of the area thus resulting in these 
three lysine residues repelling each other.  IGFBAA however, expressed better and 
maintains its pentameric stability over extended periods of incubation of up to two months 
at room temperature.  IGFBAA also showed a pronounced high weight peak after seven 
days of incubation (Figure 6-2c). This result was exciting as the ratio of high weight product 
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formed was increased compared to the wild-type CTB also containing the JR-coil2 
extension.  Therefore, the mutations contained in this mutant are presumably responsible 
for the increased level of assembly.  Part 3F contains the mutation K43P and the bio-type 
variant I47T.  As discussed for IGABAA, part 2G makes a destabilising D22S substitution, 
however, in mutant IGFBAA the free K43 is substituted with a proline which recovers the 
pentameric stability, which could be due to the relief of the local electrostatic field.   
 
Figure 6-2:  Purification, concentration and SEC of the combinatorial mutants from S#1.0.  a) A selection of SDS 
PAGE of the selected mutants.  Mutants are identified at the top of the gel and contain boiled (B), non-boiled 
(N) nickel elutions, boiled clarified precipitate fractions (P).  Lanes 3-12 show expression of the mutants, only 
IGFBAA produced viable pentamers on SDS PAGE.  After concentration of the nickel elutions CTB monomers 
are visible, lanes 15-20, however only IGFBAA has a higher concentration of CTB than contaminants.  b) SEC of 
the expressed mutants.  In green is IAABAA at 2 and 10 days incubation.  There is very little assembly of these 
mutants although in the 2 day sample there does appear to be a peak at a relative retention volume (rrv) of 0.5; 
however this does not translate into high order structures with prolonged incubation.  In blue is IGABAA at 3 
and 10 days incubation.  These show a modest increase in assembly given prolonged incubation, however there 
is also evidence of an increase in CTB monomers in solution over time, at 1.15 rrv.  The mutant IGFBAA (in 
black) at 7 days incubation.  Unfortunately due to changes in chromatography conditions and equipment this 
trace differs to other mutants, however there is evidence of a large high weight species and intermediate 
products.  c) A comparison between the wild-type BAABAA and the mutant IGFBAA both with JR-coil-2 
attached.  Despite the reduced overall expression and the shorter incubation time, IGFBAA assembles into a 
similar yield of high weight product.  Note, SEC traces have been normalised using the peak at 1 rrv in order to 
show differences in yields and ratios of assembly. 
139 
 
6.2.1.2 Characterisation of Mutants with JR-coil7 
As the wild-type CTB-JR-coil7 produced higher quality capsids (as judged by TEM) than wild-
type CTB-JR-coil2 proteins, JR-coil7 was also appended to the IGFBAA set of mutants for 
visualisation under TEM. The IGFBAA mutant gene with the JR-coil7 sequence was 
constructed by assembly PCR before expression, purification and biophysical analysis.  
IGFBAA-coil7 expressed less well than the wild-type, BAABAA-coil7, as evident from the 
gel in the Figure 6-3a.  Thus when IGFBAA-coil7 was concentrated to 1.6 mg/ml, this sample 
contained a higher concentration of contaminating species.  SEC performed on this sample 
showed an increase in the rate of assembly compared to the wild type (Figure 6-3b).  The 
wild-type BAABAA-coil7 gave a high weight peak that was 9.7% the size of the pentameric 
peak; IGFBAA-coil2 produced a high weight peak 30.4% the size of the pentamer peak; 
and the high weight peak of IGFBAA-coil7 was 20.4% the size of the pentamer peak.  
Despite the JR-coil2 variant producing more high weight product, as the SEC trace baseline 
seemed somewhat elevated throughout the latter stages it was thought that coil7 may 
actually have produced more high weight species.   The high weight fractions were pooled, 
concentrated and analysed by DLS.  As seen in Figure 6-3c, the mutant IGFBAA-coil7 
produced particles between 30 and 36 nm in diameter, which was similar to wild-type CTB 
with coil7.  Of note is the widths of the curves in the IGFBAA-coil7 trace are much 
narrower than those for the wild-type which suggests a more discreet range of particle 
sizes.  When analysed by TEM (Figure 6-3d), the IGFBAA-coil7 mutant could be seen as 
spherical particles which measured between 30 and 37 nm, with an average of 33 nm, 
which correlates well with the particle size discerned from DLS which varied between 30 
and 36 nm.  The capsid in Figure 6-3d(1) is rather ill-defined but displays a different 
morphology from the capsids in Figure 6-3d(2-6).  It is larger in size and possesses a more 
elliptical geometry.  Figure 6-3d(7) shows a capsid under lower magnification. This capsid 
also possesses a more elliptical geometry but in addition appears to house two smaller 
capsid structures.   These smaller capsid structures each have an average diameter of 31 
nm which correlates with the structures seen elsewhere.  The larger capsid has an average 
diameter of 70 nm. 
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Figure 6-3: Biophysical analysis of the IGFBAA-coil7 mutant.  a) SDS PAGE analysis of IGFBAA-coil7 compared 
to the wild-type BAABAA.  The control lanes are BAABAA without JR-coil7, boiled samples (B), non-boiled 
samples (N).  The total expression of IGFBAA is compromised with respect to the wild-type however IGFBAA 
still forms the majority of the product.  In order to achieve comparable concentrations of IGFBAA to BAABAA 
the relative concentration of the contaminants becomes increased.  b) SEC of IGFBAA-coil7 compared to the 
wild-type and the coil2 equivalent.  IGFBAA shows an increased assembly ratio compared to the wild-type, 
however less assembly than IGFBAA-coil2.  c) DLS comparison between IGFBAA-coil7 and the wild-type, with 
and without JR-coil7.  The presence of the mutations in IGFBAA seems to make the particle size distribution 
more discrete, as seen by the narrower DLS traces.  Particles of a comparable size to those achieved for the 
wild-type are seen.  d) TEM of the IGFBAA particles from the SEC high weight peak.  Panels 1-6 are at the same 
magnification as the 50 nm scale bar, whereas panel 7 matches the 100 nm scale bar. Particles measure 
approximately 33 nm which falls in line with DLS observations and theoretical predictions, note some stain 
deposits are present. 
 
 
It was also interesting to note that the number of particles visible under TEM was increased 
compared to the wild-type assemblies.  This could be due to an increased level of capsid 
stability inferred by the mutant interface.  The increase in capsid yield is exemplified in 
Figure 6-4 which shows two representative micrographs, with four structures in a 100 nm 
scaled electron micrograph and five structures in a 200 nm scaled micrograph.  In 
comparison, the wild-type protein produced far fewer capsids. 
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Figure 6-4:  Representative electron micrographs of IGFBAA-coil7 displaying frequency of capsids visualised on 
populated areas. 
 
 
6.2.1.3 Characterisation of Mutants with de Crescenzo coils. 
The de Crescenzo coiled-coils described in Chapter 4 were also appended to the IGFBAA 
mutant.  Two variants were constructed containing five heptad variants of either DeCr-coilE 
or DeCr-coilK.  These constructs were expressed, purified and concentrated as per the 
standard technique described in the methods.  Samples of the individual mutants and 
mixtures of both in ratios 1:5, 1:1 and 5:1 were left to incubate at room temperature for 2 
days, before being analysed by SEC.    
IGFBAA-coilE expressed as well as the IGFBAA-coil7 variant providing 0.6 g/L and was 
concentrated to 2.9 mg/ml, however, as seen in Figure 6-5a, IGFBAA-coilK expressed 
poorly allowing the retrieval of 0.2 g/L which was concentrated to 1 mg/ml .   The reduced 
expression level is intriguing as the only difference between the two constructs is an EKE 
motif and a KEK motif, respectively.  Translating this charge difference along the 5 heptad 
coiled-coil and around each pentamer creates a net change in charge of 50e between the 
two variants.  This charge difference may affect the folding and assembly kinetics of the 
pentamer or it may in some way restrict the export of the pentamers into the media.  The 
black arrows in Figure 6-5a show the pentameric and monomeric bands for IGFBAA-coilE.  
The red arrows highlight the position of the IGFBAA-coilK. This highlighted band in not 
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present in the non-boiled lane of IGFBAA-coilE, however it is present in the IGFBAA-coilK 
and as this is the only difference between the two samples, it is presumably attributable to 
IGFBAA-coilK.  The SEC traces can be seen in Figure 6-5b and displays some intriguing 
properties.  The concentration of the coil-K variant is very low as discernible by the SEC 
trace, however there is a small peak at the pentamer retention volume, additionally there 
is a significant high weight peak.  There is a peak for a species below the size of the 
pentamer at retention volume of 22 ml;  however, this peak is only present in the mixtures 
of the two IGFBAA variants and not in the samples of individual variants.  The greatest yield 
of high weight product comes from the 1:1 mix of E and K variants. It is interesting to note 
that this sample displays one of the lowest peak heights for the pentamer peak which 
suggests that the majority of the product has formed larger complexes.  There is also a 
peak at 15 ml which could indicate the presence of a dimer of pentamers.  Figure 6-5c 
displays a representative electron micrograph from capsid populated areas of a grid with 
the 1:1 mixture of IGFBAA variants.  As the histogram in Figure 6-5d reveals, these particles 
are relatively monodisperse averaging 27 nm in size.  In addition to the presence of these 
27 nm diameter particles, there was also a small population of larger capsids measuring 
from 30-40 nm in size.  A selection of these larger particles displaying evidence of a 3-fold 
symmetry axis can be seen in Figure 6-6.  The presence of a 3-fold symmetry axis in 
particles made from pentamers indicates a closed particle as 2D tiling of pentagons cannot 
form 3-fold symmetry axes[107]. 
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Figure 6-5:  SDS PAGE, SEC and TEM of the mutant IGFBAA.  a) Mutants are noted at the top of the gel and 
boiled samples (B) and non-boiled (N) samples are noted below.  The coil-E variant expressed well however the 
coil-K variant expresses poorly.  b) SEC of various ratios of IGFBAA-coilE and IGFBAA-coilK are indicated in the 
key: KK = pure K, E1K5 = 1:5 ratio of E:K, etc.  The 1:1 ratio of coil-E to coil-K variants gives the largest yield of 
high weight product. The traces were normalised using the peak at 26 ml retention volume. c) A representative 
micrograph of capsid populated areas of the IGFBAA-E1K1 grid.  d)  The E1K1 mix when analysed by TEM 
revealed a number of capsid-like structures with an average diameter of 27 nm; this figure shows the particle 
size distribution of these particles.  
 
Figure 6-6:  TEM of IGFBAA E1K1 variants.  These particles were found on the same grid as Figure 6-5c.  Some 
of the larger particles found displayed hints of a 3-fold axis of symmetry which is indicative of a closed particle 
when made from pentagonal subunits. 
 
144 
 
6.3 Gel Contaminants 
A few contaminants were present on SDS PAGE after nickel affinity chromatography; it was 
a point of interest to identify these contaminants.  Additionally as some of the SEC traces 
revealed species of CTB which appeared to elute at a similar retention volume to the non-
coiled CTB it was suspected that a degree of proteolysis was occurring during the 
incubation step of capsid assembly.  In order to answer some of these questions an SDS 
PAGE of IGFBAA-coilE and a mix of IGFBAA-coilE and IGFBAA-coilK were submitted for 
tryptic MS-MS analysis (Figure 6-7) which was conducted by Dr James Ault, University of 
Leeds.  The methods are available in the appendix as a personal communication from 
James Ault.  The mixture of IGFBAA-coilE/K formed part of the experiment where the 
positive and negatively charged coiled-coils were mixed together to elucidate if assembly 
occurred.  The expression of IGFBAAA-coilK was very low compared to IGFBAA-coilE so it 
was also of interest to find the IGFBAA-coilK mutant in the mixed sample. 
 
Figure 6-7: SDS PAGE trypsin digest followed by MS-MS.  Proteins are labelled above the gel and boiled (B) and 
non-boiled (N) samples are noted below the gel.  The IGFBAA-coilE/K is a sample with a 1:1 mix of both 
IGFBAA-coilE and IGFBAA-coilK.  Pixel intensities were re-coloured using GIMP (GNU Image Manipulation 
Program at various thresholds). 
Band 1 reveals IGFBAA and a number of coilE segments which due to the heptad nature of 
the coiled-coil repeat can account for the entire coil barring the C-terminal Gly residue.  
However in band 7 this final digest product, with a C-terminal Gly, is present.  As this Gly is 
unique to the C-terminus we can confirm that band 7 contains the full length coiled-coil on 
CTB which infers that band 1 also contains the full length coil (Table 6-1).   
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Band Sequence 
IGFBAA-E TPLNIIDLCAEYHNTQIHTLNSKIFSYTESLAGKREMAIITFPNGATFQVEVPGSQHIDSQKKAIERMKDT 
Band 1 LRIAYLTEAKVEKLCVWNNKTPHAIAAISMAGGGEVSALEKEVSALEKEVSALEKEVSALEKEVSALEKG 
IGFBAA-E TPLNIIDLCAEYHNTQIHTLNSKIFSYTESLAGKREMAIITFPNGATFQVEVPGSQHIDSQKKAIERMKDT 
Band 7 LRIAYLTEAKVEKLCVWNNKTPHAIAAISMAGGGEVSALEKEVSALEKEVSALEKEVSALEKEVSALEKG 
Table 6-1: Tryptic MS-MS of IGFBAA-coilE from band 1 and band 7. The sequence in red and green were 
identified from the MS-MS analysis.  The unique part of the sequence between band 1 and band 7 is in green, 
this C-terminal glycine in band 7 reveals the full length sequence is present. 
 
Band 2 corresponds to IGFBAA but does not contain fragments of the canonical heptad 
repeat. However, one of the fragments contains the C-terminal portion of IGFBAA 
followed by one whole heptad of coilE, up to the first Lys of the repeat.  In hindsight the 
band adjacent to band 2, in the boiled sample, should have been submitted as this band is 
a contaminant seen in many gels and should not contain CTB due to the boiling (this is 
currently being processed).  Band 3 contained the E. coli FKBP-type peptidyl-prolyl cis-trans 
isomerase (SlyD-PPIase), 20 kDa.  PPIase contains 196 amino acids, of which 19 are 
histidines, the sequence includes a region of HVHGAHDHHH DHDHDGCCGG HGHDHGHEHG, 
thus it is unsurprising that such a protein was captured by the nickel column.  Bands 4, 5, 6, 
8 and 9 contain the E. coil ferric uptake regulation protein, 17 kDa, of which 27% coverage 
was observed in bands 6, 8 and 9 and 16% coverage in bands 4 and 5, this is odd as this 
protein appears to run at multiple size on both boiled and non-boiled samples.  Bands 5, 6, 
8 and 9 also contain CTB.  Band 8 also confirms the presence of both IGFBAA-coilE and 
IGFBAA-coilK (Table 6-2), whereas band 9 confirms only the presence of the coilK mutant.  
Band 4 also contains the E. coli 30S ribosomal protein S15, 10 kDa. Of interest, wild-type 
CTB is hypothesised to run as a dimer of pentamers and this is confirmed by analysis of 
band 10 which runs at twice the size of the pentamer, is not found in boiled samples of CTB 
and contains CTB peptide fragments.   
 
Band 8 Sequence 
IGFBAA- TPLNIIDLCAEYHNTQIHTLNSKIFSYTESLAGKREMAIITFPNGATFQVEVPGSQHIDSQKKAIERMKDT 
coilK LRIAYLTEAKVEKLCVWNNKTPHAIAAISMAGGGKVSALKEKVSALKEKVSALKEKVSALKEKVSALKEG 
IGFBAA- TPLNIIDLCAEYHNTQIHTLNSKIFSYTESLAGKREMAIITFPNGATFQVEVPGSQHIDSQKKAIERMKDT 
coilE LRIAYLTEAKVEKLCVWNNKTPHAIAAISMAGGGEVSALEKEVSALEKEVSALEKEVSALEKEVSALEKG 
Table 6-2:  Tryptic MS-MS of band 8.  The sequence in red and green were identified from the MS-MS analysis.  
The unique parts of the sequences in green confirm both proteins are in the mixture.  However, as the rest of 
the coiled-coil is not identified, proteolysis may have occurred. 
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The three contaminating proteins are interesting as it was initially assumed these would be 
periplasmic proteins which leach into the media due to an overcrowding of the periplasm 
from CTB expression.  However all three protein are cytosolic in origin, including the SlyD 
PPIase, of which other PPIase are common in the periplasm.  The presence of these 
cytosolic proteins raises interesting questions regarding CTB periplasmic expression in E. 
coil; was their presence in the media suggestive of cell death?  This information suggests 
that alternative expression methods may help produce higher yields and reduce the level of 
contaminants.  Selected trypsin MS-MS data is available in the appendix. 
 
6.4 Further Optimisation via Computational 
Design (S#1.1) 
6.4.1  Overview 
In this section the IGFBAA mutant from S#1.0, which showed promising high order 
oligomerisation, was subjected to a further round of the computational routine.  The basic 
routine follows the flow chart in chapter 5, however, combinatorial mutant analysis was 
only performed retrospectively due to expression limitations and will not be discussed.   
6.4.1.1 Objective 
The chosen hit from S#1.0, IGFBAA, was bought forward to act as the starting model for a 
second round of computational interface design.  This mutant contains the following 
substitutions A1T, Q3L, T6I, Y18H, D22S, K43P and I47T.  It is worth noting that the 
A1T, Y18H and I47T mutations are biotype variant mutations, thus this mutant actually 
only contains four de novo mutations. 
6.4.1.2 Saturation Mutagenesis 
Saturation mutagenesis was carried out with FoldX as described in the methods on the 
mutant IGFBAA.  This investigation returned 35 substitutions with a ΔΔGstability less than -
1.0 kcal/mol. 
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Figure 6-8:  Results of saturation mutagenesis on the first round mutant IGFBAA.  a) The position scan 
revealed a number of mutations which reduced the total ∆∆Gstability of the trimer of pentamers below -1.0 
kcal/mol, presented in green.  b) The frequency of suggested mutations by position.  Notably only six positions 
are recommended to be changed more than ten times.  The colours represent the wild-type protein residue 
being hydrophobic (green), hydrogen bonding (yellow) charged (red or blue respectively). 
The saturation mutagenesis highlighted positions 7, 47, 83, 89, 92 and 103 as residues 
which are potentially repulsive to the assessed complex, each with 10 or more suggested 
substitutions. Of the top ten substitutions, only five positions were suggested for mutation. 
Position 7 and 47 were best represented in the top ten with four and three suggestions 
respectively.  The mutations with ΔΔGstability less than -1.0 kcal/mol in Figure 6-8 were 
applied to the CTB-44°-8Å model and the single mutation analysis was performed. 
6.4.1.3 Single Part Mutants 
25 mutations were selected from the 38 predictions from FoldX.  Cysteines were removed 
from the list of mutations as well as the worst performing substitutions at over-populated 
positions.  Residues with hydrogen bonding potential were included preferentially over 
hydrophobic residues.  Ensembles of these mutations were analysed by FoldX as described 
previously. 
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Figure 6-9:  Second round mutants of the S#1.0 hit IGFBAA.  a) The amino acid sequence of the wild-type 
compared to IGFBAA as well as the second round single part mutants.  b) The ∆∆Ginteraction energy in kcal/mol 
for the single part mutants compared to IGFBAA in red.  Mutants selected for experimental validation are 
highlighted in green.  c) Expression of the selected single part mutants, notably, almost all mutants cause loss of 
CTB expression, barring part 2Q. 
 
  
The single mutant analysis suggested the majority of the chosen mutations should increase 
∆∆Ginteraction compared to the IGFBAA first round mutant as seen in Figure 6-91b, where 
IGFBAA is highlighted in red.  Those highlighted in green were investigated 
experimentally, however, only 1N, 1P, 1Q, 2Q, 2S, 3R, 3T and 3R proceeded through the 
cloning stage to protein expression.  It became evident that only part 2Q expressed to 
workable concentrations (Figure 6-9c). Perhaps fortuitously mutant IQFBAA (containing 
part 2Q) was predicted to have the best estimated improvement in interaction energy 
amongst those mutants assessed.  The final lane of the gel in Figure 6-9 shows IQFBAA 
concentrated to 2mg/m., Although this gel was somewhat smeared, the pentameric band is 
the dominant band on the gel. 
6.4.1.4 Combinatorial Mutants 
A combinatorial mutant selection was performed in silico, however, due to the reduced 
expression of the single mutants further mutations were deemed too destabilising to 
experiment with further. 
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6.5 Characterising Second Generation 
Mutants (S#1.1) 
6.5.1  Expression and Characterisation of IQFBAA with JR-
coil2 
Mutant IQFBAA, the sequence of which is shown in Figure 6-10, was expressed and 
purified as per the standard technique described above. 
 
Figure 6-10:  The amino acid sequence for the single part mutant hit from S#1.1, IQFBAA based on the S#1.0 
hit, IGFBAA.  The single substitution is H18L.  The initial substitution in this position, Y18H, is CTB biotype 
variant, thus the 18L mutation introduces a novel amino acid at this position. 
IQFBAA was then analysed on SDS PAGE and when concentrated, passed through SEC 
(Figure 6-11).  IQFBAA gave very little yield of high weight product compared to the parent 
IGFBAA-coil2 mutant.  As the expression of this mutant was compromised the total yield 
of contaminants was greater than with the parent mutant, as seen on the SEC trace in 
Figure 6-11b, where the contaminant peak at 1.2 rrv is much larger for IQFBAA.  Due to 
the decline in production of the high weight peak found by SEC, no further analysis of this 
mutant was performed. 
 
Figure 6-11:  SDS PAGE and SEC of IQFBAA.  a) IQFBAA showed a reduced expression compared to its parent 
mutant IGFBAA, suggesting the H18L is a deleterious mutation.  b) Additionally 18H appears to be an 
important residue in the assembly of the capsid as the production of a high weight species of IQFBAA is 
seriously perturbed. 
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6.6 Concluding Statements 
6.6.1  Computational Routine 
The computational process used to select the mutations has been experimentally validated 
and shown  to change the behaviour of the assembling subunits.  The IGFBAA mutant was 
shown to assemble faster and to give higher yields of VLPs than were observed by SEC for 
the wild-type protein.  Under TEM, the capsids were observed in greater numbers than 
were found with the wild-type.  These results are a direct result of the computational 
studies conducted which show that our method has the ability to pick mutations which 
result in increased affinities. However, it should also be noted that the computational 
method sometimes also makes suggestions that do not express well and mutations which 
do not increase affinity. 
 
6.6.2  Capsid Structures 
The capsid structures observed appear similar to those found in the wild-type protein but 
are more numerous.  In addition, a larger, more elliptical capsid was observed as well as a 
large capsid enclosing two smaller capsids.  This observation leads to the conclusion that 
despite most capsids having a similar size, there is a degree of disordered assembly which 
gives rise to these larger structures.  Furthermore, there must presumably be a degree of 
self-association between the interior and exterior faces of the capsid to allow 
encapsulation of small capsids within larger capsids. 
 
6.6.3  The de Crescenzo Coiled-Coils 
The five heptad coilE and coilK designs described by de Crescenzo were extended from the 
IGFBAA mutant CTB.  These capsid structures assembled rapidly to form particles with an 
average diameter of 27 nm.  They were also found to create structures between 30 and 40 
nm, similar to those using the JR-coils.  The speed of the assembly and the appearance of 
these 27 nm capsids could be evidence of a kinetic trap during the assembly process, 
however as highlighted in the introduction, these structures may be forming structural 
polymorphs mediated by the higher affinity of the de Crescenzo coils as seen with differing 
scaffolds and the assembly of SV40[110] 
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6.6.4  Expression Yields 
The IGFBAA mutant expressed reasonably well, however, none of the other combinatorial 
mutants seemed to express well and even the single parts which were combined to make 
IGFBAA did not express to a reasonable level.  As discussed, this may be due to the 
substitution of the K43 residue, as this may alleviate electrostatic field tension in that area 
of the protein which could reduce the yield of stable protein.  The reduced expression 
highlights a design concern not addressed by the computational studies.  The selection of 
combinatorial mutants contained four or more substitutions: it may be more feasible to 
approach the mutagenesis from a more modest starting point. 
The next chapter describes mutations which were suggested and assessed by the same 
computational routine. However, in this case, they were biased by human design to pick 
interactions which would form on a molecular level according to the proposed orientation 
of binding discussed in chapter 5. 
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In this chapter two further design strategies are discussed (S#2 and S#3). A round of 
computational investigations for S#2.0, is followed by experimental validation of capsid 
structures and then by a second round of mutations: S#2.1 and S#2.2.  Finally a third 
strategy is discussed which involved no computational assessment: Strategy S#3.0 involved 
combining expressible mutations from the previous investigations (S#1 and S#2). 
7.1 Strategy S#2.0 
Strategy 1.0 used a degree of human interjection in selecting the initial combinatorial 
mutants, of which the parts were ultimately recombined in the second iteration of the 
computational protocol to form the combinatorial library.  The decision making was guided 
solely by ΔΔGstability and ΔΔGinteraction estimations, as well as occasionally omitting 
troublesome residues such as proline or cysteine.  In strategy 2.0, however, the decision 
making was more structurally biased.  the literature suggests most protein-protein 
interfaces maintain a degree of hydrogen bond donating and accepting residues within the 
interface to aid solubility when uncomplexed.  In order to enrich the library of S#2.0 with 
more hydrogen bonding residues, the saturation mutagenesis data from S#1.0 was directly 
compared to the structure of the proposed protein-protein interface and mutants were 
chosen which satisfied both structural constraints of the interface and the ΔΔGstability 
estimations from FoldX. This approach relied on the symmetrical docking program to have 
made adequate estimations of the interface orientation.  The CTB-44°-8Å model used to 
initiate the routine in S#1.0 was used again here. Rational mutant substitutions were 
guided by the FoldX position scan. 
7.1.1.1 Starting Structure 
In S#2.0 the wild-type-44°-8Å model was used to initiate the routine. 
7.1.2  Position Scan  
The saturation mutagenesis data from strategy S#1.0 was used to suggest mutants, 
however, in S#2.0 these suggestions were then rationally considered by inspection of the 
interface structure.  For example, the FoldX position scan data recommended T41 
substitution with M, L, P, V, I or K and T47 with I.  These are predominantly hydrophobic 
residues; however upon observation of the CTB-44°-8Å model, these two positions are in 
close proximity across the interface, which should allow the introduction of interacting 
hydrophilic residues.  The introduction of an asparagine residue in each of these positions 
should mediate hydrogen bond formation across the putative interface.  However, MD 
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simulations of the mutant (Figure 7-1) show a hydrogen bond between an N47 of one 
pentamer and an N41 of the next pentamer,  this interaction is potentially supported by 
further intra-pentamer interaction from the uncomplexed N41 and N47 residues.  T41N 
gives a ΔΔGstability improvement of -0.19 kcal/mol from the FoldX estimation, however, this 
does not account for the potential complimentary interactions including the same residue 
position interacting across the interface.  
 
 
Figure 7-1:  Example of a rational mutation based on suggestions by FoldX data.  The introduction of 
asparagines at positions 41 and 47 may lead to a hydrogen bonding inter-pentamer interaction.  Produced from 
a modified structure of pdb 3CHB. 
 
The mutations chosen for the screen are shown in Figure 7-2.  Of the choices made, eight 
were hydrophobic residues and ten were hydrogen bonding residues and a further three 
were charged.  This is quite a different ratio of hydrogen bonding residues to hydrophobic 
residues from S#1.0 which contained 15 hydrophobic residues and only six with the 
potential to form hydrogen bonds. 
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Figure 7-2: A sequence alignment of the mutant ‘parts’ ordered for assembly PCR in S#2.0.  A different 
combination of these parts allows the construction of different full length mutants.  These parts allow the 
construction of 3168 combinatorial mutants.  
 
7.1.3  Single Part Mutants 
Single mutants were not computationally assessed in this strategy as they were picked by 
hand; however verification of expression was determined experimentally.  The individual 
parts were assembled with the respective wild-type parts by PCR and cloned into the 
expression vector pSAB2.2.  Part 1M and 2L contain a complimentary mutation in their 
overlapping region; these parts were assembled together with the remaining wild-type 
parts.  The constructs were expressed, purified and ran on SDS PAGE, examples of which 
can be seen in Figure 7-3.  Mutants 2M, 2O, 2P, 3N, 3P, 4H, 6K, 6L and 6H did not express 
or expressed poorly.  Mutant 3O and 5G produced large smears between the pentamer 
and monomer band suggesting pentameric dissociation during SDS PAGE. 
 
Figure 7-3:  SDS PAGE of S#2.0 single part mutants.  SDS PAGE was conducted on non-boiled samples of the 
mutant protein.  The single mutant parts all display reduced expression compared to the wild-type CTB. 
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7.1.4  Combinatorial Mutants 
The computational combinatorial mutant analysis was performed in the same manner as 
described in S#1.0, combining each mutant part in such a way to create 1848 mutants.  This 
analysis was streamlined to include only those containing expressible parts.  Of these 
potentially expressible mutants a further selection was made base on the morphology of 
the single part mutants on the gel.  Those highlighted in Figure 7-5b were assembled by 
assembly PCR, cloned and expressed. 
 
Figure 7-4: Combinatorial mutant selection.  a)  All possible combinatorial mutations assessed for their 
∆∆Ginteraction by FoldX.  b) Expressible parts combinatorial library assessed for their ∆∆Ginteraction by FoldX.  Those 
highlighted in colour were experimentally validated. 
 
7.1.4.1 Characterisation of Mutants with JR-coil2 
Five mutants from the combinatorial computational selection were carried through for 
protein expression, shown in Figure 7-5.  Due to time constraints these mutants were only 
fused to the JR-coil2 coiled and not to the JR-coil7 variant.  These mutants were not 
analysed by DLS or EM, however mutants with promising SEC high weight peaks were 
passed on for a second round of computational design and analysis. 
 
 
Figure 7-5: The amino acid sequence for combinatorial mutants from S#2.0.  The expressible mutants from this 
round of single mutants were combined.  Only 5 were chosen for extension with coiled-coils. 
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Each of the mutant proteins was produced as described for S#1.0 mutants.  Comparatively, 
this set of mutants contained fewer substitutions than mutants in S#1.0 and as a result 
three of the five tested mutants maintained their pentameric stability on SDS PAGE, as 
seen in Figure 7-6a. However it is notable that the total protein yield was somewhat 
perturbed by these substitutions.  Predictably, as these mutants had a reduced number of 
substitutions, they assembled into higher order species at a slower rate compared to the 
S#1.0 mutants (Figure 7-6b). Nevertheless, one mutant, BAQBGA, showed a reasonable 
amount of high order species when analysed by SEC after 10 days incubation at room 
temperature.  Additionally, the mutant MLQBAA showed an increase in the total high 
weight product after 10 days when compared to 4 days incubation.  This mutant also 
displayed what is thought to be monomeric CTB at 22 ml retention volume.  This is of 
interest as it is suggestive of pentameric instability.  However the ratio of this monomeric 
peak compared to pentameric peak decreases over prolonged incubation which is 
suggestive of either pentameric reassembly or of the production of some high weight 
amorphous aggregation. 
 
 
Figure 7-6:  SDS PAGE and SEC for the S#2.0 combinatorial mutants.  a) Mutants are listed at the top of the gel 
with the wild-type AAAAAA, no coils, as the reference control, boiled samples (B), non-boiled samples (N).  Of 
the five combinatorial mutants selected for expression with the JR-coil2, BALBGA, BAQBGA and MLQBAA 
revealed viable pentamers on SDS PAGE and were at higher concentration than the contaminants.  b) Each of 
the expressible mutants was incubated for either 4 or 10-11 days before SEC was conducted.  BALBGA, in blue, 
displayed the lowest rate of assembly despite there being an increase in high weight species over the prolonged 
incubation.  MLQBAA, in green, showed a greater increase in assembly and greater yield than BALBGA.  
However, this mutant also displayed a peak at the CTB monomer retention volume of 22 ml.  Oddly this peak 
reduces given longer incubations.  BAQBGA (red) displays the greatest increase in high weight product over 
time.  However, the right-hand shoulder of the pentamer peak suggests that proteolysis has occurred resulting 
in the cleavage of some portion of the coiled-coil.  Additionally, as seen with all of the prolonged incubations 
there is a peak for monomeric CTB. 
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BAQBGA and MLQBAA both showed an increase in the high weight species over time 
(although the increase of the MLQBAA peak was marginal).  Thus these two mutants were 
selected for a second pass through the computational routine to select additional 
mutations for analysis. Optimisations S#2.1 and S#2.2 used the MLQBAA and BAQBGA 
sequences, respectively as the starting structures.  Interestingly the mutant BAQBGA was 
observed to give the greatest increase in capsid assembly, this mutant was also found to 
give the best ∆∆Ginteraction energy of -10.0 kcal/mol by the computational analysis.  Before 
assessing these mutants by DLS and TEM it was decided to put the mutants through a 
second round of computational design to attempt to increase the yield of high weight 
product. 
7.2 Strategy 2.0, Iteration 0.1 (S#2.1) 
The mutant MLQBAA, which contains the substitutions A10D and T47N compared to the 
wild-type, was found to increase the assembly of high weight products by SEC and form 
capsids under TEM.  In this iteration of the computational strategy, the mutant was 
assessed for additional mutations likely to increase the ΔΔGinteraction for the proposed 
interface.  As the total stability and expression of the single mutants was impaired, the 
combinatorial library analysis was not used. 
7.2.1  Position Scan  
The position scan revealed a number of mutations which improved the ∆Gstability compared 
to the wild-type residue.  The top seven ∆∆Gstability hits were at position 83, with E83G 
providing the best energy reduction of -4.6 kcal/mol.  MLQBAA does not contain a mutation 
at either D22 or at E83, discussed earlier as possible electrostatically repulsive residues 
against capsid formation, so it is unsurprising that these predictions follow the same trend 
as the wild-type position scan.  The remaining hits below -1.0 kcal/mol populated positions 
3, 6, 22, 47, 83 and 94 which is similar to the wild-type position scan, albeit that the 
wild-type scan also included suggestions at position 18, 28 and 41, which were under-
represented in the MLQBAA position scan.  The 1M/2L parts of MLQBAA corresponds to an 
A10D mutation which appears in the mutation frequency distribution graph (Figure 7-7b).  
Despite there being ten energy-minimising mutations at this position, the best 
improvement for a D10 substitution is ranked 51st against other possible mutations (a 
reduction of -0.89 kcal/mol).  Re-substitutions of D10 were thus not considered in this 
study.  The 3Q part of MLQBAA corresponds to an I47N substitution.  The position scan 
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predicted that N47P would give a -2.56 kcal/mol reduction in ∆∆Gstability.  Another four, 
mainly hydrophobic substitutions, were also suggested for this position.  However, the 
cavity at the interface into which this side chain protrudes has a number of backbone 
hydrogen bond donors/accepters, thus the original asparagine substitution was retained at 
this position. 
 
 
Figure 7-7:  Results of saturation mutagenesis on the first round mutant MLQBAA.  a) The position scan 
suggested a number of mutations which should give a ∆∆Gstability below -1.0 kcal/mol for the trimer of 
pentamers (presented in green).  b) The frequency of suggested mutations by position.  Notably eight positions 
are recommended to be changed more than ten times, one of which was the original first round mutation 
A10D. 
 
7.2.2  Single Mutants of MLQBAA 
Selected mutations predicted from the position scan were modelled, minimised and 
CHARMM MD trajectories were performed.  Of these, most gave a ∆∆Ginteraction energy 
improvement over the initial mutant MLQBAA.  The position scan ∆∆Gstability values 
suggested that the best energy improvements would come from the E83 substitutions, 
however, as seen in Figure 7-8b, the best improvements in ∆∆Ginteraction were predicted to 
arise from D22 substitutions.  The parts highlighted in green on Figure 7-8 were ordered, 
constructed and expressed.  As is evident from the example gel in Figure 7-8c there was a 
very low yield of protein from the few constructs which expressed.  It should be noted that 
the only mutants in this round that did express were parts 1U, 1V and 5G (5G is part 
previously used in S#2.0, but was re-predicted in this round of mutagenesis). 
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Figure 7-8:  Second round mutants of the hit MLQBAA.  a) The amino acid sequence of the wild-type compared 
to MLQBAA as well as the second round single part mutants.  b) The ∆∆Ginteraction energy in kcal/mol for the 
single part mutants compared to MLQBAA in red.  Mutants selected for experimental validation are highlighted 
in green.  c) Expression of the single part mutants. It is notable that almost all mutants cause loss of CTB 
expression, barring parts 1U and 1V. 
 
7.2.3  Capsid Formation for Mutants from Strategy S#2.1 
Sequences for the second round derivatives of mutant MLQBAA, ULQBAA and VLQBAA, 
are displayed in Figure 7-9.  These mutant genes were assembled with the JR-coil2 
sequence at their C-termini (see chapter 4 or the appendix). 
 
 
Figure 7-9:  The amino acid sequence of single part mutants ULQBAA and VLQBAA, derived from the parent 
mutant MLQBAA from S#2.0.  Each mutation is an alanine substation of 3Q or 6T respectively. 
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7.2.3.1 Characterisation of mutants with JR-coil2 
Figure 7-10a shows the SDS PAGE from the MLQBAA mutants, ULQBAA and VLQBAA.  
ULQBAA, containing a Q3A substitution, expressed to form pentamers stable under SDS 
PAGE however, VLQBAA, containing a T6A mutation, dissociated into monomers during 
SDS PAGE.  Interestingly, from a qualitative perspective, ULQBAA seemed to give a more 
intense band by SDS PAGE than MLQBAA (Figure 7-6).  MLQBAA was previously noted to 
contain monomers in solution when studied by SEC. In contrast, when ULQBAA was 
analysed by SEC (Figure 7-10b), there was a distinct lack of the monomer peak.  This 
observation suggests that the Q3A daughter mutation rescues the instability of the parent 
mutant.  The ULQBAA mutant also provided an increased yield of protein compared to the 
parent MLQBAA mutant.  ULQBAA, however, showed little increase in the high weight 
peak compared to the parent mutant.  Unfortunately, a SEC trace for VLQBAA is 
unavailable due to the corruption of the output file during a fault with the AKTA HPLC.  This 
SEC trace had revealed a modest increase in the high weight peak for VLQBAA and hence 
VLQBAA was selected for TEM over ULQBAA.  The TEM of VLQBAA produced a limited 
yield of capsid structures similar to the quantity produced for the wild-type protein.  The 
morphology of these structures differed substantially, some of which were barely viable 
rings, which could be a staining issue or artefacts of collapsed capsids. Other particles were 
solid structures which showed no internal detail and a third set resembled the wild-type 
structure in which the contrast agent has penetrated the capsid.  The capsid in Figure 
7-10c(7) and (8) are shown again in Figure 7-10d.  Figure 7-10d(8) seems to display a 
hexagonal angles in its lower half.  This hexagonal shape is also observed in Figure 7-10d(7) 
and (7.1), suggesting a 3-fold symmetry axis.  As the mutant VLQBAA showed no real 
improvement on the yield of capsids compared to the wild-type CTB-coil2, this mutant was 
not investigated with the JR-coil7 coiled-coil. 
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Figure 7-10:  SDS PAGE, SEC and TEM of the S#2.1 mutants, ULQBAA and VLQBAA.  a) Mutants are identified 
above the gel, boiled sample (B) and non-boiled samples (N) are labelled below the gel.  ULQBAA, a Q3A 
mutation of MLQBAA expresses better than VLQBAA and maintains its pentameric structure on the gel.  b) 
Comparison of the SEC trace of ULQBAA with the parent mutant MLQBAA reveals a very modest enhancement 
of high weight species However, the right-hand shoulder of the pentamer peak also suggests a degree of 
proteolysis of the coiled-coils.  ULQBAA show no monomeric peak, suggesting the mutation has recovered a 
degree of stability compared to the parent.  c) TEM of the high weight peak from VLQBAA SEC.  This mutant 
revealed only a few capsids under TEM and these were polydisperse in size and polymorphic.  However, some 
of the structures revealed interior walls and some seemed to possess 3-fold symmetry. 
 
7.3 Strategy 2.0, Iteration 0.2 (S#2.2) 
The mutant which gave the best increase in high weight product from S#2.0 was BAQBGA 
which contained the mutations A1T, I47N and E83N.  This mutant was passed through the 
computational routine for a second time in order to elucidate substitutions which will 
increase the rate and total stability of the assembly.  As the total stability and expression of 
the single mutants was impaired, the combinatorial library analysis was not used. 
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7.3.1  Position Scan  
The position scan performed on the BAQBGA mutant suggested 32 point mutations which 
reduced the ∆∆Gstability by more than -1.0 kcal/mol (Figure 7-11a).  Six of these suggestions 
were D22 substitutions. No other position was suggested more than three times and these 
suggestions were spread across positions 3, 6, 7, 16, 44, 47, 84, 89 and 94  (Figure 
7-11b). The top ranking point mutants were N44G (-3.1 kcal/mol),  K84L (-2.5 kcal/mol) 
and Q3L (-2.2 kcal/mol). The wider distribution of suggestions for positions to mutate 
could be the result of the substitution of E83 in round S#2.0 which was thought to provide 
repulsive interactions across the putative interface.  As before, models of the hits from the 
position scan were constructed and passed to CHARMM for molecular dynamic 
simulations. 
 
Figure 7-11:  Results of saturation mutagenesis on the first round mutant BAQBGA.  a) The position scan 
revealed a number of mutations which reduced the total ∆∆Gstability of the trimer of pentamers below -1.0 
kcal/mol, presented in green.  b) The frequency of suggested mutations by position.  Notably just six positions 
are recommended to be changed more than ten times, highest ranking is position D22, interestingly position 
83 is no longer recommended to be mutated since its substitution to Asn. 
 
7.3.2  Single Mutants of BAQBGA 
Conformations pulled from CHARMM trajectories of the point mutants were analysed by 
the FoldX ‘analyse complex’ function to give a ∆∆Ginteraction for the interface.  The best of the 
single part mutations was Q3L (part-1R, Figure 7-12b).  The Q3L substitution had 
previously been proposed and implemented in S#1.0, however, in S#1.0 this mutation was 
accompanied by a T6I substitution (part-1I).  T6I mutation was also suggested among 
the hits from this investigation (part-1S), therefore part-1I is a combination of the two 
parts suggested here, 1R and 1S.  Interestingly expression of part-1R with the BAQBGA 
(creating mutant RAQBGA) resulted in a loss of pentameric CTB seen under SDS PAGE, 
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Figure 7-12c, as previously discussed this is indicative of a loss of stability.  This dissociation 
during SDS PAGE is not seen for the analogous mutant containing the T6I substitution 
(part-1I).  Again, few of these second round mutants were found to express efficiently; 
only parts 1R, 1S, 3V and 3W produced protein and only the latter two remained as 
pentamers on SDS PAGE.  Additionally, part-5E is a part previously selected in S#1.0. 
 
 
Figure 7-12: Second round mutants of the hit BAQBGA.  a) The amino acid sequence of the wild-type compared 
to BAQBGA as well as the second round single part mutants.  b) The ∆∆Ginteraction energy in kcal/mol for the 
single part mutants compared to BAQBGA in red.  Mutants selected for experimental validation are highlighted 
in green.  c) Expression of the experimentally trialled single part mutants, notably, almost all mutants cause loss 
of CTB expression, barring part 1R, 1S, 3V and 3W. 
 
7.3.3  Capsid Formation for Mutants from Strategy S#2.2 
Figure 7-13 shows the mutant choices from the computational investigation that could be 
expressed.  Those which did not express are not shown.  Part-3W and part-5E are also 
interesting as these substitute out the ‘rational’ mutations that were introduced in S#2.0, 
replacing these hydrogen bonding residues with hydrophobic side-chains.  The mutants in 
the next section were single part mutants expressed with JR-coil2 extensions.  Additionally, 
three hand chosen mutants were picked to be expressed with JR-coil7, which follow the JR-
coil2 mutants. 
165 
 
 
Figure 7-13: The amino acid sequence of single part mutants from S#2.2 single part computational assessment 
on the first round hit BAQBGA from S#2.0.  Interestingly part-1R and part-1S contain single mutations, which 
if combined make part-1I, seen in S#1.0 and S#1.1.  Also part-5E, seen in S1.0, was reselected. 
7.3.3.1 Characterisation of mutants with JR-coil2 
Each mutant gene was constructed by assembly PCR with the 3’ JR-coil2 sequence.  The 
Figure 7-14a shows a gel for the expressible point mutations, based on the parent 
sequence BAQBGA.  Notably only the N44A and N47V mutants (BAVBGA and BAWBGA) 
form pentamers under SDS PAGE.  Both of these mutants also increase the total yield of 
CTB produced compared to the parent mutant.  BAWBGA also presents a slight smear 
across the gel suggesting this mutant is more destabilising than the parent mutant. 
 
Figure 7-14:  SDS PAGE and SEC of the S#2.2 mutants bearing the JR-coil2 sequence at their C-termini.  a) 
Mutants are noted above the gel. Whether the lanes contain boiled samples (B) or non-boiled samples (N) is 
noted below.  For reference, the parent mutant BAQBGA is in the last lane, and the wild-type CTB is in the first.  
Both of the part-1 mutants seem to perturb expression; however, both of the part-3 mutations seem to recover 
a degree of expression.  b) A comparison of the parent mutant to the wild-type CTB without coils.  notice the 
right-hand shoulder seems to have the same retention volume as CTB without coils, suggesting proteolysis of 
the coils.  c) This putative proteolysis is evident in some of the mutants in S#2.2.  Two mutants seem to give an 
improved rate of high weight assembly, RAQBGA and BAVBGA, however RAQBGA expresses poorly and 
BAVBGA seems to lose its coiled-coil extensions rapidly in the non-assembled pentamer peak. 
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An interesting observation is that the parent construct for this set of mutants, BAQBGA-
coil2, develops a right hand shoulder in the SEC trace after incubation for extended 
periods, such as 10 days (Figure 7-14b). This additional SEC peak for BAQBGA seems to 
have a retention volume similar to the wild-type CTB without coiled-coil extensions which 
could be suggestive some proteolysis of the coiled-coils.  Given this hypothesis, it is logical 
that assembled capsids would be sterically protected from proteolysis due to the coiled-
coils being present on the interior of the capsid.  Figure 7-14c shows the rest of the SEC 
traces from mutants in the S#2.2 set.  These traces show a disappointing level of assembly 
and a number of mutants, BAVBGA, BAWBGA and SAQBGA display SEC traces in line with 
pentamers that do not have C-terminal extensions.  Despite this potential proteolytic 
cleavage, assembly of BAVBGA and RAQBGA appeared to increase compared to other 
mutants, particularly RAQBGA, for which the high weigh peak constitutes 10% of the total 
CTB yield (considering the high weight peak and both pentamers with and without coiled-
coils).  BAVBGA displays a 4% total yield of high weight species.   
Two of these mutants were selected for TEM: RAQBGA and BAVBGA.  Samples were 
recovered from the SEC high weight and prepared for TEM as described in the methods.   
7.3.3.1.1 RAQBGA Transmission Electron Microscopy 
RAQBGA expressed reasonably poorly and was unable to maintain pentamers during SDS 
PAGE, however when concentrated to 2 mg/ml total protein, incubated for six days and 
subjected to SEC, the ratio of high weigh peak to pentamer was greater than with other 
mutants.  The total yield of the high weight peak, however, is not so different from other 
successful mutants, such as the parent BAQBGA.  The high weight peak was isolated and 
applied to an electron microscopy grid and stained as described in the methods.  Figure 
7-15 shows the particles found under TEM.  Larger particles are shown in Figure 7-15(2-15).  
These particles ranged in size from 45 nm to 105 nm.  These larger particles all seem to 
possess electron shielding particles in the middle of the structures, this maybe an artefact 
of the TEM process, but these dense black particles do not appear apart from on the inside 
of the particles.  These artefacts are not found in any other TEM of CTB capsids, which may 
be suggestive of a discrepancy in the preparation of the grid.  The small electron shielding 
particles are pure black as far as pixel intensity is concerned, haloed with rings of pure 
white.  It is possible that these black areas could be quantum dots of metal aggregates. The 
serendipitous presence of these particles apparently encapsulated is encouraging for the 
prospect of future targeting of molecules to the capsid interior.  Figure 7-15(16-17) show 
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typical populated areas of the TEM grid, where these larger round structures are dispersed 
among many smaller capsids which range in size from 18-33 nm.  Figure 7-16, displays a 
histogram of the capsid sizes found on the EM grid. The larger round structures have sizes 
that are too polydiverse and too few in number to make any statistical claims; however, 
the smaller particle size range seems to fit a Gaussian distribution. 
 
 
 
Figure 7-15:  TEM of mutant RAQBGA.  Micrographs 16 and 17 are representative of populated areas of the grid 
and contain objects of approximately 25 nm in size across a range of 20-30 nm.  However, as seen in the bottom 
right corner of 17, larger spherical structures are also produced.   Micrographs 2-15 show the range of sizes 
exhibited by these larger round structures.  Strangely, even though larger capsids are seen in other mutants, 
the large structures in this sample possess electronically-shielded structures, presumably in the interior, as 
these are only present within the confines of larger round structures.  This may be due to an inconsistency in 
sample preparation. 
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Figure 7-16:  Particle size distribution for the mutant RAQBGA.  The smaller particles seem to fit a Gaussian 
distribution, however there are too few of the larger particles to make an estimate to size groupings. 
 
 
7.3.3.1.2 BAVBGA Transmission Electron Microscopy 
BAVBGA produced a small but significant high weight peak by SEC. TEM of this high weight 
peak revealed a number of capsid structures of differing sizes.  Compared to RAQBGA, 
BAVBGA produced a large amount of medium sized particles between 40 and 60 nm in size 
as well as the smaller capsid size of between 20 and 30 nm. Figure 7-17a shows a collection 
of structures sized between 40 and 85 nm in diameter and Figure 7-17b & c show typical 
images from the capsid-populated areas of the TEM grid.  The histogram in Figure 7-18 
shows the distribution of particle size found among the grid.  It is notable that the smaller 
particles appear to have a similar range and frequency as RAQBGA. However, the BAVBGA 
mutant also seems enriched in the medium-sized particles between 40 and 60 nm, as is 
evident from the histogram (Figure 7-18).  It is of interest that a modest number of 
mutations at the proposed interface of the capsid subunits can make such dramatic 
differences in particle size.  Compared to RAQBGA, BAVBGA contains a L3Q and a N44A 
substitution, the result of which is the creation of a mixture of two distinct particles sizes. 
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Figure 7-17:  TEM of mutant BAVBGA.  a) A selection of capsid structures ranging in size from 20 to 55 nm.  
Perhaps due to inconsistencies in the stain penetration, some capsids appear solid, while in others the interior 
wall of the capsid is visible. b) & c) Representative micrographs of capsid populated areas of the grid. 
 
Figure 7-18: Particle size distribution for the mutant BAVBGA.  This mutant produced two distinct particle sizes, 
about 25 nm and 47 nm in size. Each distribution appears to fit a Gaussian distribution.  
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7.3.3.2 Characterisation of mutants with JR-coil7 
Based on the success of RAQBGA and BAVBGA in producing capsids, these mutations 
were combined to create the mutant RAVBGA.  Furthermore, as part-5E (previously 
discussed in S#1.0) was also suggested to be beneficial for BAQBGA, thus the mutant 
RAQBEA was created to test the combinatorial success of this mutant.  The sequences are 
shown below in Figure 7-19. 
 
Figure 7-19:  The amino acid sequence of the S#2.2 combinatorial mutants.  Each mutant is based on the 
success of single part mutants of the parent mutant BAQBGA from S#2.0 
Each of these mutants was constructed from scratch via assembly PCR with JR-coil7 
extension.  Expression of these mutants revealed that RAVBGA and RAQBEA maintained 
similar levels of expression to BAQBGA however RAVBEA expressed less efficiently.  High 
weight peaks were identified during SEC analysis and so these samples were used to 
prepare TEM grids (unfortunately, the AKTA data became corrupted and is no longer 
available). 
 
Figure 7-20:  SDS PAGE of S#2.2 combinatorial mutants.  Mutants are noted above the gel, boiled samples (B) 
and non-boiled samples (N) are noted below.  RAVBEA seems to express less efficiently than the other two 
combinatorial mutants RAVBGA and RAQBEA. 
 
171 
 
 
7.3.3.2.1 RAQBEA Transmission Electron Microscopy 
The RAQBEA mutant produced few capsids of discrete sizes. Figure 7-21a & b show two 
capsid structures of approximately 70 and 50 nm, respectively; the 70 nm capsid appears to 
house another 50 nm capsid.  Figure 7-21c shows a number of highly polymorphous 
structures which were found more commonly than the spherical capsid structures.  As this 
mutant failed to produce structures appropriate to our intentions, further investigations 
into this mutant were not conducted. 
 
 
Figure 7-21:  TEM of the mutant RAQBEA.  a) & b) Few capsid-like structures were seen under TEM.  c) Other 
areas of the grid revealed amorphous structures. 
 
7.3.3.2.2 RAVBGA Transmission Electron Microscopy 
The RAVBGA mutant produced a large number of capsid structures which could be found 
throughout the grid.  Many allowed the negative stain to penetrate the capsid and TEM 
thus revealed the inside capsid wall, whereas others resisted stain penetration and appear 
without discernible internal features.  Figure 7-22 shows a range of capsid structures 
measuring from 25 to 65 nm in diameter.  Figure 7-22b & c display typical TEM micrographs 
of capsid-populated areas of the grid.  Figure 7-23 shows a histogram of the particle size 
distribution for this mutant which show most capsids have a size about 36 and 48 nm in 
size, with few larger capsids present.  The morphology of these capsids seemed more 
uniform despite the broad size distribution. 
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Figure 7-22:  TEM of RAVBGA.  a) A selection of capsid structures ranging in size from 27 to 63 nm.  Many of the 
particles are stained to reveal the presence of the inside of the capsid wall.  b) and c) Representative 
micrographs of the capsid populated areas of the grid. 
 
 
Figure 7-23:  Particle size distribution for the mutant RAVBGA.  This mutant seems to produce less discrete sizes 
of particles, although there are enrichments of particles with 36 and 48 nm diameters. 
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7.4 Strategy S#3.0 
A final combinatorial selection of mutants was made by hand.  This set of mutants 
combined substitutions which had led to capsid assembly from differing strategies.  Parts 
from the S#1.0 mutant IGFBAA were combined with the S#2.0 mutant BAQBGA and the 
S#2.2 mutant RAVBGA.  Figure 7-24 shows the amino acid sequences of the two mutants 
successfully expressed. 
 
Figure 7-24:  The amino acid sequence of hand chosen mutants of S#3.0.  Part-1I and part-2G come from S#1.0, 
part-3Q and part-5G come from S#2.0 and part-3V comes from S#2.2. 
 
7.4.1  Characterisation of mutants with JR-coil7 
Both of the mutants expressed poorly: in Figure 7-25a IGVBGA barely shows a pentameric 
band and BGQBGA is only marginally better. As the overall expression of the target proteins 
is reduced, the contaminants now form the majority of these samples.  This is of course not 
favourable, however, due to time constraints at this late stage of the project another 
purification method was not investigated.  Each mutant was concentrated to ca. 1.8 mg/ml 
and incubated at room temperature for four days.  When these two mutants were 
investigated by SEC (Figure 7-25b), both mutants gave very similar traces, however 
BGQBGA gave a substantially greater yield of high weight particles.  Unfortunately, due to 
another AKTA problem, the BGQBGA SEC run was not collected and the sample went to 
waste.  Nevertheless IGVBGA was analysed by TEM (Figure 7-25c).  The average particle 
size was 33 nm and the morphology of the capsids seemed to be relatively constant.  One 
the images displays the interior walls of the capsid, and others seem to possess a 3-fold 
symmetry axis.  A histogram of the particle measurements (Figure 7-25d), displayed a 
narrow Gaussian-like particle size distribution. 
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Figure 7-25:  SDS PAGE, SEC and TEM of S#3.0 mutants.  a) SDS PAGE of IGVBGA and BGQBGA: boiled samples 
(B) and non-boiled samples (N) are noted below the gel.  Both mutants expressed very poorly.  BGQBGA is 
viable as a pentamer on the gel, however IGVBGA is barely visible.  Note that the monomer of IGVBGA is 
distinct in the boiled lane as opposed to the non-boiled lane.  b) During SEC, the BGQBGA mutant produced 
more of the high weight product than IVGBGA after 4 days incubation.  c) IGVBGA was analysed by TEM and a 
number of capsid structures were visible.  The images did not often display the interior walls of the capsid.  
However some of them do appear to display clear evidence of a 3-fold axis of symmetry indicative of enclosed 
particles.  d) A histogram of the particle size distribution for IGVBGA which averages about 33 nm in size. 
 
7.5 Structural Polymorphisms 
The structures visualised above and in the previous chapters by TEM are representative of 
the majority of the capsid populated areas of the grid.  However additional structures were 
found on the CTB grids which resembled part assembled VLP and other aberrant structures.  
In the introduction, structural polymorphisms are discussed in which natural virus coat 
proteins can assemble into aberrant structures.  Here we present a number of CTB 
pentamer polymorphisms (Figure 7-26).  Oversized capsids, malformed capsids, incomplete 
capsids, capsid-enclosed capsids and tubes are observed which appear similar to the 
aberrant structures seen with in vitro viral capsid assembly. 
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Figure 7-26:  Structural polymorphs observed under a variety of TEM magnifications.  Showing a selection of 
oversized capsids, malformed capsids, incomplete capsids, capsid-enclosed capsids and tubes. 1) RAVBGA-coil7.  
2) IGFBAA-coilE.  3) IGFBAA-coilE/coilK 1:5 ratio.  4) IGFBAA-coilE/coilK 1:1.  5) BAVBGA-coil2. 
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7.6 Concluding Statements 
In this chapter the computational routine was used to make informed hand-picked 
mutations based on the saturation mutagenesis data, this  provided alternative starting 
structures for a second iteration of the computational routine.   
One of the parent mutants initially suggested, MLQBAA, expressed poorly and the majority 
of further mutations to the sequences resulted in a complete lack of expression.  The 
daughter mutant VLQBAA produced some capsid structures but these were structurally 
polymorphic and low in number.  The frequency of encountering a capsid was similar to 
that of the wild-type.  Thus no improvement was made with this set of mutants. 
The parent mutant BAQBGA, which was shown to have the most improved ∆∆Ginteraction, 
also produced the greatest yield of high weight species.  Four substitutions suggested by 
the second iteration of the computational routine further improved the ∆∆Ginteraction.  Of 
these suggestions, the daughter mutants RAQBGA and BAVBGA were extended with the 
JR-coil2.  These two mutants produced a variety of well-populated capsid structures.  In 
both cases the highest population of capsids had diameters of 27 nm.  However, the 
BAVBGA mutant also produced a high population of capsids with a diameter of 
approximately 50 nm (Figure 7-27).  The part-1R made a Q3L substitution whereas the 
part-3V made a N44A mutation.  This subtle difference in the biochemistry of the 
interacting faces seems to be responsible for the production of the expanded capsid 
structures.  Two further daughter mutants RAQBEA and RAVBGA which were extended 
with JR-coil7 also produced capsids.  While RAQBEA produced only a few capsids 
structures, RAVBGA which combines both the Q3L and N44A mutation produced a large 
number of capsids.  Though some of these capsids had a diameter of 27 nm, there was a 
shift in population size of the smaller capsids to approximately 36 nm diameter.  
Additionally, the proportion of 50 nm diameter capsids was larger compared to BAVBGA.  
Each of the above mutants produced other structures with diameters up to 114 nm, 
however these were too few to make any estimations of distinct size distributions. 
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Figure 7-27:  The particle size distribution observed with different mutants and differing coiled-coils. 
In the final investigation, the mutant IGVBEA was constructed with the JR-coil7.  Like 
RAVBGA, this mutant contains the Q3L and N44A mutations as well as T6I, Y18H and 
D22S.  This mutant also showed a lack of 27 nm diameter particles, with most capsid 
diameters between 33 and 36 nm.  This mutant displayed no evidence of greater sized 
particles. 
These data show that the size of the structures assembled is determined by changes to the 
residues on the interacting surfaces and to the coiled-coils used (Figure 1-26).  Although the 
coiled-coils are probably responsible for the assembly of the capsid structures, the 
morphology of the capsid is still influenced by the residues at the interface.   JR-coil7 seems 
to preferentially form capsids of 33 nm and over, whereas JR-coil2 seems to mostly give 
rise to capsids of 27 nm diameter.  At present no data is available to suggest the 
mechanism by which the residues and coils confer this polymorphism.  Though, for the coils 
at least, the propensity to form either dimers (coil7) or trimers (coil2) may be partly 
responsible for the differing populations observed. 
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8.1 Expression of CTB in E. coli 
 
8.1.1  Plasmid Construction 
Although there are other species, such as Vibrio sp.60, which can be used to express CTB to 
a good yield, E. coli provided a more convenient standardised platform, for the molecular 
biology techniques used here, to generate sufficient quantities of the chosen mutations.  
The use of the SAB2.0 gene construct was instrumental in this process through the 
construction of a plasmid which could provide different expression solutions to unexpected 
expression problems for the MBP-CTA2 fusion (pSAB2.1) and as a construct to provide CTB 
expression alone (pSAB2.2).  Assembly PCR was very successful in producing combinatorial 
mutants with ease as well as adding C-terminal extensions to the CTB protein.  The use of 
this procedure, excluding C-terminal extensions, has yielded a potential combinatorial 
library of just under 5 million mutants from only 100 designed DNA parts. 
 
Although the assembly PCR method was fast and convenient, it presented a number of 
reliability issues.  Firstly, the initial assembly seemed to vary in success, during some 
experiments the final target gene was produced as the major species with few 
intermediates.  However in other experiments the intermediates dominated with little or 
no final product visible.  In both cases an amplification using just terminal primers 
produced a pure final product indicating the presence of the final product in poor 
assemblies.  These deviations in reliable amplification seemed independent of the number 
of parts used and independent of batches of oligos, suggesting that minor deviations in the 
reaction conditions may be responsible.  Secondly, due to the large size of the oligos, up to 
95nt, there was a reliable number of coupling synthesis errors.  Due to the assembly PCR 
method there was a number of miss-assemblies.  A total of 282 assembly PCR reactions 
were carried out where 14 of the assembled genes (5%) were found to be missing parts and 
59 of the assembled genes (21%) were found to contain synthesis errors.  This resulted in 
the re-picking of colonies from many of the transformation plates to sample alternate 
assembled genes from the reactions and in a number cases a repeat of the assembly PCR. 
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The reliance on the traditional restriction-cut, ligase-paste approach was a stumbling block 
for progressing mutants from assembled genes into full plasmids.  However, new 
techniques such as Gibson assembly[171] and the Golden Gate strategy[172,173] have been 
receiving a lot of attention lately.  Designing a set of overlapping DNA sequences for use 
with such techniques would allow future mutations in this system to be generated with 
greater efficiency. 
8.1.2  Protein Yield 
Another stumbling block in the project was the total yield of CTB produced.  As mutations 
were successively introduced into the structure, the level of expression was successively 
reduced.  The fractionation step of the CTB production was inefficient, requiring large 
amounts of centrifugation time after a lengthy ammonium sulfate incubation step which 
challenged the throughput of the procedure.  CTB is expressed to the periplasm where 
folding is mediated by disulfide bond isomerase, after which CTB is found in the media 
suggesting export or leaching of CTB.  Over expression of secreted proteins puts strain on 
the SEC translocon which perturbs effective translocation of proteins required for nutrient 
uptake and cell division[174], as well as straining the outer membrane.  An intracellular 
expression of CTB may alleviate the need to extract CTB from the media.  E. coli strains such 
Origami2 cells express a cytosolic version of disulfide bond isomerase which may allow 
cytosolic expression of CTB, and hence allow more traditional methods of fractionation 
such as cell disruption, this in turn may lead to enhanced yields. 
Despite this yield problem, many of the proteins trialled did express to workable yields and 
as a general conclusion the strategy employed for the production and purification of these 
CTB mutants was successful for the investigations required in this project. 
8.2 CTB Mutability 
8.2.1  Mutational Space Map 
CTB is 103 residues long and natural homologs of the CTB protein provide 85 possible 
substitutions to this sequence.  Four previous literature examples highlight the effect of a 
further 83 mutations, some expressible and some deleterious to the pentameric structure.  
In this work we have made a further 73 novel mutations to the CTB structure (Figure 8-1).  
As these mutations are sometimes incorporated in combinatorial parts or single parts, with 
either one or multiple mutations per part, the success of expression has not been indicated 
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as this is complex and often dependent on which other mutations are present in the 
structure containing the mutation of interest.  Additionally, the mutations we present are 
concentrated to an area for which little work has been conducted previously, as more 
attention has been paid to the GM1 binding site.  However an additional oligosaccharide 
binding site lies within the target PPI[122,123].  Therefore many of the mutations may have 
changed the oligosaccharide specificity for this additional site.  The mutants produced in 
this work could be used in future screens for sugar binding capacity which may highlight a 
number of under-investigated cellular targets of CTB. 
 
 
Figure 8-1:  Updated mutational space map.  Black shows the wild-type el tor CTB sequence, grey displays 
substitutions in natural homologs and strains.  Red show inexpressible mutants, orange show mutations which 
produce pentamers, green shows mutations proven to still form the holotoxin.  Light blue shows mutations 
made to the sequence during this investigation.  The boxes represent positions of interest for PPI design.  X 
represents truncation mutants at the appropriate position. 
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8.2.2  Alanine Scan 
The alanine scan conducted on the wild-type CTB revealed that the majority of positions of 
interest were mutable without serious perturbation of the pentameric stability.  The SDS 
PAGE of unboiled mutant samples together with the Tm derived from DSF experiments 
showed that only a selection of alanine substitutions caused a reduction in Tm of more than 
10 degrees.  This shows that CTB is a relatively good choice of protein for mutagenesis and 
that the interface chosen should be highly mutable. As bacterial toxins are more regularly 
becoming a choice protein for biotechnological applications this alanine scan should 
provide guidance for future biotech endeavours with this protein. 
 
8.2.3  Designer Mutations 
The designed mutations seemed to confer a higher degree of instability to the pentamer 
compared to the alanine scan mutations. This observation could be due to the fact many of 
the mutations introduced bulky hydrophobic residues at the surface and in many cases 
replaced intra-pentamer salt bridges which were identified as deleterious to capsid 
formation.  Nonetheless, many of the mutants yielded intact pentamers which went on to 
increase the rate of capsid assembly.  
 
8.3 Coiled-coils 
The use of coiled-coils as a scaffold of choice in these investigations was instrumental in the 
success of the project.  Many other scaffolding choices exist but none exhibit the same high 
degree of literature characterisation.  Coiled-coils uniquely possess a large protein-protein 
interface to volume ratio.  Thus the use of coiled-coils in bionanotechnology is useful when 
space conservation is important, such as here, on the interior of a capsid.  The fact that 
coiled-coils can form both dimers and trimers (as well as many other oligomeric states), 
again make them uniquely suitable for assembling complex structures which may rely on 
these types of interaction in the overall assembly.  Additionally, the pH dependency of 
coiled-coil association[175-177] could make these appropriate scaffolds for drug delivery 
vehicles, as following endocytosis, the intracellular vesicle is likely to follow the lysosomal 
pathway.  A lysosome/endosome-based reduction in the pH of the capsid environment 
could be a design feature for capsid disassembly and resultant drug delivery. 
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8.4 Computational Strategy 
 
8.4.1  Ensembles 
The computational approach used generated ensemble structures for analysis with FoldX.  
This ensemble approach was used to alleviate the short comings of the FoldX algorithm, 
which makes no attempt to move the backbone of the protein, dealing only with side-chain 
rotamers.  However this ensemble approach is now frequently built into programs such as 
Rosetta in order to determine more accurate energetic properties.  Of course, in nature no 
proteins exist in a single conformation so it would be counter intuitive not to use 
ensembles for the assessment of protein and complex structures.  The application of MD 
simulation to produce ensembles from a protein provides a realistic estimation of the 
solution state of the proteins conformational heterogeneity based on first principles.  This 
method, as opposed to the ensembles produced from programs such as Rosetta, is more 
accurate from a physical perspective.  The Rosetta ensembles, like FoldX side chain 
sampling, allow main-chain torsional reconfigurations, however the movements, rather 
than step wise, are bulk random movements.  Rosetta then discards high energy 
conformations.  MD however determines each new structure from the previous allowing 
time dependent observation of the proteins energetics which is not captured by Rosetta. 
8.4.2  FoldX 
Although the structural data for the interface orientations is lacking, the increases in the 
rates of capsid assembly demonstrate that the computational routine succeeded in 
providing an improvement in the binding affinity of the PPI.   Additionally these mutations 
directly impacted the size distribution of the particles assembled, which can only be 
mediated by changes in the affinity/specificity of the interface.  Although the coiled-coils 
most likely provide the majority of the binding affinity, the mutations at the interface have 
likely reduced native repulsive interactions present in the wild-type.  Possibly the most 
powerful function of FoldX is the position scan (saturation mutagenesis), as this identifies 
both individually attractive mutations as well as wild-type repulsive residues.  The 
additional studies conducted on the Im9-E9 complex demonstrate that FoldX struggles 
identifying small changes in the ∆∆Ginteraction. However, the increase in capsid assembly 
observed in this project shows that FoldX is capable of suggesting mutations which improve 
the ∆∆Ginteraction energy. 
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Future studies could use the methods described here in order to design protein-protein 
interactions.  As exemplified with the lumazine synthase study, the application of periodic 
boundary conditions to a protein of icosahedral symmetry can allow the MD simulation of 
large protein complexes.  The interaction between these subunits can then be assessed via 
MD ensembles to elucidate an estimate of the binding energy of the interface.  By 
combining this technique with in silico saturation mutagenesis or ab initio protein design, 
mutants can be selected which alter the binding affinities of the PPI.   
8.5 Capsid Assembly 
The incorporation of C-terminal coiled-coils to the CTB pentamer allowed the formation of 
spherical particles to occur.  The design of an interface, based on a putative binding 
orientation and using MD simulation followed by in silico mutagenesis to reduce the 
∆∆Ginteraction energy, promoted the rate at which these capsids assemble.  A number of 
coiled-coils were shown to promote capsid assembly and a number of mutations were 
identified which increase the rate of particle formation.   
While the CTB mutants with C-terminal coiled-coil fusions mostly assembled into a specific 
size of VLP, other sizes of capsids were also found in many cases.  This feature is also 
observed when natural viral proteins assemble in vitro[108,109,178].  Additionally, the modified 
CTB also appeared to form aberrant structures which emulates the behaviour of natural 
virus coat proteins outside of their optimum physiological environment; for example, 
malformed capsids, incomplete capsids, capsid-enclosed capsids and tubes.  These 
observations suggest that we have successfully mimicked the assembly properties of viral 
coat proteins.  Use of SEC multi-angle static light scattering (SEC-MALS) could help define 
the retention volume at which the differing sized capsids elute in order to captures capsids 
of more discrete sizes.  Refinement of the mutants, and further experimentation with 
coiled-coils should yield modified CTB that assemble readily and to completion under 
defined conditions.  The final structure of the VLP was not elucidated during the course of 
this work, however, as the capsid structures are strong enough to survive the harsh 
conditions of negative stain TEM they should also survive the cryo EM environment.  
Reconstruction of particles imaged by cryo EM could provide an envelope for the fitting of 
CTB pentamers and reveal structural features which suggest the symmetry at which the 
pentamers associate.  The use of immunogold labelling would also be advantageous to 
discriminate between the CTB VLPs and artefacts of the TEM procedure or contaminating 
proteins. 
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This work demonstrated that pentameric bacterial toxins can be modified to form putative 
drug delivery vehicles which, in the future, may provide a more robust system than current 
viral systems. 
 
8.6 Drug delivery 
At present, studies have not been conducted into the ability of these particles to enter 
cells.  However the molecular biology has been completed to emulate the process 
described by Seebeck et al.[179], in which a GFP molecule was encapsulated by the protein 
cage of Lumazine synthase via electrostatic attraction.  Once complete this experiment will 
transport a modified mCherry protein into cells only if captured by capsid structures of CTB, 
which will provide proof that once capsids have assembled, their endocytic triggering 
mechanism is preserved.  Given that the particles are around 30 nm wide and contain 3 
heptad coiled-coils, they should have an internal diameter of ca. 16 nm and a volume of ca. 
280 nm3, which would be sufficient for the delivery of small molecule, RNA and protein 
therapeutics. 
The GM1 binding site of CTB provides an exciting target for the mutagenesis.  Close 
homologs of CTB such as the heat labile enterotoxins LT-IIa and LT-IIb have been shown 
bind a number of other gangliosides (Figure8.2), the shiga toxin and verotoxin .  Each of 
these proteins contain minor mutations at the oligosaccharide binding site which tune the 
binding specificity, thus introducing binding specificity for alternate oligosaccharide should 
be attainable goal with CTB and the capsid forming mutants. 
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Figure 8-2:  Ganglioside structures which bind to CTB and CTB like bacterial toxins. The probable binding site is 
highlighted by the dotted line.  This exemplifies the range of specificity for oligosaccharide binding which may 
be achieved by mutating the GM1 binding site
[180]
. 
With the wide range of potentially designable ganglioside binding sites, a wide range of cell 
types become available for the therapeutic VLP’s to target.  For example the GD1a 
ganglioside is abundant in erythrocytes, bone marrow, testes, spleen and liver, however, 
high concentrations of the GM4 ganglioside are found in in the kidney, GM1 in 
erythrocytes, GM2 in bone marrow and GM3 in the intestine. 
The CTA2 peptide, which threads through the CTB central hole, contains the C-terminal 
KDEL sequence which targets endosomes containing the CTA2/B complex to the golgi and 
on to the endoplasmic reticulum.  CTB endocytosis without the CTA2 peptide traffics 
endosomes through the lysosome pathway.  This should allow transport of the VLP to these 
different sub-cellular locations.  The targeting of further subcellular compartments is also 
possible through nuclear localisation tags and mitochondrial targeting sequences.  
Development of differing disassembly conditions could then allow release of the 
therapeutic agents at the final desired destination. 
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Targeting specific cell types in the body and localising therapeutics to a sub-cellular level 
will reduce off target drug interactions, mitigating side effects.  Furthermore, with precise 
delivery of the therapeutic agents to the site of interest the total quantity of the 
therapeutic agent required would be severely reduced, reducing the total cost of 
manufacturing. 
There are also many uses for self-assembling proteinaceous cages outside of the context of 
drug delivery.  One such alternate use of protein cages is as bioreactors for the production, 
in vivo, of commercially interesting fine chemicals and solvents.  Many of these kinds of 
chemicals are toxic to cells and require compartmentalisation for efficient in vivo synthesis.  
These types of compartments, such as metabolosomes, also address the enzymes required 
in the production of the chemical to the compartment, which give large increases in the 
kinetics of multistep enzymatic synthesis.  Although the particles produced in this report 
are of an insufficient size for a bioreactor, the principles underlying its construction are 
transferable to bioreactor studies. 
  
188 
 
  
 
 
 
 
 
 
 
 
 
Chapter 9 
Appendix 
9 Chapter 9 - Appendix 
 
 
189 
 
9.1 Plasmids and Part Sequences 
 
9.1.1 Plasmids 
A number of plasmids were used in this work, all of which derive from pMAL-p5x.  This 
plasmid was cloned with a designed insert for the expression of CTB. 
 
9.1.1.1 The pMal-p5x Plasmid 
 
Figure 9-1:  The pMAL-p5x plasmid from New England Biolabs.  This plasmid is used for the gene fusion of MBP 
to a protein of choice.  Expression is controlled by the lac operon. 
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9.1.1.2 The pMAL-p5x Multiple Cloning Site 
 
Figure 9-2:  A detailed view of the pMAL-p5x multiple cloning site (MCS), downstream from the MalE gene 
which encode MBP.  The linker region is translated to polyasparagine, a FactorX protease site is encoded after 
the linker, before the MCS. 
 
 
 
9.1.1.3 The SAB2.0 Synthetic Gene Construct 
 
Figure 9-3:  The synthetic gene construct SAB2.0 purchased from Genscript.  This construct contains the CTA1 
gene which when cloned into pMAL-p5x will express as a C-terminal fusion of MBP.  This is followed by a 
transcriptional termination region (rrnb T2 terminator) and a further promoter and ribosome binding site, 
which initiate transcription and translation, respectively, of the CTB gene with the LTIIb periplasmic leader 
sequence. 
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9.1.1.4 Detailed Overview of the SAB2.0 Gene Construct 
 
Figure 9-4: The sequence of SAB2.0 with highlighted features, restriction sites and the translated amino acid 
sequence.  Restriction sites were intentionally spread throughout the CTB gene in areas where mutations were 
not designed, this allowed the option of using restriction enzymes to reassemble genes if desired.  
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9.1.1.5 The pSAB2.0 Plasmid 
 
Figure 9-5:  The pSAB2.0 plasmid.  This is created by cloning the SAB2.0 gene construct into pMAL-p5x via 
digestion with BamHI and PstI and subsequent ligation.  This plasmid expresses the MBP-CTA1 gene fusion and 
CTB from two separate mRNA 
 
 
193 
 
9.1.1.6 The pSAB2.1 Plasmid 
 
 
Figure 9-6:  The pSAB2.1 plasmid.  This construct is created by the digestion of pSAB2.0 with XhoI followed by 
re-ligation.  This plasmid expresses the MBP-CTA1 gene fusion and CTB from a single polycistronic mRNA 
 
 
9.1.1.7 pSAB2.2 
 
Figure 9-7:  The pSAB2.2 plasmid.  This construct is created by the digestion of pSAB2.0 with MfeI followed by 
re-ligation.  This plasmid expresses CTB from a single mRNA 
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9.1.2 Parts 
Oligonucleotides which were involved in the assembly of CTB mutants are listed below, first 
by nucleotide sequence and then by amino acid sequence. 
9.1.2.1 Nucleic acids 
1A CTGTTCAGGCGCATGCAGCTCCTCAAAATATTACTGATTTGTGCGCAGAATACCACAACAC 
1B CTGTTCAGGCGCATGCAACTCCTCAAAATATTACTGATTTGTGCGCAGAATACCACAACAC 
1C CTGTTCAGGCGCATGCAACTCCTCAGTCTATTACAGAACTATGCGCAGAATACCACAACAC 
1D CTGTTCAGGCGCATGCAACTCCTGCAAATATTACTGATTTGTGCGCAGAATACCACAACAC 
1E CTGTTCAGGCGCATGCAACTCCTCAAGCTATTACTGATTTGTGCGCAGAATACCACAACAC 
1F CTGTTCAGGCGCATGCAACTCCTCAAAATATTGCTGATTTGTGCGCAGAATACCACAACAC 
1G CTGTTCAGGCGCATGCAACTCCTCAAAATATTACTTTCTTGTGCGCAGAATACCACAACAC 
1H CTGTTCAGGCGCATGCAACTCCTGCAAATATTATTGATTTGTGCGCAGAATACCACAACAC 
1I CTGTTCAGGCGCATGCAACTCCTCTAAATATTATTGATTTGTGCGCAGAATACCACAACAC 
1J CTGTTCAGGCGCATGCAACTCCTGCAAATATTCTTGATTTGTGCGCAGAATACCACAACAC 
1K CTGTTCAGGCGCATGCAACTCCTCTAAATATTATTTATTTGTGCGCAGAATACCACAACAC 
1L CTGTTCAGGCGCATGCAACTCCTCTAAATATTATTCTCTTGTGCGCAGAATACCACAACAC 
1M CTGTTCAGGCGCATGCAACTCCTCAAAATATTACTGATTTGTGCGATGAATACCACAACAC 
1N CTGTTCAGGCGCATGCAACTCCTCTAAATATTATTTTCTTGTGCGCAGAATACCACAACAC 
1O CTGTTCAGGCGCATGCAACTCCTCTAAATATTATTTACTTGTGCGCAGAATACCACAACAC 
1P CTGTTCAGGCGCATGCAACTCCTCTAAATATTATTATGTTGTGCGCAGAATACCACAACAC 
1Q CTGTTCAGGCGCATGCAACTCCTCTAAATATTATTTGGTTGTGCGCAGAATACCACAACAC 
1R CTGTTCAGGCGCATGCAACTCCTCTTAATATTACTGATTTGTGCGCAGAATACCACAACAC 
1S CTGTTCAGGCGCATGCAACTCCTCAAAATATTATTGATTTGTGCGCAGAATACCACAACAC 
1T CTGTTCAGGCGCATGCAACTCCTCAAAATATTACTTATTTGTGCGCAGAATACCACAACAC 
1U CTGTTCAGGCGCATGCAACTCCTGCAAATATTACTGATTTGTGCGATGAATACCACAACAC 
1V CTGTTCAGGCGCATGCAACTCCTCAAAATATTGCTGATTTGTGCGATGAATACCACAACAC 
  
2A CGCAGAATACCACAACACACAAATATATACGCTAAATGATAAGATCTTTTCGTATACAGAATCGCTAGCGGGAAAAAGAG 
2a CGCAGAATACCACAACACACAAATACATACGCTAAATGATAAGATCTTTTCGTATACAGAATCGCTAGCGGGAAAAAGAG 
2B CGCAGAATACCACAACACACAAATATATACGATAAATGACAAGATACTATCATATACGGAATCGCTAGCGGGAAAAAGAG 
2C CGCAGAATACCACAACACACAAATAGCTACGCTAAATGATAAGATCTTTTCGTATACAGAATCGCTAGCGGGAAAAAGAG 
2D CGCAGAATACCACAACACACAAATACATATGCTATTTGATAAGATCTTTTCGTATACAGAATCGCTAGCGGGAAAAAGAG 
2E CGCAGAATACCACAACACACAAATACATATGCTATATGATAAGATCTTTTCGTATACAGAATCGCTAGCGGGAAAAAGAG 
2F CGCAGAATACCACAACACACAAATACATATGCTAATGGATAAGATCTTTTCGTATACAGAATCGCTAGCGGGAAAAAGAG 
2G CGCAGAATACCACAACACACAAATACATACGCTAAATTCTAAGATCTTTTCGTATACAGAATCGCTAGCGGGAAAAAGAG 
2H CGCAGAATACCACAACACACAAATACATACGCTAAATTGTAAGATCTTTTCGTATACAGAATCGCTAGCGGGAAAAAGAG 
2I CGCAGAATACCACAACACACAAATACATACGCTAAATTGTAAGATCTTTGCGTATACAGAATCGCTAGCGGGAAAAAGAG 
2J CGCAGAATACCACAACACACAAATATGGACGCTAAATGCTAAGATCTTTTCGTATCTAGAATCGCTAGCGGGAAAAAGAG 
2K CGCAGAATACCACAACACACAAATAGATACGCTAAATGATAAGATCTTTTCGTATACAGAATCGCTAGCGGGAAAAAGAG 
2L CGATGAATACCACAACACACAAATATATACGCTAAATGATAAGATCTTTTCGTATACAGAATCGCTAGCGGGAAAAAGAG 
2M CGCAGAATACCACAACACACAAATATTTACGCTAAATGATAAGATCTTTTCGTATACAGAATCGCTAGCGGGAAAAAGAG 
2N CGCAGAATACCACAACACACAATTCTTTACGCTAAATGATAAGATCTTTTCGTATACAGAATCGCTAGCGGGAAAAAGAG 
2O CGCAGAATACCACAACACACAAATATATACGCTAAATAATAAGATCTTTTCGTATACAGAATCGCTAGCGGGAAAAAGAG 
2P CGCAGAATACCACAACACACAAATATATACGCTAAATTATAAGATCTTTTCGTATACAGAATCGCTAGCGGGAAAAAGAG 
2Q CGCAGAATACCACAACACACAAATACTTACGCTAAATTCTAAGATCTTTTCGTATACAGAATCGCTAGCGGGAAAAAGAG 
2R CGCAGAATACCACAACACACAAATATTTACGCTAAATTCTAAGATCTTTTCGTATACAGAATCGCTAGCGGGAAAAAGAG 
2S CGCAGAATACCACAACACACAAATACATATCCTAAATTCTAAGATCTTTTCGTATACAGAATCGCTAGCGGGAAAAAGAG 
2T CGCAGAATACCACAACACACAAATATATACGCTAAATGCTAAGATCTTTTCGTATACAGAATCGCTAGCGGGAAAAAGAG 
2U CGATGAATACCACAACACACAAATATATACGCTAAATGGTAAGATCTTTTCGTATACAGAATCGCTAGCGGGAAAAAGAG 
2V CGATGAATACCACAACACACAAATATATACGCTAAATTTTAAGATCTTTTCGTATACAGAATCGCTAGCGGGAAAAAGAG 
2W CGATGAATACCACAACACACAAATATATACGCTAAATCGTAAGATCTTTTCGTATACAGAATCGCTAGCGGGAAAAAGAG 
2 CGATGAATACCACAACACACAAATATATACGCTAAATTATAAGATCTTTTCGTATACAGAATCGCTAGCGGGAAAAAGAG 
  
3A GCTAGCGGGAAAAAGAGAGATGGCTATCATTACTTTTAAGAATGGTGCAATTTTTCAAGTAGAGGTACCAGGTAGTC 
3B GCTAGCGGGAAAAAGAGAAATGGTTATCATTACATTTAAGAGCGGCGCAACATTTCAAGTAGAGGTACCAGGTAGTC 
3C GCTAGCGGGAAAAAGAGAGATGGCTATCATTACTTTTAAGGCTGGTGCAATTTTTCAAGTAGAGGTACCAGGTAGTC 
3D GCTAGCGGGAAAAAGAGAGATGGCTATCATTACTTTTAAGAATGGTGCAGCTTTTCAAGTAGAGGTACCAGGTAGTC 
3E GCTAGCGGGAAAAAGAGAGATGGCTATCATTACTTTTAAGAATGGTGCAACTTTTCAAGTAGAGGTACCAGGTAGTC 
3F GCTAGCGGGAAAAAGAGAGATGGCTATCATTACTTTTCCGAATGGTGCAACTTTTCAAGTAGAGGTACCAGGTAGTC 
3G GCTAGCGGGAAAAAGAGAGATGGCTATCATTGTTTTTCCGAATGGTGCAATTTTTCAAGTAGAGGTACCAGGTAGTC 
3H GCTAGCGGGAAAAAGAGAGATGGCTATCATTACTTTTAAGAATGGTGCATTTTTTCAAGTAGAGGTACCAGGTAGTC 
3I GCTAGCGGGAAAAAGAGAGATGGCTATCATTACTTTTAAGAATGGTGCATTGTTTCAAGTAGAGGTACCAGGTAGTC 
3J GCTAGCGGGAAAAAGAGAGATGGCTATCATTACTTTCTTCAATGGTGCAATTTTTCAAGTAGAGGTACCAGGTAGTC 
3K GCTAGCGGGAAAAAGAGAGATGGCTATCATTACTTTTATGAATGGTGCAATTTTTCAAGTAGAGGTACCAGGTAGTC 
3L GCTAGCGGGAAAAAGAGAGATGGCTATCATTACTTTTCAGAATGGTGCAATTTTTCAAGTAGAGGTACCAGGTAGTC 
3M GCTAGCGGGAAAAAGAGAGATGGCTATCATTGTTTTTAAGAATGGTGCAATTTTTCAAGTAGAGGTACCAGGTAGTC 
3N GCTAGCGGGAAAAAGAGAGATGGCTATCATTAATTTTAAGAATGGTGCAAATTTTCAAGTAGAGGTACCAGGTAGTC 
3O GCTAGCGGGAAAAAGAGAGATGGCTATCATTCAGTTTAAGAATGGTGCAAATTTTCAAGTAGAGGTACCAGGTAGTC 
3P GCTAGCGGGAAAAAGAGAGATGGCTATCATTACTTTTAAGATTGGTGCAATTTTTCAAGTAGAGGTACCAGGTAGTC 
3Q GCTAGCGGGAAAAAGAGAGATGGCTATCATTACTTTTAAGAATGGTGCAAATTTTCAAGTAGAGGTACCAGGTAGTC 
3R GCTAGCGGGAAAAAGAGAGATGGCTATCATTATCTTTCCGAATGGTGCAACTTTTCAAGTAGAGGTACCAGGTAGTC 
3S GCTAGCGGGAAAAAGAGAGATGGCTATCATTACTTTTCCGGCAGGTGCAACTTTTCAAGTAGAGGTACCAGGTAGTC 
3T GCTAGCGGGAAAAAGAGAGATGGCTATCATTACTTTTCCGAATGGTGCACTGTTTCAAGTAGAGGTACCAGGTAGTC 
3U GCTAGCGGGAAAAAGAGAGATGGCTATCATTACTTTTCCGAATGGTGCAATGTTTCAAGTAGAGGTACCAGGTAGTC 
3V GCTAGCGGGAAAAAGAGAGATGGCTATCATTACTTTTAAGGCTGGTGCAAATTTTCAAGTAGAGGTACCAGGTAGTC 
3W GCTAGCGGGAAAAAGAGAGATGGCTATCATTACTTTTAAGAATGGTGCAGTTTTTCAAGTAGAGGTACCAGGTAGTC 
3 GCTAGCGGGAAAAAGAGAGATGGCTATCATTACTTTTAAGAATGGTGCACCGTTTCAAGTAGAGGTACCAGGTAGTC 
  
4A CAAGTAGAGGTACCAGGTAGTCAACATATAGATTCACAAAAAAAAGCGATTGAAAGGATGAAGGATACCCTGAGGATTGC 
4B CAAGTAGAGGTACCAGGTAGTCAACATATAGATTCACAAAAAAAGGCAATCGAACGTATGAAGGATACCCTGAGGATTGC 
4C ~~~GTAGAGGTACCAGGTAGTCAACATATAGACTCCCAAAAAAAGGCAATCGAACGTATGAAGGATACCCTGAGGATTGC 
  
5A GATACCCTGAGGATTGCATATCTTACTGAAGCTAAAGTCGAAAAGTTATGTGTATGGAATAATAAA 
5B GATACCCTGAGGATTGCATATCTGACCGAGACCAAAATTGATAAGCTATGTGTATGGAATAACAAG 
5C GATACCCTGAGGATTGCATATCTTACTGAAGCTAAAGTCGCAAAGTTATGTGTATGGAATAATAAA 
5D GATACCCTGAGGATTGCATATCTTACTGAAGCTAAAGTCGAAGCGTTATGTGTATGGAATAATAAA 
5E GATACCCTGAGGATTGCATATCTTACTGAAGCTAAAGTCGTAAAGTTATGTGTATGGAATAATAAA 
5F GATACCCTGAGGATTGCATATCTTACTGAAGCTAAATCCTAAAGTTATGTGTATGGAATAATAAA 
5G GATACCCTGAGGATTGCATATCTTACTGAAGCTAAAGTCAATAAGTTATGTGTATGGAATAATAAA 
5H GATACCCTGAGGATTGCATATCTTACTGAAGCTAAAGTCATGAAGTTATGTGTATGGAATAATAAA 
5I GATACCCTGAGGATTGCATATCTTACTGAAGCTAAAGTCCTGAAGTTATGTGTATGGAATAATAAA 
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5J GATACCCTGAGGATTGCATATCTTACTGAAGCTAAAGTCGTTAAGTTATGTGTATGGAATAATAAA 
5K GATACCCTGAGGATTGCATATCTTACTGAAGCTAAAGTCAATATGTTATGTGTATGGAATAATAAA 
5L GATACCCTGAGGATTGCATATCTTACTGAAGCTAAAGTCAACAAGTTATGTGTAAAGAATAATAAA 
5M GATACCCTGAGGATTGCATATCTTACTGAAGCTAAAGTCAACATGTTATGTGTAAAGAATAATAAA 
5N GATACCCTGAGGATTGCATATCTTACTGAAGCTAAAGTCAACAAGTTATGTGTATGGAATAATAAA 
  
6A TTATGTGTATGGAATAATAAAACGCCTCATGCGATCGCCGCAATTAGTATGGCAAACTAAGTTTTCCCTGCAGGTAATTCG 
6B CTATGTGTATGGAATAACAAGACGCCTAATGCGATCGCCGCAATTAGTATG 
6C CTATGTGTATGGAATAACAAGACGCCTAATGCGATCGCCGCAATTAGTATGGAAAACTAAGTTTTCCCTGCAGG 
6D TTATGTGTATGGAATAATAAAGCGCCTCATGCGATCGCCGCAATTAGTATGGCAAACTAAGTTTTCCCTGCAGGTAATTCG 
6E TTATGTGTATGGAATAATAAAACGCCTCATGCGATCGCCGCAATTAGTATGGGAAACTAAGTTTTCCCTGCAGGTAATTCG 
6F TTATGTGTATGGAATAATAAAACGCCTCATGCGATCGCCGCAATTAGTATGGCAGCCTAAGTTTTCCCTGCAGGTAATTCG 
6G TTATGTGTATGGAATAATAAAACGCCTCATGCGATCGCCGCAATTAGTATGGGAAACTAAGTTTTCCCTGCAGGTAAT 
6I TTATGTGTATGGAATAATAAAACGCCTCATGCGATCGCCGCAATTAGTATGGCAGCCTAAGTTTTCCCTGCAGGTAAT 
6J TTATGTGTATGGAATAATAAAACGCCTCATGCGATCGCCGCAATTAGTATGGCAGGC 
6K TTATGTGTATGGAATAATAAAACGCCTAATGCGATCGCCGCAATTAGTATG 
6L TTATGTGTATGGAATAATAAAACGCCTCGCGCGATCGCCGCAATTAGTATG 
6H TTATGTGTATGGAATAATAAAACGCCTTGGGCGATCGCCGCAATTAGTATG 
6M TTATGTGTATGGAATAATAAAACGCCTTTTGCGATCGCCGCAATTAGTATG 
6N TTATGTGTATGGAATAATAAAACGCCTTTTGCGATCGCCGCAATTAGTATGGCAGGC 
6O TTATGTGTATGGAATAATAAAACGCCTCCGGCGATCGCCGCAATTAGTATG 
6Q TTATGTGTAAAGAATAATAAAACGCCTCATGCGATCGCCGCAATTAGTATG 
  
7A GCGATCGCCGCAATTAGTATGGCAAACGGTGTGTCGGCCCTGGAAAAAGAGGTATCAGCTTTGAAGGAGAAAGTCTCC 
7C GCGATCGCCGCAATTAGTATGGCAAACGGTGTGTCGGCCCTGTCTGAGAAAGTATCAGCTTTGGAGTCGAAAGTCTCC 
7D GCGATCGCCGCAATTAGTATGGCAAACGGTGGTGTGTCGGCCCTGTCTGAGAAAGTATCAGCTTTGGAGTCGAAAGTCTCC 
7E GCGATCGCCGCAATTAGTATGGCAAACGGTGGTATTTCGGCCATTTCTGAGAAAATTTCAGCTATCGAGTCGAAAATCTCC 
7F GCGATCGCCGCAATTAGTATGGCAGGCGGTGGTATTTCGGCCATTTCTGAGAAAATTTCAGCTATCGAGTCGAAAATCTCC 
7G GCGATCGCCGCAATTAGTATGGCAAACGGTGGTATTTCGGCCATTTCTGAGAAAATTTCAGCTATCGAGTCCTAAGTTTTCCCTGCAGG 
7H GCGATCGCCGCAATTAGTATGGCAAACGGTGGTATTTCTGAGAAAATTTCAGCTATCGAGTCCTAAGTTTTCCCTGCAGG 
7I GCGATCGCCGCAATTAGTATGGCATCTGGTGTGTCGGCCCTGTCTGAGAAAGTATCAGCTTTGGAGTCGAAAGTCTCC 
7J CTATGTGTATGGAATAACAAGACGCCTCATGCGATCGCCGCAATTAGTATGGCAAACGGTAACGGCGTGCCTGGTGTCGG 
7K CTATGTGTATGGAATAACAAGACGCCTCATGCGATCGCCGCAATTAGTATGGCAAACGGTAACGGCGTGCCTGGTCTGGG 
7L GCGATCGCCGCAATTAGTATGGAAAACGGTGTGTCGGCCCTGGAAAAAGAGGTATCAGCTTTGAAGGAGAAAGTCTCC 
7M GCGATCGCCGCAATTAGTATGGAAAACGGTGGTATTTCGGCCATTTCTGAGAAAATTTCAGCTATCGAGTCGAAAATCTCC 
7N GCGATCGCCGCAATTAGTATGGCAGGCGGTGGTAGGGTTGAGGCTCTTGAGAAGAAGGTCGCCGCTTTAGAGTC 
7O GCGATCGCCGCAATTAGTATGGCAGGCGGTGGTGAGGTTTCCGCGCTGGAAAAAGAGGTTTCTGCATTGGAGAAGGAAGTCTCCGCACTCG 
7P GCGATCGCCGCAATTAGTATGGCAGGCGGTGGTAAAGTGTCTGCCCTCAAGGAAAAGGTTTCGGCTCTTAAGGAGAAAGTCTCCGCACTCAAAGAG 
  
8A GCTTTGAAGGAGAAAGTCTCCGCACTCGAGTTCTAAGTTTTCCCTGCAGG 
8B GCTTTGAAGGAGAAAGTCTCCGCACTCGAGAAAGAGGTATCAGCTTTGAAGTTCTAAGTTTTCCCTGCAGG 
8C GCTTTGGAGTCGAAAGTCTCCGCACTCGAAAGCAAGGTATCAGCTTTGGAGTTCTAAGTTTTCCCTGCAGG 
8D GCTTTGGAGTCGAAAGTCTCCGCAAATGAAAGCAAGGTATCAGCTTTGGAGTTCTAAGTTTTCCCTGCAGG 
8E GCTTTGGAGTCGAAAGTCTCCGCACTCGAATCCTAAGTTTTCCCTGCAGG 
8F GCTATCGAGTCGAAAATCTCCGCAATTGAATCCTAAGTTTTCCCTGCAGG 
8G GCTATCGAGTCGAAAATCTCCGCAATTGAAGAATAAGTTTTCCCTGCAGG 
8H GCTATCGAGTCGAAAATCTCCGCAATTGAATCCGGCAATAACGGTCTGCCGGAAACCGGTGGCTAAGTTTTCCCTGCAGG 
8I GTCGCCGCTTTAGAGTCTAAAGTTCAGGCCCTGGAGAAGAAGGTTGAGGCACTCGAACATGGCTAAGTTCTGCAGGTAAGC 
8J GGAAGTCTCCGCACTCGAGAAAGAGGTGTCGGCCCTGGAAAAAGAGGTATCAGCTTTGGAGAAGGGCTAAGTTCTGCAGGTAAGC 
8K GTCTCCGCACTCAAAGAGAAGGTGTCGGCCCTGAAAGAAAAGGTATCAGCTTTGAAGGAGGGCTAAGTTCTGCAGGTAAGC 
9.1.2.2 Amino Acid sequence. 
These sequences are displayed with ‘.’ to represent the wild-type residue, thus 
highlighting the change made to the sequence.  Some parts contain silent mutations, where 
the amino acid sequence is identical but the nucleotide sequence is different.  Apart from 
part 4B, this is accidental.  Parts 7 & 8 show the whole sequences as the parts differ 
substantially. 
1A,       VQAHAAPQNITDLCAEYHN                                                                                
1B,       .....T.............                                                                                
1C,       .....T..S..E.......                                                                                
1D,       .....T.A...........                                                                                
1E,       .....T..A..........                                                                                
1F,       .....T....A........                                                                                
1G,       .....T.....F.......                                                                                
1H,       .....T.A..I........                                                                                
1I,       .....T.L..I........                                                                                
1J,       .....T.A..L........                                                                                
1K,       .....T.L..IY.......                                                                                
1L,       .....T.L..IL.......                                                                                
1M,       .....T........D....                                                                                
1N,       .....T.L..IF.......                                                                                
1O,       .....T.L..IY.......                                                                                
1P,       .....T.L..IM.......                                                                                
1Q,       .....T.L..IW.......                                                                                
1R,       .....T.L...........                                                                                
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1S,       .....T....I........                                                                                
1T,       .....T.....Y.......                                                                                
1U,       .....T.A......D....                                                                                
1V,       .....T....A...D....    
2A,       AEYHNTQIYTLNDKIFSYTESLAGKR       
2a,       ........H.................       
2B,       ..........I....L..........       
2C,       ........A.................       
2D,       ........HM.F..............       
2E,       ........HM.Y..............       
2F,       ........HM.M..............       
2G,       ........H...S.............       
2H,       ........H...C.............       
2I,       ........H...C...A.........       
2J,       ........W...A.....L.......       
2K,       ........D.................       
2L,       D.........................       
2M,       ........F.................       
2N,       .......FF.................       
2O,       ............N.............       
2P,       ............Y.............       
2Q,       ........L...S.............       
2R,       ........F...S.............       
2S,       ........HI..S.............       
2T,       ............A.............       
2U,       D...........G.............       
2V,       D...........F.............       
2W,       D...........R.............       
2,        D...........Y.............    
3A,        LAGKREMAIITFKNGAIFQVEVPGS     
3B,        .......V.....S..T........       
3C,        .............A...........        
3D,        ................A........      
3E,        ................T........ 
3F,        ............P...T........       
3G,        ..........V.P............     
3H,        ................F........    
3I,        ................L........      
3J,        ............F............     
3K,        ............M............        
3L,        ............Q............        
3M,        ..........V..............        
3N,        ..........N.....N........       
3O,        ..........Q.....N........        
3P,        .............I...........        
3Q,        ................N........        
3R,        ..........I.P...T........        
3S,        ............PA..T........        
3T,        ............P...L........        
3U,        ............P...M........        
3V,        .............A..N........       
3W,        ................V........     
3,         ................P........ 
4A,       QVEVPGSQHIDSQKKAIERMKDTLRI       
4B,       ..........................        
4C,       ~.........................  
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5A,       DTLRIAYLTEAKVEKLCVWNNK           
5B,       ..........T.ID........           
5C,       .............A........            
5D,       ..............A.......           
5E,       .............V........            
5F,       .............L........ 
5G,       .............N........            
5H,       .............M........       
5I,       .............L........           
5J,       .............V........            
5K,       .............NM.......            
5L,       .............N....K...            
5M,       .............NM...K...            
5N        .............N........   
6A,       LCVWNNKTPHAIAAISMAN*VFPAGNS                                                                              
6B,       .........N.......          
6C,       .........N.......E.*....          
6D,       .......A...........*.......       
6E,       .................G.*.......       
6F,       ..................A*.......       
6G,       .................G.*......        
6I,       ..................A*......        
6J,       ..................G               
6K,       .........N.......                 
6L,       .........R.......                 
6H,       .........W.......                 
6M,       .........F.......                 
6N,       .........F........G               
6O,       .........P.......           
6Q,       ...K.............       
           
7A,       AIAAISMANGVSALEKEVSALKEKVS                                                                          
7C,       AIAAISMANGVSALSEKVSALESKVS                                                                          
7D,       AIAAISMANGGVSALSEKVSALESKVS                                                                         
7E,       AIAAISMANGGISAISEKISAIESKIS                                                                         
7F,       AIAAISMAGGGISAISEKISAIESKIS                                                                         
7G,       AIAAISMANGGISAISEKISAIES*VFPA                                                                       
7H,       AIAAISMANGGISEKISAIES*VFPA                                                                          
7I,       AIAAISMASGVSALSEKVSALESKVS                                                                          
7J,       LCVWNNKTPHAIAAISMANGNGVPGV                                                                          
7K,       LCVWNNKTPHAIAAISMANGNGVPGL                                                                          
7L,       AIAAISMENGVSALEKEVSALKEKVS                                                                          
7M,       AIAAISMENGGISAISEKISAIESKIS                                                                         
7N,       AIAAISMAGGGRVEALEKKVAALE                                                                            
7O,       AIAAISMAGGGEVSALEKEVSALEKEVSAL                                                                      
7P,       AIAAISMAGGGKVSALKEKVSALKEKVSALKE                                                                    
                                                                                                                            
                                                                                                                            
                                                                                                                            
8A,       ALKEKVSALEF*VFPA                                                                                    
8B,       ALKEKVSALEKEVSALKF*VFPA                                                                             
8C,       ALESKVSALESKVSALEF*VFPA                                                                             
8D,       ALESKVSANESKVSALEF*VFPA                                                                             
8E,       ALESKVSALES*VFPA                                                                                    
8F,       AIESKISAIES*VFPA                                                                                    
8G,       AIESKISAIEE*VFPA                                                                                    
8H,       AIESKISAIESGNNGLPETGG*VFPA                                                                          
8I,       VAALESKVQALEKKVEALEHG*VLQVS                                                                         
8J,       EVSALEKEVSALEKEVSALEKG*VLQVS                                                                       
8K,       VSALKEKVSALKEKVSALKEG*VLQVS     
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9.1.3 Expressed sequences 
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          ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
AAAAAA??  APQNITDLCAEYHNTQIYTLNDKIFSYTESLAGKREMAIITFKNGAIFQVEVPGSQHIDSQKKAIERMKDTLRIAYLTEAKVEKLCVWNNKTPHAIAAISMAN*VFPAGN                                                  
?HFA?N??  T.P..I...........H...C....................P...T...................................L..........F........G*......                                                  
?JGAEN??  T.P..L...........W...A.....L............V.P.......................................V..........F........G*......                                                  
GDEA????  T.....F..........HM.F.........................T....................................L.........R.......W.*......                                                  
DAAAAA??  T.A....................................................................................................*......                                                  
EAAAAA??  T..A...................................................................................................*......                                                  
FAAAAA??  T....A.................................................................................................*......                                                  
?AAAAA??  ......A................................................................................................*......                                                  
??AAAA??  .........G.............................................................................................*......                                                  
A?AAAA??  ...............A.......................................................................................*......                                                  
A?AAAA??  ................A......................................................................................*......                                                  
A?AAAA??  ..................A....................................................................................*......                                                  
A?AAAA??  ....................A..................................................................................*......                                                  
A?AAAA??  ......................A................................................................................*......                                                  
A?AAAA??  ........................A..............................................................................*......                                                  
A?AAAA??  .........................A.............................................................................*......                                                  
A?AAAA??  ...........................A...........................................................................*......                                                  
A??AAA??  ................................E......................................................................*......                                                  
AA?AAA??  ........................................A..............................................................*......                                                  
AA?AAA??  ..........................................A............................................................*......                                                  
BACAAA??  T..........................................A...........................................................*......                                                  
AA?AAA??  .............................................G.........................................................*......                                                  
BADAAA??  T.............................................A........................................................*......                                                  
AAAA?A??  ................................................................................A......................*......                                                  
BAAACA??  T.................................................................................A....................*......                                                  
BAAADA??  T..................................................................................A...................*......                                                  
AAAA?Q??  .......................................................................................K...............*......                                                  
AAAA????  ........................................................................................A..............*......                                                  
BAAAAD??  T..........................................................................................A...........*......                                                  
AAAAA???  .............................................................................................A.........*......                                                  
BAAAAA??  T......................................................................................................*......                                                  
BAAAAAAA  T......................................................................................................G.SALEKEVSALKEKVSALEF*VFPAGN                             
BAAAAAAB  T......................................................................................................G.SALEKEVSALKEKVSALEKEVSALKF*VFPAGN                      
BAAAAAEF  T......................................................................................................GGIS.ISEKISAIESKISAIES*VFPAGN                            
BAAAAJ??  T.....................................................................................................G*......                                                  
BAAAAN??  T............................................................................................F........G*......                                                  
BAAAEA??  T.................................................................................V....................*......                                                  
BAAAGA??  T.................................................................................N....................*......                                                  
BAAAFA??  T.................................................................................L....................*......                                                  
BAAAHA??  T.................................................................................M....................*......                                                  
BAABAQI?  T.....................................................................................................SG.SALSEKVSALESKVSALEF*VFPAGN                             
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BAABAACC  T......................................................................................................G.SALSEKVSALESKVSALESKVSALEF*VFPAGN                      
                   10        20        30        40        50        60        70        80        90       100       110       120       130       140       
          ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
AAAAAA??  APQNITDLCAEYHNTQIYTLNDKIFSYTESLAGKREMAIITFKNGAIFQVEVPGSQHIDSQKKAIERMKDTLRIAYLTEAKVEKLCVWNNKTPHAIAAISMAN*VFPAGN                                                  
BAABAACD  T......................................................................................................G.SALSEKVSALESKVSANESKVSALEF*VFPAGN                      
BAABAAG?  T......................................................................................................GGIS.ISEKISAIES*VFPAGN                                   
BAABAAH?  T......................................................................................................GGISEKISAIES*VFPAGN                                      
BAEAAA??  T.............................................T........................................................*......                                                  
BAFAAA??  T.........................................P...T........................................................*......                                                  
BAHBAA??  T.............................................F........................................................*......                                                  
BAIAAA??  T.............................................L........................................................*......                                                  
BAJAAA??  T.........................................F............................................................*......                                                  
BAKAAA??  T.........................................M............................................................*......                                                  
BALBAA??  T.........................................Q............................................................*......                                                  
BALBGAAA  T.........................................Q.......................................N....................G.SALEKEVSALKEKVSALEF*VFPAGN                             
BAMAAA??  T.......................................V..............................................................*......                                                  
BAOAAA??  T.......................................Q.....N........................................................*......                                                  
BAPAAA??  T..........................................I...........................................................*......                                                  
BAQAAA??  T.............................................N........................................................*......                                                  
BAQBGAEF  T.............................................N...................................N....................GGIS.ISEKISAIESKISAIES*VFPAGN                            
BAQBKAAA  T.............................................N...................................NM...................G.SALEKEVSALKEKVSALEF*VFPAGN                             
BAVBGAAA  T..........................................A..N...................................N....................G.SALEKEVSALKEKVSALEF*VFPAGN                             
BAWBGAAA  T.............................................V...................................N....................G.SALEKEVSALKEKVSALEF*VFPAGN                             
BCAAAA??  T................A.....................................................................................*......                                                  
BGQBGAEF  T................H...S........................N...................................N....................GGIS.ISEKISAIESKISAIES*VFPAGN                            
BHAAAA??  T................H...C.................................................................................*......                                                  
BIAAAA??  T................H...C...A.............................................................................*......                                                  
BJAAAA??  T................W...A.....L...........................................................................*......                                                  
BMABAA??  T................F.....................................................................................*......                                                  
BNKBGAAA  T...............FF........................M.......................................N....................G.SALEKEVSALKEKVSALEF*VFPAGN                             
BOAAAA??  T....................N.................................................................................*......                                                  
BTQBGAAA  T....................A........................N...................................N....................G.SALEKEVSALKEKVSALEF*VFPAGN                             
GAAAAA??  T.....F................................................................................................*......                                                  
IAABAAAA  T.L..I.................................................................................................G.SALEKEVSALKEKVSALEF*VFPAGN                             
IAQBGAEF  T.L..I........................................N...................................N....................GGIS.ISEKISAIESKISAIES*VFPAGN                            
IAVBGAEF  T.L..I.....................................A..N...................................N....................GGIS.ISEKISAIESKISAIES*VFPAGN                            
IGFAFAAA  T.L..I...........H...S....................P...T...................................L....................G.SALEKEVSALKEKVSALEF*VFPAGN                             
IGFAAAAA  T.L..I...........H...S....................P...T........................................................G.SALEKEVSALKEKVSALEF*VFPAGN                             
IGFAEAAA  T.L..I...........H...S....................P...T...................................V....................G.SALEKEVSALKEKVSALEF*VFPAGN                             
IGFBAAEF  T.L..I...........H...S....................P...T........................................................GGIS.ISEKISAIESKISAIES*VFPAGN                            
IGFBAAEG  T.L..I...........H...S....................P...T........................................................GGIS.ISEKISAIESKISAIEE*VFPAGN                            
IGFBGAEF  T.L..I...........H...S....................P...T...................................N....................GGIS.ISEKISAIESKISAIES*VFPAGN                            
IGFBLQEH  T.L..I...........H...S....................P...T...................................N....K...............GGIS.ISEKISAIESKISAIESGNNGLPETGG*VFPAGN                  
IGFBNAEH  T.L..I...........H...S....................P...T...................................N....................GGIS.ISEKISAIESKISAIESGNNGLPETGG*VFPAGN                  
IGQBAAEF  T.L..I...........H...S........................N........................................................GGIS.ISEKISAIESKISAIES*VFPAGN                            
IGQBGAEF  T.L..I...........H...S........................N...................................N....................GGIS.ISEKISAIESKISAIES*VFPAGN                            
IGRBAAAA  T.L..I...........H...S..................I.P...T........................................................G.SALEKEVSALKEKVSALEF*VFPAGN                             
IGSBAAAA  T.L..I...........H...S....................PA..T........................................................G.SALEKEVSALKEKVSALEF*VFPAGN                             
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IGTBAAAA  T.L..I...........H...S....................P...L........................................................G.SALEKEVSALKEKVSALEF*VFPAGN                             
                   10        20        30        40        50        60        70        80        90       100       110       120       130       140       
          ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
AAAAAA??  APQNITDLCAEYHNTQIYTLNDKIFSYTESLAGKREMAIITFKNGAIFQVEVPGSQHIDSQKKAIERMKDTLRIAYLTEAKVEKLCVWNNKTPHAIAAISMAN*VFPAGN                                                  
IGUBAAAA  T.L..I...........H...S....................P...M........................................................G.SALEKEVSALKEKVSALEF*VFPAGN                             
IGVBGAEF  T.L..I...........H...S.....................A..N...................................N....................GGIS.ISEKISAIESKISAIES*VFPAGN                            
IQFBAAAA  T.L..I...........L...S....................P...T........................................................G.SALEKEVSALKEKVSALEF*VFPAGN                             
IRFBAAAA  T.L..I...........F...S....................P...T........................................................G.SALEKEVSALKEKVSALEF*VFPAGN                             
ISFBAAAA  T.L..I...........HI..S....................P...T........................................................G.SALEKEVSALKEKVSALEF*VFPAGN                             
JAAAAA??  T.A..L.................................................................................................*......                                                  
JGABAAAA  T.A..L...........H...S.................................................................................G.SALEKEVSALKEKVSALEF*VFPAGN                             
JGFAFAAA  T.A..L...........H...S....................P...T...................................L....................G.SALEKEVSALKEKVSALEF*VFPAGN                             
MLQBAAAA  T........D....................................N........................................................G.SALEKEVSALKEKVSALEF*VFPAGN                             
MLQBAAAA  T........D....................................N........................................................G.SALEKEVSALKEKVSALEF*VFPAGN                             
MLQBAAEF  T........D....................................N........................................................GGIS.ISEKISAIESKISAIES*VFPAGN                            
MLXBAAAA  T........D....................................P........................................................G.SALEKEVSALKEKVSALEF*VFPAGN                             
MUQBAAAA  T........D...........G........................N........................................................G.SALEKEVSALKEKVSALEF*VFPAGN                             
MVQBAAAA  T........D...........F........................N........................................................G.SALEKEVSALKEKVSALEF*VFPAGN                             
MWQBAAAA  T........D...........R........................N........................................................G.SALEKEVSALKEKVSALEF*VFPAGN                             
MXQBAAAA  T........D...........Y........................N........................................................G.SALEKEVSALKEKVSALEF*VFPAGN                             
NGFBAAAA  T.L..IF..........H...S....................P...T........................................................G.SALEKEVSALKEKVSALEF*VFPAGN                             
PGFBAAAA  T.L..IM..........H...S....................P...T........................................................G.SALEKEVSALKEKVSALEF*VFPAGN                             
QGFBAAAA  T.L..IW..........H...S....................P...T........................................................G.SALEKEVSALKEKVSALEF*VFPAGN                             
RAQBEAEF  T.L...........................................N...................................V....................GGIS.ISEKISAIESKISAIES*VFPAGN                            
RAQBEAEF  T.L...........................................N...................................V....................GGIS.ISEKISAIESKISAIES*VFPAGN                            
RAQBGAAA  T.L...........................................N...................................N....................G.SALEKEVSALKEKVSALEF*VFPAGN                             
RAQBGAEF  T.L...........................................N...................................N....................GGIS.ISEKISAIESKISAIES*VFPAGN                            
RAVBEAEF  T.L........................................A..N...................................V....................GGIS.ISEKISAIESKISAIES*VFPAGN                            
RAVBGAEF  T.L........................................A..N...................................N....................GGIS.ISEKISAIESKISAIES*VFPAGN                            
RAVBGAEG  T.L........................................A..N...................................N....................GGIS.ISEKISAIESKISAIEE*VFPAGN                            
RAVBLQEH  T.L........................................A..N...................................N....K...............GGIS.ISEKISAIESKISAIESGNNGLPETGG*VFPAGN                  
SAQBGAAA  T....I........................................N...................................N....................G.SALEKEVSALKEKVSALEF*VFPAGN                             
TAQBGAAA  T.....Y.......................................N...................................N....................G.SALEKEVSALKEKVSALEF*VFPAGN                             
ULQBAAAA  T.A......D....................................N........................................................G.SALEKEVSALKEKVSALEF*VFPAGN                             
ULQBAAAA  T.A......D....................................N........................................................G.SALEKEVSALKEKVSALEF*VFPAGN                             
VLQBAAAA  T....A...D....................................N........................................................G.SALEKEVSALKEKVSALEF*VFPAGN                             
??GAAA??  T........E..............................V.P............................................................*......                                                  
IGQBG???  T.L..I...........H...S........................N...................................N................ES*VFPAGN                                                    
MUQBA??A  T........D...........G........................N....................................................RANGVSALEKEVSALKEKVSALEF*VFPAGN                              
IGF?FAAA  T.L..I...........H...S....................P...T...........N.......................L....................G.SALEKEVSALKEKVSALEF*VFPAGN 
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9.2 Supplementary Information 
9.2.1 Chapter 1-Introduction 
No additional information. 
9.2.2 Chapter 2-Materials and Methods 
No additional information. 
9.2.3 Chapter 3-Assessing CTB Stability 
The DSF traces for the alanine scans are presented here. 
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9.2.4 Chapter 4-Intrinsic Scaffolds 
 
9.2.4.1 Additional Coiled-Coils 
In Chapter 4 we refer to a range of trialled coiled-coils on the wild-type CTB.  The additional 
coils listed below were also tried but were less effective at producing high order 
assemblies.  The DeCr-coils are listed for reference only. 
 
 
DeCr-coilK GGGKVSALKEKVSALKEKVSALKEKVSALKEKVSALKEG 
DeCr-coilE GGGEVSALEKEVSALEKEVSALEKEVSALEKEVSALEKG 
JR-coil2 -----------------GVSALEKEVSALKEKVSALEF 
JR-coil3 ----------GVSALEKEVSALKEKVSALEKEVSALKF 
JR-coil4 ----------GVSALSEKVSALESKVSALESKVSALEF 
JR-coil5 ----------GVSALSEKVSALESKVSANESKVSALEF 
JR-coil7 ----------------GGISAISEKISAIESKISAIES 
JR-coil8 -----------------------GGISAISEKISAIES 
JR-coil9 --------------------------GGISEKISAIES 
 
 
JR-coil3:  In case JR-coil2 proves too short for assembly to occur a ‘four heptad’ coil, minus 
N-terminal electrostatics, was created which should promote increased rates of assembly.  
However an increase in coil length adds to the potential that internal overcrowding of the 
VLP will become problematic.  This coil also contains electrostatic interactions which may 
allow competition between parallel and antiparallel interactions.  JR-coil4:  This coil was 
designed to alleviate the potential for antiparallel interactions by reshuffling the 
electrostatic interactions while also maintaining homodimerisation.  An additional note for 
concern is as coiled-coil length increases, the five coils protruding from the C-terminal face 
of a CTB pentamer have more likely-hood to interact with each other.  This is of little 
concern for DeCr-coilK and E variants due to their electronic repulsion, however with the 
homomeric coils this is a perceivable problem.  JR-coil5:  To reduce the affinity of the c-
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terminal half of these coiled-coils a ‘d’ position asparagine was introduced into heptad 
three of four.  This was hoped to reduce the overall affinity of the C-terminal half, 
promoting coiled-coil interaction inter-CTB rather than intra-CTB, as intra-CTB interactions 
cannot occur over the first heptad as they are not in proximity, based on the position of the 
C-terminus, however, inter-CTB interactions are able to form interactions across the length 
of the coiled-coil.  JR-coil8 and JR-coil9:  These coils are truncations of JR-coil7.  As 
mutations, discussed in later chapters, are introduced to CTB and refined to mediated 
increases in assembly independent of the coiled-coils, these truncations will be used to 
bridge the gap between large coils and no coils. 
 
 
9.2.4.2 Cloning for pMaCo 
Cytosolic expression was required to the MBP-coiled-coil fusions, thus pMAL-c5x was used 
as a backbone plasmid (Figure 9-8).  pSAB2.1 contains a modified linker region which was 
introduced into pMAL-c5x through a digestion and ligation of the SacI – PstI insert from 
pSAB2.1 into pMAL-c5x.  This created the pMaCo plasmid.  Assembly PCR inserts of the 
coiled-coil sequences where ligated into the pMaCo plasmid after BamHI – PstI digestion.  
This produced a plasmid which expressed MBP-coiled-coil to the cytosol. 
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Figure 9-8: Cloning methodology for the construction of the pMaCo plasmid and splicing of coiled-coil fusions 
into pMaCo. 
9.2.4.2.1  pMaCo Assembly PCR Parts 
Each assembly PCR used the terminal primers MaCoWtFT and MaCoWtRT with one part A, 
B and C.  Part A (MaCoWtA0) was the same for all reactions.  Parts B and C code for the 
coiled-coil.  The Tb parts are for the JR-coiled-coil extensions requiring B and C relative to 
the number of the coil required.  Dk parts construct the de Crescenzo coilK[64], De parts 
construct the de Crescenzo coilE, St parts construct the SynTri coil[164] To construct the JR-
coil2 insert, assembly PCR is conducted with part-A MaCoWtA0, part-B MaCoTbB2/3, 
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part-C MaCoTbC3, and the terminal primers.  The protocol for assembly PCR from the 
methods is followed with a 55 °C annealing temperature. 
MaCoWtFT   CACATGGGATCCGAGAAC 
MaCoWtRT   GCTTACCTGCAGAACTTAG 
MaCoWtA0   CACATGGGATCCGAGAACCTGTACTTTCAGGGTAATAACGG 
MaCoTbB2/3 GAGACTTTCTCCTTCAAAGCTGATACCTCTTTTTCCAGGGCCGACACACCGTTATTACCCTGAAAGTAC 
MaCoTbC2   GCTTACCTGCAGAACTTAGAACTCGAGTGCGGAGACTTTCTCCTTCAAAGC 
MaCoTbC3   GCTTACCTGCAGAACTTAGAACTTCAAAGCTGATACCTCTTTCTCGAGTGCGGAGACTTTCTCCTTCAAAGC 
MaCoTbB4/5 GAGACTTTCGACTCCAAAGCTGATACTTTCTCAGACAGGGCCGACACACCGTTATTACCCTGAAAGTAC 
MaCoTbC4   GCTTACCTGCAGAACTTAGAACTCCAAAGCTGATACCTTGCTTTCGAGTGCGGAGACTTTCGACTCCAAAGC 
MaCoTbC5   GCTTACCTGCAGAACTTAGAACTCCAAAGCTGATACCTTGCTTTCATTTGCGGAGACTTTCGACTCCAAAGC 
MaCoTbB7   CGATAGCTGAAATTTTCTCAGAAATGGCCGAAATACCACCGTTATTACCCTGAAAGTAC 
MaCoTbC7   GCTTACCTGCAGAACTTAGGATTCAATTGCGGAGATTTTCGACTCGATAGCTGAAATTTTCTCAG 
MaCoTbB8   CGATAGCTGAAATTTTCTCAGAAATGGCCGAAATACCCCGTTATTACCCTGAAAGTAC 
MaCoTbB9   CGATAGCTGAAATTTTCTCAGAAATACCACCGTTATTACCCTGAAAGTAC 
MaCoTbC8/9 GCTTACCTGCAGAACTTAGGACTCGATAGCTGAAATTTTCTCAG 
MaCoDkB0   CTCTTTGAGTGCGGAGACTTTCTCCTTAAGAGCCGAAACCTTTTCCTTGAGGGCAGACACTTTACCGTTATTACCCTGAAAGTAC 
MaCoDkC0   GCTTACCTGCAGAACTTAgccCTCCTTCAAAGCTGATACCTTTTCTTTCAGGGCCGACACCTTCTCTTTGAGTGCGGAGAC 
MaCoDeB0   CGAGTGCGGAGACTTCCTTCTCCAATGCAGAAACCTCTTTTTCCAGCGCGGAAACCTCACCGTTATTACCCTGAAAGTAC 
MaCoDeC0   GCTTACCTGCAGAACTTAgccCTTCTCCAAAGCTGATACCTCTTTTTCCAGGGCCGACACCTCTTTCTCGAGTGCGGAGACTTCC 
MaCoStB0   GACTCTAAAGCGGCGACCTTCTTCTCAAGAGCCTCAACCCTCCCGTTATTACCCTGAAAGTAC 
MaCoStC0   GCTTACCTGCAGAACTTAgCCATGTTCGAGTGCCTCAACCTTCTTCTCCAGGGCCTGAACTTTAGACTCTAAAGCGGCGAC 
9.2.5 Chapter 5-Computational Interface Design 
Scripts are included on the accompanying DVD for the computational design protocol. 
9.2.6 Chapter 6-Characterisation of Scaffolded Mutants 
9.2.6.1 SDS PAGE Tryptic Digest. 
Dr James Ault, University of Leeds, supplied the following description of the methodology 
for the SDS PAGE tryptic digest. 
9.2.6.1.1  Gel processing and tryptic digestion.  
Gel bands were excised and chopped into small pieces ( ~ 1 mm3 ), covered with 30 % 
ethanol in a 1.5 mL microcentrifuge and heated to 70 °C for 30 min with shaking. The 
supernatant was removed and replaced with fresh ethanol solution was again heated to 70 
°C for 30 min. This was repeated until all coomassie stain was removed from the gel. The 
destain solution was replaced with 50 µL 25 mM ammonium bicarbonate and was vortexed 
for one hour.  The wash solution was discarded and the gel slices covered with 25 mM 
ammonium bicarbonate/50% acetonitrile and vortexed for ten minutes.  The gel slices were 
then covered with 100% acetonitrile and left for five minutes with vortexing before the 
supernatant was discarded and replaced with a fresh aliquot of acetonitrile.  Acetonitrile 
was removed and the gel pieces were completely dried under vacuum centrifugation for 30 
mins.  Once dry, the gel slices were cooled on ice.  The gel slices were then covered with ice 
cold trypsin solution (20 ng µL-1 in 25 mM ammonium bicarbonate) and left on ice for 30 
mins to rehydrate.  Excess trypsin solution was removed and the gel slices were covered 
with a minimal amount of 25 mM ammonium bicarbonate.  After briefly vortexing and 
centrifuging, the gel slices were incubated at 37 °C with shaking for 18 hours.  The resulting 
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digest was vortexed, centrifuged and 50 µL water was added.  Following vortexing for 10 
mins,  the supernatant was recovered and added to an eppendorf containing 5 µL 
acetonitrile/ water/ formic acid (60/35/5; v/v).  50 µL acetonitrile/ water/ formic acid 
(60/35/5; v/v) was added to the gel slices and vortexed for an additional 10 mins.  The 
supernatant was pooled with the previous wash and one additional wash of the gel slices 
was performed.  The pool of three washes was dried by vacuum centrifugation.  The 
peptides were reconstituted in 20 µL acetonitrile/ water/ formic acid (2/97.9/0.1; v/v).  
  
9.2.6.1.2  Liquid chromatography-mass spectrometry.  
LC separation of the peptide mixtures was performed on an Ultimate 3000 nano LC 
system.  2 µL of each sample in water was loaded onto a C18 guard column and washed 
with 2% acetonitrile/0.1% formic acid for 5 min at 25 µL min-1.  After valve switching, the 
peptides were then separated on a PepMap C18, 100 µm i.d. x 15 cm analytical column 
(Dionex, Amsterdam, NL) by gradient elution of 2-60% solvent B in A over 60 min. at 0.3 µL 
min-1. Solvent A was 0.05% formic acid in 98% water/2% acetonitrile, solvent B was 0.05% 
formic acid in 20% water/80% acetonitrile.  
The column eluant was directly interfaced to a quadrupole-ion mobility - orthogonal time 
of flight mass spectrometer (Synapt HDMS, Waters UK, Manchester) via a Z-spray nanoflow 
electrospray source.  The MS was operated in positive TOF mode using a capillary voltage 
of 3.2 kV, cone voltage of 25 V, backing pressure of 2.47 mbar and a trap bias of 4 V. The 
source temperature was 80°C.  Argon was used as the buffer gas at a pressure of 5.0 × 10-4 
mbar in the trap and transfer regions.    Mass calibration was performed by a separate 
injection of sodium iodide at a concentration of 2 µg/ µl.  GluFib was infused as a lock mass 
calibrant with a one second lock spray scan taken every 30 s during acquisition. Ten scans 
were averaged to determine the lock mass correction factor.  Data acquisition was using 
data dependent analysis with a one second MS over m/z 350-3000 being followed by three 
1 s MS/MS over m/z 50-2000 taken of the three most intense ions in the MS spectrum.  CE 
applied was dependent upon charge state and mass of the ion selected.  Dynamic exclusion 
of 60 s was used. Data processing was performed using the MassLynx v4.1 suite of software 
supplied with the mass spectrometer. Peptide MS/MS data were processed with 
ProteinLynx Global Server (Waters) and searched against UniProtKB/SwissProt database 
(release 2012_11). 
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The MS/MS data is verbose.  Two examples will be presented here, CTB and a contaminant. 
9.2.6.1.3  Band 1 
 
Where 1320-165_2 is the sequence for IGFBAA-DeCrE.  Also identified were TRYP_PIG, the 
trypsin protease used and four false positives from extraneous organisms. 
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9.2.6.1.4  Band 4 
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9.2.7 Chapter 7- Further Capsid Mutant Strategies 
Mutants, mutations, molecular weights and yields. 
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9.2.8 Chapter 8- General Conclusions 
No additional Information. 
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